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Summary 
Hepatocellular carcinoma (HCC) is one of the most lethal tumors worldwide. So far, the only 
treatment option for unresectable HCC is the multikinase inhibitor sorafenib, an inhibitor of 
the Raf/MEK/ERK (MAPK) signaling pathway, which is one of the major pathways 
implicated in HCC. Although HCC cannot be cured by sorafenib treatment, targeting the 
MAPK pathway may be a promising strategy for HCC therapy. In order to improve HCC 
treatment, it is of particular importance to understand the action of sorafenib in more detail. 
Therefore, a comprehensive analysis of its effects was performed in HCC cells and tissue and 
compared to specific inhibitors of the MAPK pathway. In my thesis, the following aspects 
could be demonstrated: 
 
1. Both, Sorafenib and MEK-specific inhibitors repressed the MAPK signaling pathway, but 
had partially opposite effects on other signaling pathways like Akt signaling. As a 
consequence, HCC cell numbers were reduced after sorafenib and MEK inhibitor 
treatment, but cell division was mainly inhibited by sorafenib and to a low extent by the 
MEK inhibitors. In contrast, apoptosis was stronger induced by the MEK inhibitors, but 
differences were observed between the cell lines. This suggests that in HCC besides the 
MAPK pathway other signaling pathways play an important role and need to be targeted in 
addition to the MAPK pathway. 
2. HCC cell lines expressed a variety of surface molecules which are associated with tumor 
progression. In addition, they secreted several chemokines and growth factors which favor 
tumorigenesis and angiogenesis. Inhibition of the MAPK pathway modulated both surface 
molecule expression and secretion of several chemokines and growth factors, whereby, 
tumor progression is inhibited.  
3. NK cells are supposed to be important for fighting against HCC, but in HCC tumor tissue, 
NK cells were almost absent. There, the microenvironment was altered with an increase of 
several chemokines and angiogenic factors. These alterations might account for the 
decreased numbers of NK cells. In vitro treatment of resected HCC tissue with sorafenib 
resulted in a substantial decrease in the concentration of these increased factors. This 
indicates that alterations of the microenvironment might be also induced by sorafenib in 
HCC patients and, thereby, affecting recruitment of immune cells, NK cells in particular, 
into the tumor tissue.   
Zusammenfassung 
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Zusammenfassung 
Das Hepatozelluläre Karzinom (HCC) ist einer der bösartigsten Tumore weltweit. Das bisher 
einzige erfolgreiche Medikament ist der Multi-Kinase-Inhibitor Sorafenib, der eines der 
Hauptsignalwege des HCC, den Raf/MEK/ERK (MAPK) Signalweg, hemmt. Obwohl 
Sorafenib nur zu einer gewissen Verlängerung des Überlebens der HCC-Patienten führt, stellt 
die Hemmung des MAPK-Signalweges dennoch eine vielverspechende Strategie da. Um in 
Zukunft aber die HCC Behandlung zu verbessern, ist es notwendig den Wirkmechanismus 
von Sorafenib auch jenseits der Signalkaskaden zu verstehen. Daher wurde eine umfassende 
Analyse von Sorafenib im Bezug auf die Wirksamkeit bei HCC Tumorzellen und im HCC-
Gewebe durchgeführt, wobei eine Besonderheit in dem direkten Vergleich mit spezifischen 
MEK-Inhibitoren besteht. In meiner Arbeit konnte folgendes gezeigt werden: 
 
1. Sowohl Sorafenib als auch die MEK-Inhibitoren hemmen den MAPK Signalweg, aber 
haben teilweise unterschiedliche Effekte auf andere Signalwege wie Akt. Dies hat zur 
Folge, dass Tumorzellzahlen durch Sorafenib und den MEK-Inhibitoren gesenkt wurden, 
aber die Zellteilung wurde hauptsächlich von Sorafenib und weniger durch die MEK 
Inhibitoren gehemmt. Im Gegensatz induzierten die MEK-Inhibitoren stärker Apoptose, 
wobei es aber Unterschiede zwischen den verschiedenen Zelllinien gab. Dies deutet darauf 
hin, dass neben dem MAPK-Signalweg auch andere Signalwege eine wichtige Rolle 
spielen und für eine erfolgreiche Behandlung des HCC zusätzlich inhibiert werden müssen. 
2. Zum einen exprimieren HCC Zellen eine Vielzahl an Oberflächenmolekülen, welche z.T. 
bei der Tumorprogression beteiligt sind. Zum anderen sekretieren sie Chemokine und 
Wachstumsfaktoren, welche das Tumorwachstum weiter fördern. Die Hemmung des 
MAPK-Signalweges durch Sorafenib bzw. MEK-Inhibitoren verändert die Expression 
dieser Oberflächenmoleküle und reduziert vor allem die Sekretion der Chemokine und 
Wachstumsfaktoren, was sich inhibierend auf die Tumorprogression auswirkt. 
3. NK Zellen spielen bei der Tumorbekämpfung eine zentrale Rolle und sind im HCC 
Tumorgewebe stark reduziert. Im HCC ist das Mikromilieu verändert, wobei einige 
Chemokine und Wachstumsfaktoren signifikant erhöht sind. Diese Veränderung könnte 
auch ein Grund für den Ausschluss der NK Zellen im HCC-Gewebe sein. Bei in vitro 
Behandlungen von reseziertem HCC-Gewebe mit Sorafenib, konnte eine signifikante 
Senkung dieser Faktoren erzielt werden, was darauf hindeutet, dass auch in Patienten eine 
Veränderung des Mikromilieus durch Sorafenib hervorgerufen werden könnte und die 
Rekrutierung der NK Zellen beeinflusst. 
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1 Introduction 
 
Hepatocellular carcinoma (HCC) is the 5th most prevalent cancer worldwide and represents 
the 3rd most lethal cancer with 500,000 to 600,000 deaths per year, worldwide (El-Serag and 
Rudolph, 2007; Llovet et al., 2003). The incidence of HCC is increasing in Europe and in the 
United States mainly due to hepatitis C virus (HCV) infection with an estimated fivefold 
increase until 2015 (Severi et al., 2010). HCC does not only arise as a result of HCV 
infections, but can also develop through hepatitis B virus (HBV) infections or non-infectious 
destructive conditions like alcohol intoxication, which is called alcoholic steatohepatitis 
(ASH), or fat deposition, called non-alcoholic steatohepatitis (NASH) (Figure 1) (Korangy et 
al., 2010a; Severi et al., 2010). Moreover, in most of the cases, HCC is associated with 
advanced fibrosis or with cirrhosis, which makes the situation for the patient even more 
difficult (Severi et al., 2010). Because the development of cirrhosis and progression towards 
HCC are poorly understood, intensive research still has to be performed. 
 
The main problem in HCC therapy is that conventional chemotherapy has failed in terms of 
curing the disease. Surgical resection or liver transplantation would be the most effective 
treatment for improving survival of the patients, but only few patients are candidates for these 
operations due to diagnosis of HCC at stages too advanced for a curative therapy. Because of 
this and a lack of treatment options, patients with unresectable HCC typically have a very 
poor prognosis with a five year survival of only 5% – 9% (Farazi and DePinho, 2006; 
Mendez-Sanchez et al., 2008). In this situation, the small molecule sorafenib (Nexavar) is the  
 
 
 
 
Figure 1: Development of hepatocellular carcinoma. Hepatocellular carcinoma (HCC) can 
develop through HBV and HCV infections or non-infectious destructive conditions like alcohol 
intoxication (alcoholic steatohepatitis, ASH) or fat deposition (non-alcoholic steatohepatitis, NASH). 
This might lead to liver fibrosis and cirrhosis, which then can transform into HCC. Figure was 
modified from (Korangy et al., 2010a). 
Healthy Fibrosis Cirrhosis HCCHBV, HCV,ASH, NASH
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only treatment option for unresectable HCC which showed a survival benefit compared to 
non-treated patients with an average of three to four months. 
 
Due to the fact that sorafenib is not a curative therapy but has effects for unresectable HCC, it 
is of particular importance to understand its mechanism of action. This will help to understand 
how to improve drug development and drug administration. Therefore, it is very important to 
have a comprehensive analysis of the mechanism of the action of sorafenib in order to 
understand where sorafenib benefits are and where HCC treatment can be improved. 
Sorafenib is a multikinase inhibitor targeting the Raf/MEK/ERK (MAPK) signaling pathway, 
as well as growth factor receptors (receptor tyrosine kinases). Because it is thought that the 
antitumor effect is mainly achieved through the inhibition of the Raf/MEK/ERK signaling 
pathway, sorafenib is compared to specific inhibitors of the MEK kinase and a specific B-Raf 
inhibitor, which are currently used in clinical and pre-clinical evaluations. With this 
comparison, it can be concluded which effects are mediated through the MAPK pathway and 
whether inhibition of only this pathway is sufficient for successful treatment of HCC. 
To get a broad view of how the inhibitors work, analyses were performed regarding their 
effects on (1) different signaling pathways, how the inhibitors influence cell proliferation, to 
what extent they induce apoptosis, and (2) how they modulate the immune cell recruitment 
and cytotoxicity. Moreover, the change of the (3) hepatic microenvironment in HCC and 
changes in vitro-treated HCC tissue will be investigated. In this thesis, significant findings in 
this respect are presented that contribute to this comprehensive analysis of HCC and signaling 
pathway inhibitors. 
Before showing the results, the basic principles about liver immunology and hepatocellular 
carcinoma are introduced, as far as they are important for a better understanding of the results 
and the discussion. Section 1.1 gives an overview of the importance of the liver for the 
immune system with its diversity of cells and distinct cytokine and chemokine milieu 
(microenvironment). Section 1.2 explains the pivotal signaling pathways in HCC and the 
importance of natural killer cells, which play a central role for tumor cell killing, with their 
mechanisms of tumor recognition. Moreover, an overview of currently tested signaling 
pathway inhibitors for the treatment of HCC will be given. 
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1.1 Liver Immunology 
 
The liver is one of the largest human organs with a daily blood flow of more than 2000 liters 
(Gershwin et al., 2007c). This is necessary, because the function of the liver is to regulate the 
composition of the blood by detoxification of harmful substances, metabolism of 
carbohydrates, lipids, and proteins, storage of glycogens, uptake of amino acids, and the 
production of uric acid. Furthermore, the liver is involved in the clearance of bacterial 
products and toxins from the blood (Knolle and Gerken, 2000). Moreover, the liver produces 
and secretes bile, which is stored in the gallbladder. Besides this, the liver plays a pivotal role 
for the immune system. In the following section (1.1.1), the basic function and mechanisms of 
the immune system in the liver are described. Section 1.1.2 explains the communication 
signals of the cells in the liver. 
1.1.1 Function of the immune system in the liver 
 
The liver is the first organ, which receives blood from the gastrointestinal (GI) tract, but it 
also gets the blood from the systemic circulation. Its central location in the body and the 
position as the first checkpoint for substances from the GI tract makes the liver an important 
organ also for the immune system since it represents a boarder for foreign substances 
(Racanelli and Rehermann, 2006). The blood from the GI tract and the systemic circulation 
enter the liver through the portal vein and the hepatic artery, respectively, and flows together 
into the hepatic sinusoids (Figure 2) (Adams and Eksteen, 2006; Fox, 2006). This mixed 
blood in the hepatic sinusoids is then transported to the central veins, which collect the blood 
into the vena cava inferior. Therefore, via these routes, the liver receives antigen-rich (e.g. 
from pathogens) blood from the gut but also from the stomach, spleen, and pancreas. In the 
sinusoids the blood flow is slow, which leads to a vivid exchange of molecules between the 
sinusoidal space and cells of the liver (Adams and Eksteen, 2006). The sinusoids are lined by 
liver sinusoidal endothelial cells (LSECs), which have open “fenestrae” to allow the antigens 
to pass the LSEC layer (Figure 2). Kupffer cells, which are liver-resident macrophages, are 
attached to the endothelial cells. Hepatic stellate cells (HSCs) and dendritic cells (DCs) are 
found in the space of Dissé, the location between the endothelial cells and the hepatocytes 
(Figure 2). Through the fenestrates of the LSECs, DCs and HSCs can reach into the sinusoids 
1 Introduction 
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and get in contact with circulating antigens and lymphocytes (Adams and Eksteen, 2006). 
They are important liver-resident antigen-presenting cells (APCs) that can take up antigens 
from the blood stream or from the liver tissue and present them to lymphocytes, primarily 
CD8+ and CD4+ T cells (Racanelli and Rehermann, 2006; Winau et al., 2008). 
 
 
Through the blood stream, not only pathogen-derived antigens are transported to the liver, the 
liver itself can also be a target of potentially harmful pathogens under infectious conditions. 
In the liver, hepatocytes, APCs and effector cells of the innate (NK and NKT cells) and 
adaptive (T and B cells) immune system are able to induce an immune response (Klein and 
Crispe 2006). Hepatocytes, which account for about two-third of all hepatic cells, can secrete 
acute-phase proteins and complement components, which are important for the first line 
defense during infections (Weiler-Normann and Rehermann, 2004). Moreover, they play an 
 
 
Figure 2: Structure of hepatic lobule. The liver is perfused by the blood from the gut and the 
systemic circulation flowing through the portal vein and the hepatic artery, respectively, into the 
hepatic sinusoids. In the hepatic sinusoids the blood from the portal vein and hepatic artery is 
mixed and transported to the central veins, which collect the blood into the vena cava inferior. In 
the sinusoids a vivid exchange of molecules occurs between the sinusoidal space and cells of the 
liver. The sinusoids are lined by liver sinusoidal endothelial cells, which have open fenestrae. 
Kupffer cells are attached to the endothelial cells and hepatic stellate cells and dendritic cells are 
found in the space of Dissé, the location between the endothelial cells and the hepatocytes. Figure 
was adapted from (Adams and Eksteen, 2006). 
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important role for the induction of the innate immune system by the secretion of pattern 
recognition receptors. These proteins bind to pathogens and lead to their clearance by 
activation of the complement system and marking them for the uptake by phagocytes (Gao et 
al., 2008). 
 
Hepatic NK cells account for 30-50% of all liver lymphocytes and are located in the lumen of 
the hepatic sinusoid (Gao et al., 2008; Lotze and Thomson, 2010; Norris et al., 1998). They 
carry out a major part of the hepatic innate immune response by fighting against viruses, 
intracellular bacteria and parasites, and in the defense against primary liver tumors and liver 
metastases (Gao et al., 2008; Racanelli and Rehermann, 2006). Moreover, NK cells are 
important for the recruitment of T and B cells, and neutrophils to the liver, where several 
cytokines and chemokines are involved (Crispe, 2003).  
For the recognition of presented antigens of infected cells, T lymphocytes play an important 
role. In the liver, regarding the classical T lymphocytes, CD8+ T cells outnumber CD4+ T 
cells, which is in contrast to the distribution in the blood, where CD4+ T cells are almost twice 
as much as CD8+ T cells (Crispe, 2003). For the recognition of non-peptide antigens, natural 
killer T (NKT) cells play a pivotal role in the liver. They recognize non-peptide antigen 
targets such as glycolipids in the context of the non-classical antigen-presenting molecule 
CD1d. They contribute to immune responses against bacteria, viruses, and tumors (Kawano et 
al., 1997; Kronenberg, 2005). 
 
Besides antigens from pathogens, food-derived antigens are transported to the liver and taken 
up by APCs and presented to the immune system (Crispe, 2003). Since food-derived antigens 
are constantly present, it is mandatory to avoid an activation of the immune system to prevent 
damage of the liver and other organs (Gershwin et al., 2007c). This is achieved by inhibiting 
the immune system by peripheral tolerance against these antigens (Knolle and Gerken, 2000). 
In the liver, mainly LSECs, but also DCs, NKT cells, and regulatory CD4+ CD25+ T cells 
(Tregs) play an important role for the induction of tolerance towards oral antigens (Gershwin 
et al., 2007c; Kronenberg, 2005; Weiler-Normann and Rehermann, 2004). 
 
This shows that the liver is able to induce an immune response but also maintain peripheral 
tolerance. This intra-hepatic balance between inflammatory and tolerogenic conditions is 
maintained by an intensive crosstalk between the different cells of the liver. For this crosstalk, 
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signal molecules like cytokines and chemokines are essential among other factors. 
Modifications of the cytokine and chemokine secretion can cause a shift in the balance 
between inflammatory and tolerogenic conditions. These modifications play a role in liver 
diseases like HCC, but the exact mechanisms have to be elucidated. Therefore, it is important 
to understand the regulation of cytokines and chemokines and the alterations during disease 
progression especially in HCC. 
 
1.1.2 Hepatic cytokine milieu 
 
The communication between the different hepatic cells is obligatory to maintain a 
coordinative interaction with their environment in order to react immediately when conditions 
change. In this scenario, cytokines and chemokines play an essential role. In general, most of 
the cytokines and chemokines are not constitutively produced and in the liver the normal 
cytokine production is rather at a low level (Gershwin et al., 2007a). Under pathogenic 
stimulation, various cells are activated and release cytokines as a consequence of activation. 
Cytokines are a diverse group of small soluble cell signaling proteins, which are secreted by 
different hematopoietic cells, including lymphocytes, monocytes, and granulocytes in 
response of an activation impulse. Cytokines and their receptors are grouped according to 
their structure. The large cytokine superfamily is separated in the hematopoietic family with 
four alpha-helices, which includes many interleukins (IL), the IL-1 family, gp130 utilizing 
cytokines (IL-6 family), the IL-12 family, the IL-10 superfamily, IL-17, interferons (IFNs) 
and tumor necrosis factor (TNF) superfamily. They are distinct from the chemoattractant 
families, called chemokines (Commins et al., 2010; Janeway et al., 2005). 
Binding of a cytokine to its corresponding receptor on the target cell triggers an intracellular 
signal transduction cascade which leads to proliferation and to a rapid change in gene 
expression. Cytokines act on different cell types and have partly overlapping effects on the 
cell. They play major roles in immunity and inflammation, but also in lymphoid development, 
differentiation, and homeostasis. Many cytokines also regulate cell cycle transition and can 
protect cells from going into apoptosis (Gururaj and Kumar, 2005). 
Several cytokines like IL-2, IL-15, IL-16, IL-21, TNFβ and IFNγ can induce cell-mediated 
immunity, whereas other cytokines like IL-1 receptor antagonist (IL-1RA), transforming 
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growth factor β (TGFβ) and IL-10 are involved in anti-inflammatory effects (Steinke and 
Borish, 2006). 
 
In contrast to cytokines, chemokines play an important role in tissues, especially the liver, 
because they are needed to attract leukocytes subsets to specific tissue sites and, thereby, play 
a pivotal role for the maintenance of the cellular constellation in the liver. Moreover, they 
recruit immune cells to the liver and influence the immune responses including intrahepatic 
inflammation (Oo and Adams, 2010). However, chemokines also play an important role for 
liver regeneration and angiogenesis, but they are also “abused” during tumor development, 
progression and tumor angiogenesis (Keeley et al., 2011; Simpson et al., 2003). During tumor 
development, chemokine secretion is changed in such a way that the balance between 
inflammatory and tolerogenic conditions is shifted to a more tolerogenic microenvironment 
which support tumor growth. One of the key chemokines acting as a double-edged sword is 
CXCL8 (IL-8), which has been shown to recruit immune cells and to promote tumor growth.  
 
Chemokines, which were first named mostly according to their defined function, were newly 
classified according to their structure (Table 1).They are separated into four families, the C, 
CC, CXC and CX3C chemokines, which are based on the position of the conserved first two 
cysteine residues close to the N-terminus (Keeley et al., 2011). Most of them fall into the 
group of CC and CXC chemokines (Table 1). The C and CX3C chemokines only consist of 
one member each, XCL1 (lymphotactin) and CX3CL1 (fractalkine), respectively. The CC and 
CXC chemokines differ from each other that the CC chemokines have two cysteine residues 
lying next to each other, while the CXC chemokines have also two cysteine residues, but 
these are separated by one non-conserved amino acid (Keeley et al., 2011; Simpson et al., 
2003). The CXC chemokines are even further sub-grouped, depending on being ELR-positive 
or ELR-negative (Table 1). ELR is a motif of the three amino acids glutamine (E), leucine (L) 
and arginine (R), which lies immediately next to the CXC motif. 
All chemokines achieve their activities through the binding to specific G-protein-coupled 
seven-transmembrane receptors (GPCR). The difference to other cytokines is that chemokines 
can bind to and therewith activate several related receptors (Table 1) (Platanias, 2005). Many 
chemokines bind to the same chemokine receptor. For example, most ELR-positive 
chemokines bind to the CXC chemokine receptor 1 (CXCR1) and/or CXCR2, while the ELR-
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negative chemokines bind to CXCR3 and some also to CXCR4 (Simpson et al., 2003). The 
most common chemokines and their receptors are listed in Table 1. 
ELR-positive CXC chemokines and several CC chemokines like CCL2 (MCP-1), CCL11 
(Eotaxin) and CCL16 (NCC-4) are potent promoters for the induction of angiogenesis, which 
are also called angiogenic chemokines (Keeley et al., 2011). In contrast, ELR-negative CXC 
chemokines often inhibit angiogenesis (angiostatic). Moreover, the ELR-negative CXC 
chemokines can induce IFNs and promote Th1-dependent immunity by the recruitment of 
CXCR3+ T and NK cells (Keeley et al., 2011). 
 
 
In the liver, many different cytokines, chemokines and growth factors like IFNs, IL-10, 
CXCL8 (IL-8), CXCL10 (IP-10), TGFβ, vascular endothelial growth factor (VEGF) and 
hepatocyte growth factor (HGF) are produced by the liver-resident hepatocytes, APCs and 
cells of the innate and adaptive immune system for the balance of immune response and 
tolerogenic conditions. For example, Kupffer cells, which are important phagocytes in the 
liver, can be secretors of inflammatory cytokines like IL-1, IL-6 and TNFα and chemokines 
like CCL2 (MCP-1), CCL3 (MIP-1α) and CCL5 (RANTES), but also express IL-10 and 
TGFβ in response to LPS (Germano et al., 2008; Gershwin et al., 2007b; Knolle and Gerken, 
2000). Hepatic NK cells can produce IFNγ and at low levels TNFα, but rarely IL-2 (Simpson 
et al., 2003). Through the secretion of IL-10 and TGFβ by Kupffer cells and LSECs, hepatic 
Table 1: CC and CXC chemokine classification and corresponding receptors. 
 
 
CC Chemokines CXC Chemokines
Systemic 
nomenclature Old nomenclature Receptor
Systemic 
nomenclature Old nomenclature Receptor ELR motif
CCL2 MCP-1 CCR2
CCL3 MIP-1α CCR1, CCR5 Angiogenic
CCL4 MIP-1β CCR5 CXCL1 Gro-α CXCR2 +
CCL5 RANTES CCR1, CCR3, CCR5 CXCL2 Gro-β CXCR2 +
CCL7 MCP-3 CCR1, CCR2, CCR3 CXCL3 Gro-γ CXCR2 +
CCL8 MCP-2 CCR2, CCR3, CCR5 CXCL5 ENA-78 CXCR2 +
CCL11 Eotaxin CCR3 CXCL6 GCP-2 CXCR2 +
CCL12 MCP-5 CCR2 CXCL7 NAP-2 CXCR2 +
CCL13 MCP-4 CCR1, CCR2, CCR3 CXCL8 IL-8 CXCR2 +
CCL14 HCC-1 CCR1
CCL15 HCC-2 / leukotactin CCR1, CCR3, CCR5 Angiostatic
CCL16 LEC / NCC-4 CCR1 CXCL4 PF-4 CXCR3 -
CCL17 TARC CCR4 CXCL9 Mig CXCR3 -
CCL18 MIP-4 unknown CXCL10 IP-10 CXCR3 -
CCL20 LARC / MIP-3α CCR6 CXCL11 I-TAC CXCR3/CXCR7 -
CCL21 SLC CCR7
CCL22 MDC CCR4 Others / Unknown 
CCL24 Eotaxin-2 CCR3 CXCL12 SDF-1 CXCR4/CXCR7 -
CCL25 TECK CCR9 CXCL13 BCA-1 CXCR5 -
CCL26 Eotaxin-3 CCR3 CXCL14 BRAK ? -
CCL27 CTACK CCR3, CCR2, CCR10 CXCL15 Lungkine CXCR6 +
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DCs become tolerogenic. These resting DCs can then inhibit the proliferation of tissue-
infiltrating lymphocytes through the expression of inhibitory molecules like CTLA-4 and 
PD-1. When DCs get activated, they downregulate these molecules and migrate to the 
extrahepatic lymph nodes to activate the immune response (Racanelli and Rehermann, 2006). 
 
In general, the cytokine and chemokine microenvironment of the liver plays an important role 
for the recruitment of immune cells. In HCC, the cytokine and chemokine milieu, which is 
important for a good balance of immune response and tolerance, is changed in such a way that 
the tumor can escape the immune system and is able to induce angiogenesis for its own 
oxygen and nutrient supply. The initial alterations can be caused by factors like HBV or HCV 
infection which first lead to cirrhosis and can progress towards to HCC (Figure 1). Although a 
lot of research is performed in this area, surprisingly little is still known about the altered 
cytokine and chemokine milieu during cirrhosis and HCC. Therefore, it is mandatory to 
analyze the cytokine and chemokine milieu in the healthy liver in comparison to liver 
cirrhosis and HCC and the consequences for the recruitment of cells to the liver. The initial 
steps of tumor development which can lead to a change in the cytokine and chemokine milieu 
are often caused by mutations in the cell within central regulators of the signal transduction or 
the cell cycle. These mutations often affect signaling pathways which regulate many cell 
functions including cell proliferation, induction of apoptosis, as well as secretion of cytokine 
and chemokines. Therefore, it is also very important to elucidate how the signaling pathways 
regulate these cellular functions and how they are altered during HCC tumorigenesis. 
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1.2 Hepatocellular Carcinoma  
 
As described at the beginning, hepatocellular carcinoma is one of the most prevalent and 
lethal tumors worldwide with increasing incidences. Due to the lack of treatment options and 
diagnosis at a late unresectable stage, patients with HCC have a very poor survival prognosis. 
As shown in Figure 1, HBV and HCV infections or alcohol intoxication and fat deposition 
can lead to liver fibrosis and cirrhosis, which then can transform into HCC. 
For the development of HCC, a tumor cell or the whole tumor respectively, needs to acquire 
several modifications, which were classified by Hanahan and Weinberg as the hallmarks of 
cancer as depicted in Figure 3 (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
They include sustained proliferative signaling, evasion from growth suppressors, resistance 
against programmed cell death (apoptosis), acquisition of replicative immortality, induction of 
angiogenesis, tissue invasion and metastasis. Moreover, recently the hallmarks were extended 
with two enabling hallmarks, which are genome instability and tumor-promoting 
inflammation, and two emerging hallmarks, which are reprogramming energy metabolism and 
avoiding immune destruction.  
 
 
 
 
Figure 3: Hallmarks of cancer. Hanahan and Weinberg suggested this “hallmark of cancer” in 
2000, which include 6 essential hallmarks. In 2011 they were extended with two enabling 
hallmarks: the genome instability and tumor-promoting inflammation, and the two emerging 
hallmarks: reprogramming energy metabolism and avoiding immune destruction. Figure was 
modified from (Hanahan and Weinberg, 2011). 
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This shows that the development of a tumor like HCC occurs in several steps with frequent 
mutations. Since these mutations often include players of signaling pathways, which are 
important for the regulation of the cell fate, the main altered signaling pathways of HCC are 
described in section 1.2.1. Moreover, tumor cells are altered in such a way that they can 
escape the immune system. Since NK cells play a pivotal role for the elimination of tumor 
cells, their regulation and main function are described in section 1.2.2. As the growth factor 
signaling pathways are often altered or mutated in HCC, they represent a promising target for 
therapy. Section 1.2.3 summarizes potential signaling inhibitors for the treatment of HCC. 
 
1.2.1 Oncogenic signaling in HCC 
 
For the reason that a variety of molecular mechanisms and signaling pathways can be altered 
in hepatocarcinogenesis, it is important to understand the main signaling pathways. In HCC, 
alterations are mostly seen in the growth factor receptor-mediated MAPK (mitogen activated 
protein kinase) signaling pathway (Ras/Raf/MEK/ERK), the wnt/β-catenin pathway and the 
p53 gateway (Aravalli et al., 2008; Breuhahn et al., 2006; Llovet and Bruix, 2008). 
The MAPK signaling cascade (Figure 4) is one of the major pathways implicated in HCC 
(Whittaker et al., 2010). At the time this pathway was elucidated, the groups of Rony Seger 
and Edwin Krebs described the MAPK signaling cascade as an information highway, used by 
many extracellular signals, e.g. growth factors, to trigger intracellular targets mediated by a 
network of interacting proteins that regulate a large number of cellular processes (Seger and 
Krebs, 1995). It is a constitutively present signal transduction pathway that regulates central 
cellular processes, including proliferation, differentiation, angiogenesis and survival (Gollob 
et al., 2006). 
 
The MAPK pathway lies downstream of various growth factors and bind to their 
corresponding receptors at the cell surface, i.e. receptor tyrosine kinases (RTKs), which 
include VEGF receptor (VEGFR), epidermal growth factor receptor (EGFR), fibroblast 
growth factor receptor (FGFR), HGF receptor (HGFR or c-Met) and insulin-like growth 
factor receptor (IGFR) (Figure 4). Upon binding of the growth factor, the receptor dimerizes 
and gets activated by trans-phosphorylation of tyrosine residues. This leads to an activation of 
an adaptor molecule complex composed of growth factor receptor bound 2 (GRB2), SH2 
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domain protein C (SHC) and Son of Sevenless (SOS). The complex, in turn, activates the 
Ras/Raf/MEK/ERK pathway, which releases a cascade of specific phosphorylation events 
(Avila et al., 2006). Within this pathway, activated SOS leads the removal of GDP from a 
member of the inactivated plasma membrane-bound small GTPase Ras subfamily including 
KRas, NRas, and HRas (Friday and Adjei, 2008). Ras can then bind GTP and becomes active, 
while binding of GTP leads to a conformational change of Ras and allows binding and 
activation of different effector molecules like Raf for the MAPK pathway and 
phosphatidylinositol 3-kinases (PI3K) for the Akt pathway (Figure 4). 
 
The lipid kinase PI3K also regulates a number of cellular processes, like transcription, 
migration, angiogenesis, cell growth, proliferation and apoptosis, which, in turn, can play an 
important role in cancer (Osaki et al., 2004). PI3K phosphorylates phosphatidylinositols of 
the cell membrane, e.g. phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 at the cell membrane recruits protein kinases such as Akt, 
which bind with their pleckstrin homology (PH)-domain to PIP3 (Hennessy et al., 2005; 
Tanaka and Arii, 2010; Whittaker et al., 2010). Akt in turn, phosphorylates a variety of 
cellular signaling molecules like MDM2, mTOR and modulates several pro- and anti-
apoptotic molecules. MDM2 can bind to p53 leading to ubiquitination and degradation of p53 
(Figure 4). Phosphorylation of p53 at serine 15, however, protects p53 from MDM2-mediated 
degradation, therefore, the phosphorylation status of these molecules contribute to their 
stabilization and degradation respectively. Alterations in PI3K/Akt signaling components are 
frequent in HCC and thus, contribute to hepatocarcinogenesis (Huynh, 2010; Whittaker et al., 
2010). 
 
In the Raf/MEK/ERK pathway, the serine/threonine kinase Raf, consisting of three main 
isoforms A-Raf, B-Raf and C-Raf, is recruited by one of the Ras proteins to the plasma 
membrane (Whittaker et al., 2010). Raf was shown to bind efficiently to Ras only when Ras 
is bound to GTP, not GDP. It is postulated that Raf is activated through phosphorylation upon 
binding to Ras (Friday and Adjei, 2008). This phosphorylation locks Raf into an activated 
conformation that is then independent of binding to Ras for the continued activity of Raf. 
From Raf, the signal is transmitted via the cascade of MAPK and ERK kinases 1 and 2 
(MEK1/2). MEK1/2 is activated through serine phosphorylation in its activation loop 
(Ser217/Ser221 and Ser222/Ser226). The activated MEKs are dual specificity kinases (act as 
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both tyrosine and serine/threonine kinases) and activate ERK1/2 through phosphorylation of 
threonine and tyrosine residues at Thr202/Tyr204 (ERK1) and Thr185/Tyr187 (ERK2) in the 
activation loop. ERK phosphorylates several substrates in the cytosol and in the nucleus, 
many of them involved in cell proliferation and survival (Keshet and Seger, 2010). 
 
 
 
 
 
Figure 4: MAPK signaling pathway. Extracellular growth factors bind to the receptor tyrosine 
kinase (RTK). This results in Ras activation through the adaptor molecule complex 
GRB2/SHC/SOS, which then can activate Raf and PI3K. Binding of cytokine like MIF to its receptor 
leads to an activation of PI3K and MEKK1-4. Raf phosphorylates and activates MEK, which then 
phosphorylates and activates ERK. PI3K ultimately leads to Akt activation. Stress signals induce 
the activation of JNK and p38 signaling pathway. Several transcription factors like p90RSK, CREB, 
p53, c-Jun and ATF-2 are activated through these signaling pathways leading to cell proliferation or 
apoptosis. P: phosphorylation; RTK: receptor tyrosine kinase; CR: Cytokine receptor; GPCR: G-
protein-coupled receptor. Pathway was generated with the pathway builder from 
www.proteinlounge.com. 
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The p38 and JNK signaling pathways, which also belong to the MAPK family, play an 
important role in the response to stress stimuli, immune responses and inflammation. These 
two cascades are induced by several stress factors and ligands that activate different receptors 
including death receptors, GPCRs and RTKs (Figure 4) (Keshet and Seger, 2010). JNK and 
p38 phosphorylate and therewith activate several transcription factors like ATF-2, ELK-1, 
and c-Jun. p38 also activates p53 and c-Jun, but the activation of c-Jun is controversially 
discussed (Hui et al., 2007; Keshet and Seger, 2010). The duration and intensity of signaling 
pathway activity affects the cellular response to extracellular signals such as growth factors 
for instance. Therefore, it is important to study several pathways in parallel in order to get a 
more comprehensive view on signal events and their consequences for the microenvironment. 
 
The abnormal regulation of these MAPK cascades has been shown to contribute to tumor 
development and other human diseases. It was described that the MAPK expression and 
activity is increased in primary human hepatocellular carcinoma (Schmidt 1997). This 
overexpression or increased activation of components of the MAPK pathway is believed to 
contribute to tumorigenesis, tumor progression and disease metastasis in a variety of solid 
tumors (Leicht et al., 2007). For example, it has been reported that from all tested HCC 
samples, 100% of the MEK1/2 proteins were activated, i.e. constitutively phosphorylated 
(Huynh et al., 2003). 
The increased activation of the Raf/MEK/ERK pathway in solid tumors (HCC) usually occurs 
by two main mechanisms. The first mechanism is mediated by oncogenic mutations within 
the NRas gene primarily, which lead to constitutive pathway activation through Raf (Gollob 
et al., 2006). Oncogenic Ras mutations occur in about 30% of HCC (Downward, 2003; 
Gollob et al., 2006). The second main mechanism for activating the Raf/MEK/ERK pathway 
is a constitutive Raf activation due to overexpression of either growth factors (VEGF, EGF, 
IGF or c-Met) or their receptors (e.g. VEGFR, EGFR, IGFR or c-Met) (Gollob et al., 2006; 
Lachenmayer et al., 2010). Mutations in the Raf gene are only a rare event in HCC as 
compared to other tumors like melanoma or papillary thyroid cancer (Friday and Adjei, 
2008). Since in HCC the MAPK pathway is constitutively activated by these mutations or 
overexpression, it represents a good target for therapeutic intervention. 
 
There are also other genetic changes besides the activation of the MAPK pathway, which are 
involved in the pathogenesis of HCC. The PI3K/Akt pathway is often constitutively activated 
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in HCC, which is mostly due to anomalies of the PTEN function, the inhibitor of Akt 
(Whittaker et al., 2010). This activation of the PI3K/Akt pathway is correlated with a poor 
prognosis in HCC (Schmitz et al., 2008). Additional mutations are found in the tumor 
suppressor gene p53 and in the WNT signaling pathway (Hussain et al., 2007). P53 and its 
family members p63 and p73 are central players for several cellular functions. It is a 
transcription factor that mediates cellular responses to diverse stresses, e.g. DNA damage, 
which include cell cycle arrest, apoptosis, senescence, DNA repair or alteration of metabolism 
(Muller et al., 2006). Therefore, mutations of p53 can often lead to resistance to apoptosis as 
well as to changes in gene expression. 
Besides having a major influence on cell proliferation and apoptosis, the MAPK family, 
PI3K/Akt pathways and the p53 family are involved in the regulation of a broad variety of 
cellular functions like cell differentiation, cell migration and adhesion, cytokine and 
chemokine secretion, and regulation of cell surface molecule expression, which is important 
for the recognition by immune cells. Therefore, it is important to understand the alterations of 
the signaling pathways leading to the development of HCC. 
 
1.2.2 NK cells and the recognition of hepatocellular carcinoma cells 
 
Natural killer (NK) cells, which represent a lymphocytic population, are important players of 
the first line defense in the body, the so-called innate immune system, which is able to kill 
virus-infected or malignant cells. Moreover, NK cells are classified as innate immune effector 
cells because in contrast to T cells they do not need priming for activation and their receptors 
are not generated via the process of somatic recombination. Recent data, however, suggest 
that NK cells also have functions of the adaptive immune system and even may seem to have 
a memory (Paust et al., 2010; Vivier et al., 2011). 
NK cells can kill target cells by cytotoxicity, i.e. secretion of perforins and granzymes, or by 
receptor-mediated apoptosis induction via Fas ligand (CD95L) or Tumor Necrosis Factor 
Related Apoptosis Inducing Ligand (TRAIL). It has been described that a subset of human 
hepatic NK cells may have a reduced effector function, but under appropriate inflammatory 
conditions develops into potent killers (Norris et al., 1998). In another study it could be 
shown that hepatic NK cells can “spontaneously” without prior activation lyse NK-sensitive 
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HLA class I negative K562 target cells (Doherty et al., 1999). Besides their cytotoxic 
functions, NK cells can secrete a variety of pro- and anti-inflammatory cytokines like IFNγ, 
TNFα, GM-CSF and IL-10 and chemokines like CCL3-5, CXCL9 and CXCL10, which leads 
to an indirect modulation of the immune response by shaping the microenvironment (Di 
Santo, 2006). 
 
Human peripheral blood NK cells can be divided into CD56dim CD16+ (~90%) and CD56bright 
CD16- (~10%) NK cells. As described in 1.1.1, NK cells are enriched in the liver tissue and it 
could be shown that the liver comprises a different distribution of CD56dim CD16+ and 
CD56bright CD16- NK cells, but the exact characterization of hepatic NK cells has to analyzed 
(Cai et al., 2008; Moroso et al., 2010). 
 
 
 
 
Figure 5: Activation of NK cells. Normal cells bind both the stimulatory and the inhibitory NK cell 
receptors. Signals delivered through the inhibitory receptors dominate and prevent NK cell 
activation and the lysis of normal cell. Transformed or infected cells downregulate expression of 
inhibitory ligands (“missing self recognition”) and/or up-regulate ligands for activating NK cell 
receptors (“induced-self recognition”) allowing NK cell activation and killing of the target cell. Figure 
was adapted from (Raulet and Vance, 2006). 
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The activity of NK cells is regulated via a large variety of activating and inhibitory receptors 
on their cell surface. This is a tightly regulated balance, because the up- and downregulation 
of the ligand binding to the activating and inhibitory receptor will determine the function of 
NK cells (Figure 5). Negative regulatory receptors on NK cells, that interact with MHC 
ligands and inhibit target cell destruction by NK cells, were first described by Klas Kärre in 
his missing-self hypothesis (Figure 5) (Ljunggren and Karre, 1990). As depicted in Table 2, 
there are several classes of inhibitory receptors with MHC ligands, including the killer cell 
immunoglobulin-like receptor (KIR) family and the CD94/NKG2A complex (Di Santo, 
2006). These inhibitory receptors mostly bind to HLA class I molecules, but do not depend on 
specific peptides presented by HLA class I. This interaction between self MHC and inhibitory 
ligand causes NK cell “tolerance” of HLA class I positive, “self”, cells. The inhibitory 
receptors are each differently expressed by a subset of NK cells and most NK cells have at 
least one inhibitory receptor on their surface. In the disarming model proposed by Raulet, it 
has been described that NK cells that do not have any inhibitory receptors for self-MHC get 
“shut down” or inactivated (“self-tolerance”) (Fernandez et al., 2005). In the licensing model, 
the group of Yokohama describes that NK cells become only functionally competent when 
inhibitor receptors have interacted with self-MHC molecules during NK cell development and 
acquisition of full functional competence (Kim et al., 2005). In another model, the group of 
Vivier postulated that NK cells require an education to complete their development (Anfossi 
et al., 2006). In this model, NK cells only reach their full competence if they receive a signal 
by an inhibitory receptor binding to a self-MHC-molecule. 
Table 2: Human activating and inhibitory NK cell receptors. 
Table was adapted and modified from (Ljunggren and Malmberg, 2007). 
 
Receptors Cellular ligands Receptors Cellular ligands
Activating receptors Inhibitory receptors
NKG2D ULBP1-6, MICA and MICB KIR2DL2 / KIR2DL3 HLA-C1 group
CD94/NKG2C HLA-E KIR2DL1 HLA-C2 group
NKp30 B7-H6 KIR3DL1 HLA-Bw4
NKp44 ND KIR3DL2 HLA-A3 and HLA-A11
NKp46 HA CD85j/LIR-1/ILT-2 several HLA class I molecules
NKp80 AICL KLRG1 Cadherins
DNAM1 (CD226) CD155 (PVR) and CD112 (nectin-2) NKR-1A (CD161) LLT1
CD96 CD155 (PVR) and CD112 (nectin-2) CD94/NKG2A HLA-E
CD16 (FcγRIIIA) IgG siglec 7/9 sialic acid
KIR2DS1 HLA-C2 group
KIR2DS2,3 HLA-C1 group Receptors with dual functions
KIR3DS1 ND 2B4 CD48
KIR2DS4 HLA-C1 group NTB-A NTB-A
CD2 LFA-3 (CD58) KIR2DL4 HLA-G (soluble)
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Besides the variety of inhibitory receptors, there are also several activating receptors (Table 
2), because loss of the ligands for the inhibitory receptor is not always sufficient to trigger full 
NK cell activation. The activating receptors consist of NKG2D, DNAM-1, the CD94/NKG2C 
complex, the activating part of the KIR family and the natural cytotoxicity receptors (NCR, 
NKp46, 44, 30). These receptors recognize a variety of different ligands on target cells which 
are in part higher expressed on infected, transformed and stressed cells or are derived from 
pathogens (Figure 5). However, several ligands for these receptors are still unknown. The 
NKG2D receptor binds to MHC class I like ligands, which consist of eight molecules: 
MICA/B and ULBP1-6 (Eagle et al., 2009a; Eagle et al., 2009b; Nausch and Cerwenka, 
2008). These are stress induced ligands, which are usually not expressed or only to a low level 
on healthy cells. During infection or malignant transformation, these ligands are expressed at 
the cell surface and can be recognized by NK cell through NKG2D. This binding triggers lytic 
activity as well as the production of cytokines. Another important activating receptor is 
DNAM-1 (CD226), which binds to CD155 (polio-virus receptor, PVR) and CD112 (Nectin-
2). These ligands are expressed by several tumors like HCC. 
In general, NK cell triggering occurs through an imbalance of stimulating and inhibitory 
ligands (Figure 5). In this setting, cytokines and costimulatory molecules are also important 
for the regulation of NK cell activity (Carayannopoulos and Yokoyama, 2004). Tumor cells 
or virus-infected cells often lose or downregulate their MHC class I molecules in order to 
evade cytotoxic T cell response, which requires the peptide / MHC class I complex for 
recognition and subsequent activation. NK cells are in some situations important to fight 
against the tumor also through direct killing of the tumor cells. It has been reported that 
hepatic NK cells show higher cytotoxicity against tumor cells than peripheral blood or splenic 
NK cells (Gao et al., 2008). This observation underlines the difference between peripheral 
and hepatic NK cells both in phenotype and function, also in the human situation (Moroso et 
al., 2010). Of note, tumor cells and virus-infected cells have evolved mechanisms to avoid 
recognition and killing by NK cells. It was described that NK cells of patients with HCC have 
a reduced activity and HCV-infected hepatocytes can escape NK cells by inhibition of NK 
cell function (Cai et al., 2008; Deignan et al., 2002). Because NK cells are very important for 
fighting against tumor cells, the exact alterations of hepatic NK cells in cirrhotic and tumor 
tissue and the tumor evasion mechanisms of HCC against NK cells have to be analyzed in 
more detail. In consequence, tumor therapy is not only performed by influencing the tumor 
cells alone, but also needs to be analyzed in the content of the whole microenvironment. It is 
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still unknown, to what extent HCC treatment by small molecules, for instance, is influencing 
the immune system, the microenvironment and especially the killing capacity of hepatic NK 
cells towards tumor cells. In this hepatic environment, the tissue contribution to the local 
milieu in this organ should not be underestimated. 
 
 
1.2.3 Overview of immunological and signaling treatment options 
 
As described above, HCC is often diagnosed at an unresectable stage and chemotherapy has 
failed for HCC treatment. Therefore other treatment options are needed for HCC therapy. As 
one of the central players in hepatocarcinogenesis, the MAPK signaling pathway has been a 
focus of intense research for therapeutic targeting (Friday and Adjei 2008). Therefore, a 
number of new drugs, mostly small molecules or monoclonal antibodies, which target 
molecules involved in HCC tumorigenesis, are under clinical investigations (Greten et al., 
2009; Huynh, 2010). The multikinase inhibitor sorafenib (Nexavar) is the first and so far only 
approved small molecule for the treatment of advanced HCC. In a randomized phase III 
double-blind placebo-controlled clinical trial (SHARP trial), it was shown that patients with 
advanced HCC had an increased median overall survival of about three months when they 
were treated with sorafenib compared to the control group (Llovet et al., 2008). Sorafenib 
inhibits B-Raf and C-Raf, but also the autophosphorylation of several receptor tyrosine 
kinases like VEGFR1,2 and 3, FGFR1, platelet-derived growth factor receptor (PDGFR), 
c-kit and others, making it a broad acting substance (Figure 6) (Wilhelm et al., 2006; Wilhelm 
et al., 2004). It has been reported that sorafenib induces antitumor effects in HCC through the 
inhibition of angiogenesis, which is done by the blockage of the receptor tyrosine kinases. In 
addition, sorafenib inhibits cell proliferation and induces apoptosis of the tumor cells 
(Whittaker et al., 2010). Although several mechanisms of sorafenib antitumor activity have 
been revealed, many are still unclear and need to be discovered. 
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Besides multikinase inhibitors, also selective inhibitors are currently tested. Erlotinib is a 
specific inhibitor of EGFR and it was observed that it clinically mainly stabilized HCC 
disease. Monoclonal antibodies are also being tested for the treatment of HCC like 
bevacizumab (Avastin), which is directed against VEGF and has been approved for several 
other tumors (Greten et al., 2009). 
There are also some rather new specific inhibitors tested for targeting the MAPK pathway. 
Among different MEK inhibitors, AZD6244 (Selumetinib) showed high potency of MEK1/2 
inhibition and good efficacy in in vitro and in vivo models (Yeh et al., 2007). Currently, 
AZD6244 is tested in a phase II study for advanced or metastatic hepatocellular carcinoma. 
Another potent MEK inhibitor is PD0325901, which has shown promising results with 
decrease growth in HCC in vitro and in mouse model systems (Hennig et al., 2010). 
For the treatment of other tumors like melanoma, also mutant-specific inhibitors like the 
B-RafV600E inhibitor has been developed (Tsai et al., 2008). PLX4720 has been described has 
a specific inhibitor of B-Raf and the mutant V600E form. For melanoma treatment it is under 
clinical evaluation and shows promising effects, but there are also some reports which 
describe that PLX4720 can have some adverse effect with increase of the MAPK pathway and 
cell proliferation (Heidorn et al., 2010; Poulikakos et al., 2010). Its effect for the treatment of 
HCC has not yet been performed. 
Besides single agent therapy, there are also several clinical and pre-clinical trials for the 
combination of sorafenib with other targeted and cytotoxic drugs. Sorafenib is currently tested 
in a randomized phase III study for the treatment of HCC in combination with the 
chemotherapeutic agent doxorubicin (Abou-Alfa et al., 2010). 
The testing of variety of drugs shows that the development of effective therapies for HCC is 
very important. But still, extensive research has to be performed to fully understand the 
mechanisms of action of the therapeutic drug and the reasons why there is such a remarkable 
discrepancy between experimental efficacy of a drug and its clinical success in terms of 
disease free survival or overall survival.  
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2 Goals of the Thesis 
 
Therapy options for unresectable hepatocellular carcinoma are very poor with the multikinase 
inhibitor sorafenib being the only effective treatment. It shows survival benefits for HCC 
patients, however unresectable HCC cannot be cured by sorafenib treatment. In order to 
improve HCC treatment, it is of particular importance to understand the mechanism of the 
action of sorafenib especially in comparison with other MAPK inhibitors. In the long run, this 
will help to improve drug development and drug administration. Regarding this big problem 
for HCC therapy, a comprehensive analysis of the effects of sorafenib and other MAPK 
inhibitors was performed on HCC cells and tissues in my thesis and had the following goals: 
 
1. In HCC, the MAPK pathway is often permanently activated, suggesting a pivotal role 
for this pathway in tumor development. This activation is often due to a mutation in 
upstream molecules of the cascade. Thus, targeting the MAPK pathways seems to be a 
potential target for the treatment of HCC. Several small molecules are under clinical 
evaluation for HCC. In my thesis, I analyzed the currently used multikinase inhibitor 
sorafenib with potential new MAPK inhibitors such as MEK inhibitors U0126, 
AZD6244 and PD0325901, and a new mutation specific B-Raf inhibitor PLX4720 for 
HCC treatment regarding their mechanism of action. Since in many tumor lines, 
additional pathways are usually activated, I unraveled the effects of the different 
MAPK inhibitors on several other signaling pathways. Moreover, inhibitors were 
compared for their potency regarding the inhibition of cell proliferation and induction 
of apoptosis, which are important requirements of effective anti-tumor drugs. 
 
2. Many surface molecules, also those which are important for cell-cell interaction and 
recognition by the immune cells, are regulated by the MAPK and closely linked 
pathways. Because these signaling pathways are often activated in HCC, I investigated 
the differences in surface molecules between HCC cell lines. Moreover, I determined 
whether treatment of HCC cells with MAPK inhibitors can alter the surface molecule 
expression in such a way that the tumor cell recognition and killing by NK cells is 
modulated. Due to the dependency on the chemokine and cytokine milieu for the 
infiltration of immune cells into the tumor, I examined the proportion of NK and T 
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cells in cirrhotic and HCC liver tissue in comparison to healthy liver. The secretion of 
cytokines, chemokine and growth factors are often regulated by the MAPK or related 
signaling pathways. Especially in HCC, many chemokines and growth factors are 
upregulated by the tumor cells. In my work, the secretion of chemokines and growth 
factors was analyzed in HCC cell lines and tested whether inhibition of the MAPK 
pathway by several MAPK inhibitors is able to alter the chemokine and growth factor 
secretion. 
 
3. In the liver, the cytokine and chemokine microenvironment play an important role for 
the recruitment of immune cells and for organ function, in general. In hepatocellular 
carcinoma, the cytokine and chemokine milieu, which is important for a good balance 
of immune response and tolerance, seems to be changed in such a way that the tumor 
can escape the immune system and is able to induce angiogenesis. In a comprehensive 
analysis, I unraveled the alterations of the cytokine, chemokine and growth factor 
milieu in cirrhotic and HCC tissue in comparison to healthy liver tissue. In addition, I 
aimed to define the consequences of MAPK inhibition on the microenvironment.  
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3 Materials 
 
3.1 Cell Culture 
3.1.1 Media 
 
Table 3: Medium for cell culture. Medium used for cultivation of primary cells and cell cultures. 
NEAA: Non-Essential Amino Acids; FBS: Fetal Bovine Serum 
 
Cell medium Composition 
RPMI III RPMI 1640, 2 mM L-Glutamin, 1 mM Na-Pyruvat, 1x NEAA 
TM RPMI 1640, 10% FBS, 2 mM L-Glutamin, 1 mM Na-Pyruvat, 1x NEAA 
HepG2 medium DMEM, 10% FBS, 2 mM L-Glutamin, 1x NEAA, 1x HEPES buffer, 1x Gentamycin 
Hep3B medium MEM, 10% FBS, 2 mM L-Glutamin, 1x HEPES buffer, 1x Gentamycin 
Huh-7 medium DMEM, 10% FBS, 1x Pen/Strep 
primary NK cell medium RPMI III, 500 U/ml IL-2 
NKL medium RPMI III, 5% T cell growth factor (AG Falk), 15% FBS, 5% human serum, 100 U/ml IL-2 
NK92 medium RPMI 1640, 5% T cell growth factor (AG Falk), 15% FBS, 10% human serum, 200 U/ml IL-2 
 
 
3.1.2 Cell lines 
 
Table 4: Cell lines. 
 
Name Origin Medium Source 
HepG2 
Human hepatoblastoma cell line from 15 year old 
caucasian male adolescent; 
NRas-mutant (Q61L); β-catenin mutant 
HepG2 medium 
 M. Müller-Schilling 
(University Hospital 
Heidelberg) 
Hep3B 
Human hepatocellular carcinoma cell line from a 8 year 
old black male juvenile;  
p53-/-; contains an integrated hepatitis B virus genome 
Hep3B medium 
 M. Müller-Schilling 
(University Hospital 
Heidelberg) 
Huh-7 
Human hepatocellular carcinoma cell line from a 57 
year old Japanese male adolescent; 
p53 mutant (Y220C) 
Huh-7 medium 
M. Müller-Schilling 
(University Hospital 
Heidelberg)  
K562 Human erythroleukemia line, HLA class I negative TM D. Schendel (HZGU) 
NK92 Human NK cell leukemia line NK92 medium M. Uhrberg (University Düsseldorf) 
NKL Human NK cell leukemia line NKL medium M. Lopez-Botet (UPF Barcelona, Spain) 
 
 
RPMI 1640, DMEM, MEM, FBS, L-glutamine, sodium-pyruvate, 10x Pen/Strep, 10x HEPES 
buffer, 10x gentamycin and non-essential amino acids were purchased from Invitrogen. Cell 
lines have been tested for mycoplasma contaminations at least once a month.  
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3.2 Antibodies 
 
Table 5: Primary antibodies. Antibodies used for direct or indirect flow cytometry. BD: Beckton 
Dickinson, BC: Beckman Coulter 
 
Antigen Conjugation Isotype Clone Concentration Source 
Isotype control - IgG1 MOPC21  5 µg/ml Sigma 
Isotype control - IgG2a UPC10  5 µg/ml Sigma 
Isotype control - IgM MOPC104E  5 µg/ml Sigma 
HLA class I - IgG2a W6/32 hybridoma 
supernatant J.Johnson 
HLA-A2 + B17 - IgG1 HB54 hybridoma 
supernatant ATCC 
HLA-A24 -  IgM   5 µg/ml  One Lambda Inc.  
HLA-DR -  IgG L243 hybridoma 
supernatant J. Johnson  
ULBP1 - IgG2a 170818 5 µg/ml  R&D  
ULBP2 - IgG2a 165903 5 µg/ml R&D  
ULBP3 - IgG2a JFY02 5 µg/ml R&D  
ULBP4 - IgG2a 7H7, Ratte hybridoma 
supernatant E. Kremmer 
MICA - IgG2b 159227 5 µg/ml R&D  
MICB - IgG2b 236511 5 µg/ml R&D  
ICAM-1 - IgG2a   hybridoma 
supernatant J. Johnson 
LFA-3 -  IgG   hybridoma 
supernatant J. Johnson  
CD155 - IgG1 PV.404 5 µg/ml BC 
Apo1 - IgG2a AHO0152 5 µg/ml Invitrogen 
TRAIL-R2 -  IgG1 HS201  5 µg/ml M. Müller-Schilling  
TNF-R1 -  IgG1 16803  5 µg/ml M. Müller-Schilling 
Isotype control FITC IgG2b MOPC19 2 µl BD 
Isotype control PE IgG2a 7T4-1F5 2 µl BC  
Isotype control PerCP IgG2a X39 2 µl BD 
Isotype control APC IgG2a X39 2 µl BD 
CD3 FITC IgG1 UCHT1 2 µl BC 
CD4 APC IgG1 13B8.2 2 µl BC 
CD6 PE IgG1 M-T605 2 µl BD 
CD8 PE IgG1 B9.11 2 µl BC 
CD16 FITC, Pacific Blue IgG1 3G8 2 µl BC 
CD25 FITC IgG2a B1.49.9 2 µl BC 
CD44 FITC IgG1 37.51.1 2 µl BC 
CD56 APC,  IgG1 NKH-1 2 µl BC 
CD107a FITC, PE IgG1 H4A3 10 µl BD 
CD166 PE IgG1 3A6 2 µl BC 
c-Met APC IgG1 95106 4 µl R&D Systems 
 
 
Table 6: Secondary antibodies. Secondary antibodies used for indirect flow cytometry. 
 
Antigen Conjugation Species Concentration Source 
αMaus-IgG PE goat 1:100 Jackson ImmunoResearch 
αMaus-IgG/M PE goat 1:100 Jackson ImmunoResearch 
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Table 7: Western blot antibodies. Primary and secondary antibodies used for western blot. 
 
Antigen Conjugation Clone Isotype Source 
Mouse anti-human p53 - DO-1 IgG2a Invitrogen 
Mouse anti-human p63 (4A4) - sc-8431 IgG2a Santa Cruz Biotechnology 
Mouse anti-human p73 - GC15 IgG Upstate Biotechnology / Millipore 
Rabbit anti-human Mcl-1 (S-19) - sc-819 IgG Santa Cruz Biotechnology 
Rabbit anti-human Bcl-x - E18 IgG Epitomics 
Mouse anti-human β-actin - B11V08 
 
Promokine 
Goat anti-mouse IgG Peroxidase 
  
Jackson ImmunoResearch 
 
 
 
 
 
3.3 Buffers, Chemicals, Reagents and Special Machines 
 
Table 8: Sub-G1 method. 
 
Sub-G1 Method Components, Source 
Nicoletti buffer 0.1% sodium citrate, 0.1% Triton X-100, pH 7.4 
PBS Invitrogen 
Propidium Iodide Sigma 
 
 
Table 9: Western blot buffers. 
 
Western Blot Components, Source 
Gel electrophoresis running buffer NuPage MOPS SDS running buffer 20x NP0001 
10x transfer buffer 120 mM Tris base, 960 mM glycine 
1x transfer buffer 10% 10x transfer buffer, 20% methanol, 70% water 
6x Laemmli buffer 150 mM Tris-HCl, pH 6.8, 6% SDS, 30% glycerine, 0.15% bromphenolblue, 0.3 M DTT 
Blocking buffer PBS, 0.1% Tween 20, 5% non fat dried milk, AppliChem A0830 
Wash buffer PBS, 0.05% Tween 20 
First antibody dilution buffer PBS, 5% BSA fraction V, 0.2% Tween 20 
Second antibody dilution buffer PBS, 2.5% nonfat dried milk, 0.1% Tween 20 
Precision Plus Protein Standards All Blue Bio-Rad 161-0373 
Super Signal West Dura Extended Duration 
Substrate Thermo Scientific 34075 
 
 
Table 10: Bio-Plex. Buffers, cytokines and filter plates. 
 
Cytokine multiplex measurements Source 
Reagent Kit A (wash buffer, assay buffer, detection antibody diluents) Bio-Rad 
Human cytokine tests: 
Bio-Rad 
IL-1β, IL-RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, Eotaxin, 
FGF basic, G-CSF, GM-CSF, IFNγ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-bb, RANTES, TNFα, 
VEGF, CTACK, Gro-α, HGF, ICAM-1, IFN-α2, IL-2Rα, IL-3, IL-12(p40), IL-16, IL-18, LIF, MCP-3, 
M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF-1α, TNFβ, TRAIL, VCAM-1, IL-1α 
96-well filter plates Millipore 
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Table 11: Phosphoplex. 
 
Phosphoprotein multiplex measurements Source 
Cell lysis kit + protease inhibitors Bio-Rad 
PMSF (Phenylmethylsulfonfluorid) Sigma 
Phosphoprotein reagent kit Bio-Rad 
96-well filter plates Millipore 
Total-protein tests: 
Bio-Rad 
Akt, p53, IκB-α, ATF-2, c-Jun, ERK1/2, JNK, MEK1, p38 MAPK, CREB 
Phospho protein tests: 
Bio-Rad Akt (Ser473), GSK-3α/β (Ser21/Ser9), p53 (Ser15), IκB-α (Ser32/Ser36), NF-κB p65 (Ser536), 
ATF-2 (Thr71), c-Jun (Ser63), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), JNK (Thr183/Tyr185), 
MEK1 (Ser217/Ser221), p38 MAPK (Thr180/Tyr182), CREB (Ser133) 
 
 
Table 12: ELISA. 
 
ELISA Source 
TGFβ RnD Systems #DY240 
MICA RnD Systems #DY1300 
MICB RnD Systems #DY1599 
Substrate solution RnD Systems #DY995 
Stop solution RnD Systems #DY994 
96-well plates NUNC 
 
 
Table 13: MAPK inhibitors. 
 
MAPK Inhibitors Source 
DMSO (solvent) Sigma (#472301) 
Sorafenib (Nexavar, BAY 43-9006) Bayer AG 
PLX4720 Selleck Chemicals (#S152) 
U0126 Promega (#V1121) 
AZD6244 (Selumetinib, ARRY-142886) Astra Zeneca / Selleck Chemicals (#S1008) 
PD0325901 Selleck Chemicals (#S1036) 
 
 
Table 14: Special machines. 
 
Special machines Source 
xCELLigence system: RTCA-DP, E-Plate-16 Roche Diagnostics 
Luminex 100 system  Bio-Rad 
FACS Calibur BD 
FACS LSR II BD 
ELISA Reader TECAN sunrise TECAN 
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4 Methods 
4.1 Cell Culture 
 
Cells were cultured in an incubator at 37°C with 5% CO2. In general, cells were frozen in 
50% FBS, RPMI III, 10% DMSO at -80°C. FBS was inactivated by incubation at 56°C for 
45 minutes (min).  
 
4.1.1 Cultivation of adherent and suspension cells 
Adherent tumor cells (HepG2, Hep3B and Huh-7) were split every two to three days using 
trypsin/EDTA for 5 min at 37°C to detach cells. The proteolytic cleavage reaction by trypsin 
was stopped by adding new FBS containing medium to the cells. For cells in suspension, new 
medium was added every two to three days. 
The three cell lines HepG2, Hep3B and Huh-7 were used as an in vitro model system for 
HCC. These cell lines have been used for the analysis of functional features of liver cells, 
because they have different mutations. The hepatocellular carcinoma in different patients 
shows a molecular diversity (Hoshida et al., 2010; Zucman-Rossi, 2010). HepG2 cells, which 
derived from the liver tissue of a 15 year old Caucasian American male with a well 
differentiated hepatocellular carcinoma, have a mutation in NRas (Q61L) leading to a 
constant activation of the MAPK pathway. The Hep3B cells, which were derived from a HCC 
of an 8 year old black male, have a deletion of p53 and are often used to analyze the effects of 
p53. Huh-7 cells, which were derived of a well differentiated HCC of a 57-year-old Japanese 
male, have a gain of function mutation in p53 (Y220C) leading to a lack of p53 transcriptional 
activity and more resistance to apoptosis (Muller et al., 1998). Not much is known about the 
p53 (Y220C) mutation. It has been described by the group of Brachmann that the mutant p53 
(Y220C) is uniquely localized to the cytoplasm in H1299 cells (Baroni et al., 2004). These 
results suggest that p53 (Y220C) is not functional in activating p53 target genes. 
 
 
4.1.2 Isolation of peripheral blood mononuclear cells (PBMCs) 
Isolation of PBMCs from blood of healthy donors or patients with HCC was performed using 
the polysaccharide Ficoll (Biochrom AG), which has a density of 1077 mg/ml (Noble and 
Cutts, 1967). Thus, the components of the blood were separated by Ficoll gradients according 
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to their density during centrifugation. The blood, which was collected in EDTA of heparin 
collection tubes, was diluted with PBS at a ratio of 1:2 and slowly placed on 15 ml Ficoll in a 
50 ml tube. Then, the tube was centrifuged at 840 g for 25 min without brake. This caused the 
separation of the blood components according to their densities. PBMCs were in the white 
interphase, which can be found between the above blood plasma and the below Ficoll 
solution, and transferred into a fresh 50 ml tube and centrifuged. To remove the remaining 
erythrocytes, cell pellet was incubated with erythrocyte lysis buffer for 5 min at room 
temperature (RT). After two washing steps with PBS, cells were resuspended in RPMI III and 
cell number was determined by trypan blue staining and counting the living cells under the 
microscope. 
 
4.1.3 Isolation of NK cells from PBMCs 
NK cells from PBMC were isolated using the magnetic Dynal-bead untouched human NK 
cells kit (Invitrogen/Dynal). The NK cells were isolated according the manufacture´s 
protocol. In principle, a mixture of biotinylated monoclonal antibodies against the non-NK 
cells was added to PBMC. During a short incubation time, the depletion MyOne SA 
Dynalbeads bound the non-NK cells. The bead-bound cells were then separated from NK 
cells with a magnet. Bead-bound cells were discarded, and the remaining untouched NK cells 
used for further experiments. Purity of the NK cell fraction was checked by flow cytometry 
with CD3 and CD56 staining. 
 
 
4.1.4 Treatment of hepatocellular carcinoma cells with MAPK inhibitors 
The MAPK signaling pathway in HCC cell lines was inhibited by using small molecule 
inhibitors. Five different inhibitors were used: sorafenib, PLX4720, U0126, AZD6244 and 
PD0325901 (Figure 7). 
 
Sorafenib, also called Nexavar (Bayer AG), inhibits C-Raf (Raf-1), wild-type B-Raf, mutant-
specific B-RafV600E and receptor tyrosine kinases (e.g. VEGFR-2,3; PDFR-b, Flt-3 and c-KIT), 
which leads to inhibition of MEK/ERK signaling  (Gollob et al., 2006; Wilhelm et al., 2004). 
One pill of sorafenib (tosylated 200 mg, Bayer AG) was solved in 31.4 ml DMSO (stock 
solution, 10 mM) and used at final concentrations between 0.5 and 15 µM, as indicated in 
figure legends. 
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PLX4720 (Selleck Chemicals) preferentially inhibits mutated B-RafV600E and with lower 
affinity to wild-type B-Raf (Tsai et al., 2008). It is solved in DMSO (stock solution, 10 mM), 
and used at final concentrations between 2.5 and 10 µM. 
 
U0126 (Promega) binds MEK1/2, inhibiting its catalytic activity and therefore activation of 
downstream kinases ERK1/2 (Favata et al., 1998). It is solved in DMSO (stock solution, 
10 mM), and used at final concentrations between 2.5 and 15 µM.  
 
AZD6244, also called selumetinib or ARRY-142886 (Astra Zeneca and Selleck Chemicals), 
is a selective, non-ATP competitive inhibitor of MEK1/2 and therefore activation of ERK1/2 
(Davies et al., 2007). It is solved in DMSO (stock solution, 10 mM), and used at final 
concentrations between 2.5 and 15 µM.  
 
PD0325901 (Selleck Chemicals) is non-competitive with ATP and is specific and highly 
potent against MEK1/2 and therefore activation of ERK1/2 (LoRusso et al., 2010). It is 
solved in DMSO (stock solution, 10 mM), and used at final concentrations between 5 and 
10 µM. 
 
 
 
 
Figure 7: Chemical structures of MAPK inhibitors. (A) B-Raf inhibitors. (B) MEK inhibitors. 
Chemical structures were drawn with ISIS Draw 2.1.4. 
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In order to analyze short-term as well as long-term effects of MAPK inhibition, the following 
time points were chosen for analysis: 0, 30 min, 6, 12, 24, 48, 72 and 96 hours (h). 1x105 
HepG2, Hep3B and Huh-7 cells were seeded in 6-well plates, one 6-well plate for each time-
point. Cells were seeded the day before treatment and allowed to adhere and grow for about 
24 h. For treatment with MAPK inhibitors, the medium was discarded and 1.5 ml of the drug-
containing medium was added. In addition to the inhibitors, cells were cultured in medium 
only and treated with DMSO as controls. Since most of the inhibitors are not stable and get 
degraded at 37°C, medium was changed after 48 h of treatment. After the respective 
incubation times, we harvested cell culture medium supernatants for the detection of 
chemokines and growth factors and lysed the cells using the cell lysis kit for phospho-protein 
detection (Bio-Rad). 
For flow cytometry analysis, cells were seeded in 10 cm cell culture dishes 24 h before 
treatment. Then, medium was discarded and medium with inhibitors and DMSO control was 
added. After their respective incubation time, supernatant was collected and cells detached 
using trypsin/EDTA. 
 
 
4.1.5 Preparation of protein lysates 
We used the cell lysis kit (Bio-Rad) for the preparation of tumor cell lysates, because this 
lysis procedure maintains the binding site for both, capture and detection antibody. The 
treatment with different small molecule inhibitors of the MAPK pathway was performed as 
described above. After treatment, the supernatant was collected for cytokine and chemokine 
detection, and cells were washed with 2 ml ice-cold PBS per well. After adding 150 µl cold 
lysis buffer to each well, cells were detached with a cell scraper and lysates were transferred 
to 1.5 ml microcentrifuge tubes. Next, the tubes were incubated during gentle rotation at 4°C 
for 20 min, and then shock-frozen at -80°C to increase cell digestion. After thawing the 
lysates on ice, they were centrifuged at 15,000 g for 20 min at 4°C. The supernatants were 
transferred to new tubes, and stored at -80°C. 20 µl lysate were used for detection of total 
protein concentrations. 
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4.1.6 Determination of protein lysate concentrations and adjustment to assay 
concentrations 
For the determination of protein concentration, we used the Pierce BCA Protein Assay Kit 
(Thermo Scientific). A standard dilution series using bovine serum albumin (BSA) was 
prepared. 10 µl of each standard dilution or sample was pipetted into a 96-well microtiter 
plate well in duplicates. 200 µl of the working reagent were added to each well, and mixed on 
a plate shaker for about 30 seconds (sec). The plate was covered and incubated at 37°C for 
30 min. After the incubation time, the plate was cooled down to RT and the absorption was 
measured at 562 nm with an ELISA reader (TECAN sunrise). The Magellan software of the 
ELISA reader calculated the concentration of the protein lysates using the standard curve with 
a 4 parameter Marquardt algorithm. Protein concentrations were set to the lowest measured 
concentration amongst all lysates within one group, diluted with human serum diluent for the 
detection of cytokines and with assay buffer and lysis buffer in a 1:1 dilution for the detection 
of phosphorylated proteins. 
 
 
4.2 Tissue Preparation 
 
4.2.1 Preparation of tissue lysates 
For generation of tissue lysates we also used the cell lysis (Bio-Rad). Depending on the tissue 
size, 250 to 500 µl ice-cold lysis buffer were added to a 1.5 ml microcentrifuge tube. Frozen 
liver tissue was placed into a Petri dish, which lies on an ice-cold metal block. A small piece 
was cut off the frozen tissue sample and the rest was stored again at -80°C. The small tissue 
piece was chopped up as much as possible and transferred into the microcentrifuge tube 
containing the lysis buffer. After vortexing, the tissue was shock-frozen at -80°C to increase 
cell digestion. Thawing the lysates on ice, they were put in a cold ultrasonic bath (Bandelin 
electronics) for 10 min. To increase cell lysis, lysates were pipetted up and down. After 
repeated shock-freezing and thawing on ice, tissue lysates were ultrasonicated again and then 
centrifuged at 15,000 g for 20 min at 4°C. The supernatant was transferred into a new tube, 
and stored at -80°C. 20 µl lysate was used for detection of total protein concentrations as 
described above. 
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4.2.2 Isolation of liver lymphocytes 
Liver lymphocytes were isolated according to Morsy et al. 2005. Freshly isolated hepatic 
tissue was washed once with HBSS medium (Invitrogen) to remove the remaining blood. The 
tissue was gently chopped up with a sterile blade into small pieces (1-2 mm³) and transferred 
into a 50 ml tube with HBSS-containing collagenase (500 mg/l (312 U/mg)), DNase I 
(50 mg/l) and FBS (2%). The tissue suspension was incubated at 37°C for 30 to 60 min and 
then passed through a 30 mm nylon mesh filter to remove cell clumps and undissociated 
tissue. To increase the amount of cells, a plunger from a 20 ml syringe was used to dissociate 
the tissue further. The nylon mesh was washed three times with HBSS medium. The filtered 
suspension was centrifuged at 500 g for 10 min at 4°C and the cell pellet washed twice in 
HBSS. To remove hepatocytes, the final pellet was resuspended in HBSS and centrifuged at 
36 g for 1 min at 4°C. The resulting supernatant was transferred into a new 50 ml tube. The 
supernatant was centrifuged once again at 500 g for 10 min at 4°C. The pellet was 
resuspended in 15 ml HBSS medium and slowly added on 15 ml Ficoll in a 50 ml tube and 
centrifuged at 840 g for 25 min without brake. The white interphase containing the liver 
lymphocytes was transferred into a new tube and washed with HBSS medium. The pellet was 
resuspended in TM medium containing 100 U/ml IL-2, counted and a fraction was used for 
flow cytometry staining. 
 
 
4.2.3 Ex vivo treatment of liver tissue samples  
Explants from freshly isolated liver of HCC individuals were divided into small pieces, each 
having the same size, under sterile conditions and incubated with 1 ml medium with and 
without 5 µM sorafenib, PLX4720, U0126, AZD6244 or PD0325901 for 8 h at 37°C. After 
treatment, supernatants were transferred into 1.5 ml tubes and stored at -80°C until multiplex 
and ELISA analysis. 
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4.3 Flow Cytometry 
 
4.3.1 Principle of flow cytometry 
Flow cytometry is used to simultaneously analyze large numbers of cells regarding to their 
size, granularity and surface expression of fluorescently stained molecules. 
As a cell passes through the laser beam, it refracts or scatters light and subsequently is 
detected in two modes (forward and sideward scatter, FSC and SSC). FSC represents the 
amount of light that is scattered in the forward direction as laser light strikes the cell. The 
magnitude of forward scatter is roughly proportional to the size of the cell. SSC captures 
granularity and structural complexity of cells. Therefore, the cell size and the viability of the 
cells can be measured in these modes (Robinson, 2004). Moreover, fluorescent dyes or 
fluorochrome-labeled antibodies can be used to mark extrinsic properties of cells, which make 
it possible to distinguish between different cell populations, e.g. lymphocytes, monocytes and 
granulocytes, and to analyze membrane-expressed or intra-cytoplasmic molecules. Several 
dyes can be separated with one measurement. Since large numbers of cells are analyzed in a 
short time, statistically valid information about cell populations are quickly obtained 
(Robinson, 2004). 
 
Flow cytometry analysis was used to characterize surface expression of ligands for NK and T 
cells, and adhesion molecules on hepatocellular carcinoma and hepatoma cell lines. In 
addition, PBMCs and subpopulations of hepatic lymphocytes were analyzed. HLA class I 
expression, CD155 expression and various other markers were used in indirect staining FACS 
assays to identify changes in surface expression following exposition to MAPK inhibitors. 
For cytotoxicity assays with NK cells, it was necessary to define the NK cell population, and 
other subpopulations within PBMC for specific analysis. CD107a staining was used as marker 
for detection of degranulating effector cells following contact with target cells. Measurements 
were performed with BD FACS Calibur or BD LSR II and analyzed using the BD CellQuest 
software and BD FACS Diva software, respectively. 
 
 
 
 
 4.3 Flow Cytometry 
37 
 
4.3.2 Measurement of flow cytometry 
 
Sample preparation for indirect staining  
For indirect staining, unlabeled primary antibodies were used. 50,000 to 200,000 cells were 
resuspended in 50 µl FACS buffer per staining and transferred in a 96-well microtiter plate. 
40 µl of primary antibody (5 µg/ml) or 50 µl of hybridoma supernatant was then added to the 
cell suspension, and incubated on ice for 45 min. Following a washing step with FACS buffer, 
secondary goat or rabbit anti-mouse antibody conjugated with PE was added in 50 µl FACS 
buffer. After a further incubation period of 20 min on ice in the dark, cells were washed in 
FACS buffer and measured immediately, or fixed with 1% PFA in PBS. Isotype control 
monoclonal antibodies were used to determine nonspecific background staining. 
 
Sample preparation for direct staining 
Direct antibody staining was performed in 96-well microtiter plates. 50,000 to 200,000 cells 
per sample were resuspended in 50 µl FACS buffer, and respective antibodies in different 
combinations were added. After incubation on ice and in the dark for 30 min, cells were 
washed with 150 µl FACS buffer, and if necessary, cells were fixed using 1% PFA in PBS. 
Isotype controls for each color were used to determine nonspecific background staining.  
 
 
4.3.3 CD107a Degranulation assay 
During the killing process of target cells, NK and T cells release cytotoxic granules into the 
immunological synapse. With the fusion of the lysosomes to the cell membrane, lysosomal-
associated membrane protein-1 (LAMP-1, CD107a), which is associated with the granula 
membrane, becomes transiently detectable at the cell surface of activated NK and T cells 
(Alter et al., 2004). Specific antibodies were used to detect these CD107a expressing effector 
cells as a marker for target cell-induced cytotoxic activity. 
Isolated NK cells from PBMC were stimulated for 24 h to 48 h with 500 U/ml IL-2. In 96-
well plates target and effector cells were mixed in a 1:1 ratio in 200 µl medium, and 10 µl 
CD107a antibody (PE-labeled) per well was immediately added. After 1 h of incubation, 
2 mM monensin (BD Bioscience) was added to prevent the acidification of endocytic 
vesicles, thus avoiding the degradation of reinternalized CD107a proteins from the surface, 
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and allowing the visualization of this marker following stimulation (Alter et al., 2004). Three 
hours later, after a washing step, further antibody staining was used to characterize the 
effector cell population, with e.g. DNAM-1 FITC, CD3 PerCP, CD56 APC and CD16 Pacific 
blue, as previously described. 
 
 
4.4 Detection of Cell Proliferation 
 
4.4.1 Cell Count 
Proliferation can be determined just by measuring the cell number. About 1x105 cells were 
seeded into a 6-well plate and grown for 24 h. Then cells were treated with MAPK inhibitor at 
a concentration of 5 µM. Cell number was analyzed at the time points 0, 24 h, 48 h, 72 h and 
96 h. Cells were counted after trypan blue staining using a Neubauer counting chamber under 
a light microscope. Trypan blue is a vital stain used to selectively color dead cells. Live cells 
with intact membrane are not colored. 
 
 
4.4.2 CFSE proliferation 
Cell proliferation can be measured with carboxy-fluorescein diacetate succinimidyl ester 
(CFDA-SE). The non-fluorescent CFDA-SE has two acetate side chains, which makes the 
molecule highly membrane permeable (Figure 8). CFDA-SE is taken up by the cell, but could 
easily exit the cell again. Yet, in the cytosol, the two acetate side chains are removed by 
esterases. The potent carboxy-fluorescein succinimidyl ester (CFSE) is fluorescent; almost 
membrane impermeable and can covalently bind to intracellular molecules. CFSE reacts with 
amine groups, which then form a stable amine bond and stable fluorescent labeling of the cell 
is achieved (Parish, 1999; Weston and Parish, 1990). Proliferating cells sequentially halve the 
CFSE fluorescence upon each cell division, because CFSE gets equally distributed to the 
daughter cells (Figure 8) (Hasbold et al., 1999; Lyons and Parish, 1994). 
For CFSE proliferation assays, cells were centrifuged and the pellet was resuspended in 
2.5 µM CFSE in PBS. After incubation for 10 min at 37°C, cells were washed with PBS and 
the pellet was resuspended in 5 ml RPMI III + 10% human serum and incubated for 30 min at 
37°C. After a washing step with medium, cells were adjusted to 1x105 cells/ml and seeded 
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into a 6-well plate with 1 ml medium per well. After 24 h, cells were treated with 1 ml 
medium containing MAPK inhibitor at a concentration of 5 µM. Cell proliferation was 
analyzed after 0 and 96 h by flow cytometry (FACS Calibur, BD).  
 
 
4.4.3 xCELLigence system 
The xCELLigence system (Roche Diagnostic) monitors cellular processes such as 
proliferation, cytotoxicity and morphological changes (adhesion) in real-time without 
incorporation of labels or dyes. It utilizes an electronic readout called impedance across 
interdigitated micro-electrodes integrated on the bottom of microtiter plates called E-plates. 
The gold electrodes at the bottom of E-plates cover about 80% of the bottom of the wells 
(Atienza et al., 2005; Kirstein et al., 2006). 
The presence of adherent cells on the electrode sensor surface will alter the local ionic 
environment at the interface between electrode and solution, leading to an increase in the 
impedance. The more cells attach to the bottom of the E-plate, the larger the increase in 
 
Figure 8: CFSE labeling of the cell. The non-fluorescent carboxy-fluorescein diacetate 
succinimidyl ester (CFDA-SE) is highly membrane permeable because of its two acetate side 
chains. CFDA-SE is taken up by the cell, but because CFDA-SE is highly lipophilic it can exit the 
cell again. In the cytosol the acetate side chains are removed by esterases, which make the 
fluorescent carboxy-fluorescein succinimidyl ester (CFSE) less membrane permeable and 
therefore CFSE exits from the cell at a slower rate. CFSE can covalently couple to molecules in the 
cytosol. It couples to molecules (R1-NH2) to form conjugates (CFR1), which can still exit from the 
cell or are rapidly degraded. CFSE can also be bound to long-lived molecules (R2-NH2) to form 
conjugates (CFR2), which cannot escape from the cell. Figure was adapted from (Parish, 1999). 
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electrode impedance (Figure 9). In addition, the impedance depends on the quality of the cell 
interaction with the electrodes. For example, increased cell adhesion or spreading will lead to 
a larger change in electrode impedance. To quantify cell status based on the measured cell-
electrode impedance, a dimensionless parameter termed cell index (CI) is used. CI is derived 
as a relative change in measured electrical impedance to represent the status of cells in the 
wells. When cells are not present or do not adhere on the electrodes, the CI is zero. Under the 
same physiological conditions, when cells attach on the electrodes, the CI value increases. 
Thus, CI is a quantitative measure of cell number present in a well. Additionally, changes in 
cell status, such as cell morphology, cell adhesion, or cell viability will lead to changes in CI. 
Thus, the CI can be used to monitor cell viability, cell number, morphology, and degree of 
adhesion. However, it is not possible to discriminate between these events. 
 
In the xCELLigence system the real-time cell analyzer dual plate (RTCA DP) instrument was 
used, which composes slots for three E-plates 16, to perform proliferation assays, measure the 
effects of MAPK inhibitors, and the extent of NK cell killing. The instrument was placed in 
an incubator set to 37°C and 5% CO2. 
 
 
 
Figure 9: xCELLigence technology and derivation of the cell index. Cell index (CI) is a relative 
metric, and requires a background measurement as a starting point for evaluation. Changes in 
impedance by cell adhesion and proliferation lead to higher impedance and higher values of CI. 
Image used from Roche Diagnostics. 
 
 4.4 Detection of Cell Proliferation 
41 
 
Monitoring of cell proliferation 
Proliferation assays 
For proliferation tests, between 2500 and 10000 cells of HepG2, Hep3B and Huh-7 were 
seeded in duplicate or triplicate E-plate 16 wells for each cell line. Control wells contained 
only medium and the initial background measurement was performed with 100 µl medium 
only in each well. After addition of the cells, they were allowed to sink for 30 min at RT, 
before initiating the measurement. Incubation of the cells occurred at 37°C and 5% CO2 for 
the indicated times. In the absence of inhibitors or other drugs, increasing impedance 
correlates with cell proliferation.  
 
Monitoring of MAPK inhibitors on cell proliferation 
MAPK inhibitors aim to reduce cell proliferation and possibly induce cell death of tumor 
cells. The real-time monitoring technique of the xCELLigence system is especially suited to 
continuously analyze the effects of MAPK inhibition on cell status and proliferation without 
any further intervention over long incubation periods. 
Cells were seeded in the E-plate 16 wells one day before addition of inhibitor or solvent 
control. After adjusting the background measurement with 100 µl medium, 2500 to 5000 cells 
were added in a total volume of 50 µl medium per well, and rested for 30 min at RT. Then the 
E-plate 16 was placed in the RTCA instrument and the measurement was started. After about 
24 h, MAPK inhibitors were diluted in 50 µl medium and added to the E-Plate wells. To test 
the concentration dependency of the MAPK inhibitors, concentrations from 2.5 µM to 15 µM 
were used. The measurement was immediately continued for 96 h. 
 
 
4.5  Detection of Apoptosis 
 
Sub-G1 staining (Nicoletti) 
A typical characteristic of apoptosis is the degradation of DNA by endonucleases leading to 
DNA fragments with the size of ~180 bp. The sub-G1 method is based on the fact that the 
small DNA fragments can be eluted following washing in sodium-citrate buffer, but which 
does not happen in vital cells. After staining the DNA with propidium iodide (PI), these 
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apoptotic cells that have lost the DNA will take up less stain and will appear to the left of the 
G1 peak as depicted in Figure 10 (Nicoletti et al., 1991). 
For the analysis of the apoptotic cells, HepG2 and Hep3B cells were treated with MAPK 
inhibitors as described in 4.1. After treatment, the supernatant was collected and transferred 
into a 1.5 ml tube. The remaining adherent cells were washed with ice-cold PBS and 
trypsinated. In the meantime, the 1.5 ml tube was centrifuged at 3,000 rpm for 8 min at 4°C 
and the supernatant was removed. The trypsinated cells were added to the microcentrifuge 
tube and centrifuged again. The cell pellet was washed with PBS. After centrifugation, the 
cell pellet was resuspended in 300 µl Nicoletti solution, which induced the elution of the 
small DNA fragments, containing 20 µg/ml PI and cells were measured within 30 min using 
the FACS Calibur. 
 
 
 
 
4.6  Multiplex Analysis of Cytokines and Phosphorylated Proteins 
 
4.6.1 Principle of multiplex analysis 
The Luminex system is a bead based immunoassay and allows the simultaneous detection of 
several proteins, like cytokines, chemokines or kinases in cell culture supernatants or cell 
lysates respectively. This method uses a panel of up to 100 different fluorescence-labeled-
 
Figure 10: Apoptosis measurement with sub-G1 peak method. Profile of the DNA content in 
normal (A) and apoptotic cells (B), stained with PI. A prominent “sub-G1” peak appears in apoptotic 
cells, but not in normal cells. 
 
normal cells apoptotic cells
apoptotic G1 S G2/MG1 S G2/M
PI intensity PI intensity
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beads, which can be differentiated from another due to two different dyes by the Luminex 
machine (Figure 11). The bead sets are colored in different ratios of red dye and infrared dye. 
10 different levels of fluorescence intensity for each dye create a panel of 100 beads; each is 
specific for a different target molecule. Thus, this bead set allows the simultaneous detection 
of different proteins within one sample. Each bead carries thousands of capture antibodies for 
one specific protein. Quantification of the protein of interest occurs by the addition of a 
second biotinylated specific antibody, which binds to another epitope of the protein of 
interest, and thus addition of streptavidin-PE (SAPE) enables quantification according to 
fluorescence intensity. The Luminex reader is equipped with two lasers, a classification laser 
(635 nm) which excites the beads and allocates them into specific regions, and a reporter laser 
(532 nm), which excites the molecular tags, i.e. PE. The amount of fluorescent intensity 
(reporter laser) is proportional to the amount of the captured molecule. For each analyte, 25 to 
100 beads are measured, and the median fluorescence intensity of these beads is reported. 
 
 
4.6.2 Quantification of cytokines, chemokines and growth factors 
The Luminex technique was used to create a cytokine and chemokine secretion profile for 
hepatocellular carcinoma cell lines and human liver tissue of healthy liver, resected liver 
tissue of colorectal metastases, cirrhotic tissue and HCC tissue, and to determine the effects of 
MAPK inhibition on this profile. Bio-Plex assays (Bio-Rad) contain standard concentrations 
of each analyte, and the calculation of respective standard curves allows the calculation of 
protein concentrations. 
The assay was performed according to the manufacturer’s protocol. In brief, lyophilized 
cytokine standard was resuspended in 500 µl RPMI III, and incubated on ice for 30 min. 
Serial dilution series to generate standard curves for each cytokine, chemokine and growth 
factor of interest were performed. The bead mixture, specific for the analyzed cytokines, 
chemokines and growth factors, was incubated with 50 µl supernatant in a 96-well filter plate 
for 30 min at RT. All incubation steps have been carried out on a plate shaker in the dark, to 
avoid bead aggregations, as well as bleaching of the beads and SAPE-labeled detection 
antibodies. Medium or lysis buffer served as background controls. Several washing steps were 
performed with 100 µl wash buffer/well, to remove unbound proteins. We used a vacuum 
pump (Millipore) for all washing steps to remove the fluid in the wells. Since the beads are 
bigger than the filter pores, they remain in the wells. After addition of secondary biotinylated 
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4.6.3 Phosphorylation of kinases and transcription factors 
With the multiplex technology, also phosphorylated proteins were measured according to the 
manufactures protocol. Bio-Rad does not provide standards with defined protein 
concentrations, but positive control lysates to test for general assay performance. The median 
fluorescence intensity of at least 50 beads for each analyte is a measure for the total or 
phosphorylated protein content in the samples. It is important to quantify changes in 
phosphorylated kinase protein in comparison with corresponding total protein content.  
 
 
 
4.7  Enzyme-Linked Immunosorbent Assay (ELISA) 
 
ELISA is a widely used quantitative immunoassay. We used this method to detect human 
MICA/B and TGFβ. These sandwich ELISAs were performed according to the manufacturers 
protocol (RnD Systems). In brief, first the 96-well microtiter plates were coated with the 
capture antibody diluted in PBS by incubating the plates overnight. For the assay procedure, 
the samples and standards were added to the wells and incubated for 2 h at RT. For the 
measurement of immuno-reactive TGFβ, the supernatant has to be acidulated with 1 M HCL 
prior the 2 h incubation. After washing, the detection antibody is added and incubated again 
for 2 h. Afterwards the working dilution of streptavidin- horseradish peroxidase (HRP) is 
added for 20 min. Then the substrate solution is pipetted to each well. After 20 min the stop 
solution is added and the optical density is determined using the TECAN sunrise microplate 
reader at a wavelength of 450 nm. 
 
 
 
4.8 Western Blot Analysis 
 
SDS-Polyacrylamid gel-electrophoresis  
The samples were denaturated in Laemmli buffer and put them on ice after boiling them for 
5 min at 95°C. Next, the samples were separated on NuPage gels, running at 150V constant 
for 50-90 min in 1x MOPS buffer. 
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Western Blot 
After SDS/PAGE proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
for 90 min at 200 mA in Western Blot transfer buffer. Prior to use, the PVDF membrane was 
activated in methanol and washed in transfer buffer. After blotting, the membrane was placed 
in blocking buffer for 2 h at RT or over night at 4°C. Primary antibody was then added and 
incubated over night at 4°C. After rinsing the membrane in wash buffer, the blot membrane 
was incubated with HRP-conjugated secondary antibody for 1 h at RT, and following a 
washing step, the blot membrane was developed in SuperSignal Substrate Working Solution 
for approximately 5 min. Band intensities were analyzed using the software Quantity One 
(BioRad). 
 
 
4.9 Signaling Pathway Drawing 
The signaling pathway models were generated with the help of the pathway builder from 
www.proteinlounge.com. 
 
 
4.10 Generation of Classification Trees  
Generation of the classification tree was performed by A. Skoeries (N. Halama, Bioquant 
Heidelberg) using the programming language R.  
 
 
4.11 Statistics 
To determine the statistically significant differences between different treatments in HCC cell 
lines or between the cytokine milieu of healthy liver, resected liver of colorectal metastases, 
cirrhotic liver tissue and HCC tissue, the software GraphPad Prism 5 was used. Depending on 
whether data was distributed normally or not, student t-tests or Mann-Whitney U-tests were 
used respectively. 
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5 Results 
5.1 Signaling Pathways in HCC and Small Molecule Inhibitors 
 
In hepatocellular carcinoma, the MAPK pathway is often permanently activated, suggesting a 
pivotal role for this pathway in tumor development. This activation is often due to a mutation 
in one of the upstream molecules. It usually occurs by two main mechanisms, oncogenic 
mutations within the Ras or B-Raf gene or constitutive Raf activation due to either over-
expression of growth factors or their receptors (e.g. VEGFR, EGFR, IGFR or c-Met) (Gollob 
et al., 2006; Lachenmayer et al., 2010). 
Several strategies for blocking the Raf/MEK/ERK signaling pathway are now being evaluated 
as cancer therapies. A number of different small molecules, which are currently under clinical 
investigation, inhibit these pathways at different levels (Favata et al., 1998; Friday and Adjei, 
2008; Gollob et al., 2006; Roberts and Der, 2007; Smith et al., 2006). 
To assess the effect of MAPK pathway inhibition on cell signaling, proliferation, apoptosis, 
cell surface molecule expression and immune cell recognition, the three cell lines HepG2, 
Hep3B and Huh-7 were used as an in vitro model system for HCC. These cell lines have been 
used for the analysis of functional features of liver cells. Since HCC in different patients 
shows a substantial molecular diversity, a more potential understanding requires studies on 
pathway analyses as well as functional tests (Hoshida et al., 2010; Zucman-Rossi, 2010). The 
three cell lines, which derived from patients with HCC, have different mutations. HepG2 cells 
have a mutation in NRas (Q61L) leading to a constant activation of the MAPK pathway. The 
Hep3B cells have a deletion of p53 and are often used to analyze the effects of p53. Huh-7 
cells have a gain of function mutation in p53 (Y220C) leading to a lack of p53 transcriptional 
activity and more resistance to apoptosis (Muller et al., 1998). Therefore, these three cell lines 
represent different HCC tumors. In order to have a detailed analysis of the effects of the Raf 
inhibitor sorafenib on HCC, the three cell lines were treated with sorafenib and compared 
with mutation-specific B-RafV600E inhibitor PLX4720 and three MEK inhibitors U0126, 
AZD6244 and PD0325901 (Figure 12).  
 
In previous studies of MAPK inhibition in colorectal carcinoma and melanoma cell lines, we 
have shown that MAPK signaling disruption can have short-term effects, like inhibition of 
phosphorylation of downstream targets, but also long-term effects like alterations in HLA 
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class I expression and DNA methyltransferase activity (Sers et al., 2009) (Dissertations Braun 
2008; Massen submitted). In order to enable for treatment periods of up to 96 h for HCC cells, 
the inhibitor concentrations had to be downscaled to a concentrations that could be used for 
all cell lines. 5 µM was chosen for all three cells lines for treatments up to 96 h with low toxic 
effects. By using the same concentration for all inhibitors, these compounds can be directly 
compared and the different sensitivities of the cell lines to these inhibitors can be determined. 
For several experiments, different concentrations were used to analyze the concentration 
dependent effects. 
 
 
 
Figure 12: MAPK family and Akt signaling pathway and inhibitors of the MAPK pathway. The 
multi-kinase inhibitor sorafenib, the mutant-specific B-RafV600E inhibitor PLX4720 and the MEK 
inhibitors U0126, AZD6244 and PD0325901 were used. Several different kinases and transcription 
factors like MEK1, ERK1/2, Akt, JNK, p38, c-Jun, ATF-2, and p53 were analyzed. Pathway was 
generated with the pathway builder from www.proteinlounge.com.  
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5.1.1 Comparison of MAPK inhibitors at the phosphorylation level 
 
The efficiency of MAPK inhibitor is often measured according to the decreased 
phosphorylation of downstream kinases, mostly ERK1/2 at Thr202/Tyr204 and 
Thr185/Tyr187. Due to the assumed linear signaling within the MAPK pathway, blockage of 
B-Raf or MEK should both lead to a reduction of ERK phosphorylation. 
It was tested whether the B-Raf inhibitors sorafenib and PLX4720 and the MEK inhibitors 
U0126, AZD6244 and PD0325901 efficiently inhibit MEK1 and ERK1/2 phosphorylation 
(Figure 12). For this, HepG2, Hep3B and Huh-7 cells were treated up to 96 h with these 
inhibitors or DMSO as a solvent control. Lysates were analyzed for phosphorylated and total 
MEK1 and ERK1/2 (Figure 13A,B). 
The analysis of phosphorylated MEK1 (p-MEK1) and p-ERK1/2 revealed several differences 
between the inhibitors as well as the cell lines. While sorafenib led to a decreased 
phosphorylation of MEK1, the MEK inhibitors U0126, AZD6244 and PD0325901 resulted in 
an increase in phosphorylation (Figure 13A) (data not shown for PD0325901). The effect of 
U0126 was weaker in comparison to AZD6244 and PD0325901. Interestingly, in contrast to 
sorafenib, the mutant-specific B-RafV600E inhibitor PLX4720 did not inhibit MEK1 
phosphorylation, but rather led to a strong increase in phosphorylation in NRas-mutant 
HepG2 cells and to a moderate increase in NRas wild-type Hep3B cells (Huh-7 cells not 
tested). 
At the ERK1/2 level, which is just downstream of MEK, differences in phosphorylation were 
also detected between the MAPK inhibitors and between the HCC lines (Figure 13A). 
AZD6244 and PD0325901 decreased phosphorylation already after 30 min with continued 
inhibition evident still at 96 h for all three cell lines. U0126 led to a continued decrease in 
phosphorylation in HepG2 cells, while in Hep3B and Huh-7 cells ERK1/2 phosphorylation 
went back to the DMSO control level after 12 h. Sorafenib showed differential effects 
between the three cells lines. In HepG2 cells, sorafenib reduced ERK1/2 phosphorylation 
within the first 12 h, but then in a “rebound” effects, it increased ERK1/2 phosphorylation, 
although MEK1 phosphorylation was still inhibited. In Hep3B and Huh-7 cells, ERK1/2 was 
almost completely and constantly inhibited by sorafenib. Only after 72 h, ERK 
phosphorylation was back to the DMSO level. In sharp contrast to sorafenib and the MEK 
inhibitors, PLX4720 elevated the ERK1/2 phosphorylation in HepG2 and partly in Hep3B 
cells (Huh-7 not tested). 
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This contradictory effect on a mutant-specific B-Raf inhibitor was so far only shown for 
NRas-mutant melanoma lines but not for other tumor cells (Heidorn et al., 2010; Kaplan et al., 
2011). This effect results from a drug-driven heterodimerization of B- and C-Raf in which C-
Raf continues to signal and, thereby, phosphorylates MEK1. This can only occur because 
PLX4720 does not simultaneously inhibit C-Raf. This is not seen in sorafenib treated cells, 
since sorafenib is also a C-Raf inhibitor. In melanoma, this perplexing Plexicon effect was 
assigned to NRas-mutant melanoma cells, but I could show that even in NRas wild-type 
Hep3B cells this phenomenon was observed. 
These findings already demonstrate that inhibitors of the same molecule can have differential 
effects upstream as well as downstream of the original target. 
 
Besides the phosphorylated kinases, also the total amount of MEK1 and ERK1/2 was 
measured (Figure 13B). All three cell lines had a high constitutive basal level of total MEK 
and ERK as indicated with the DMSO control. U0126 treatment did not change substantially 
total-MEK1 (t-MEK1) levels. Sorafenib only showed a slight degradation of t-MEK after 
72 h, but AZD6244 induced a strong decline in the t-MEK1 levels. Interestingly, this decrease 
is in strong contrast with the high increase in p-MEK1 indicating that p-MEK1 may be 
resistant to degradation. Although U0126 and AZD6244 inhibited both the MAPK at the 
MEK level, they have different binding sites at the MEK protein and therefore showed 
differences in the effect on phosphorylated and total MEK1. For technical reasons, t-MEK1 
levels could not be tested for PD0325901 and PLX4720 treatment. 
At the t-ERK1/2 level (Figure 13B), sorafenib led to a slight degradation in HepG2 cells, to a 
stronger degradation in Hep3B cells and equal levels in Huh-7 cells. In contrast, U0126 and 
AZD6244 did not have any effects on t-ERK1/2, even though AZD6244 mediated a strong 
decline in the t-MEK1 content. Surprisingly, PLX4720 reduced t-ERK1/2 in HepG2 cells 
although a strong increase in p-MEK1 and p-ERK1/2 was measured again indicating that 
phosphorylated kinases are not affected by degradation. This total-kinase degradation is not 
Figure 13: Modulation of MEK1 and ERK1/2 after treatment with MAPK inhibitor. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitor or DMSO as control for up to 96 h. 
(A) Phosphorylation of MEK1 and ERK1/2. (B) Total protein concentration of MEK1 and ERK1/2. 
Total MEK1 was not tested (n.t.) for treatment with PLX4720. Shown is one representative 
experiment of up to three independent experiments. For each experiment, protein concentration 
was adjusted to 500 µg/ml and a minimum of 50 beads was measured and MFI was calculated. 
The readout of the phosphoplex is the MFI of > 50 beads detecting either phosphorylated or total 
kinase protein. 
 
5 Results 
52 
 
mediated by cascases since treatment with pan-caspase inhibitor had no effect (not shown). In 
Hep3B cells phosphorylation of ERK1/2 was slightly reduced. 
 
In summary, sorafenib was the only inhibitor, which inhibited B- and C-Raf activity in the 
tested cells. U0126, AZD6244 and PD0325901 inhibited kinase activity of MEK, although 
they bind at different sites. MEK inhibition is not necessarily associated with a decrease in 
MEK phosphorylation itself. It seems that U0126, AZD6244 and PD0325901 stabilized MEK 
phosphorylation and therefore Raf was still able to phosphorylate MEK1. Although 
differences were seen at the p-MEK level, ERK phosphorylation was effectively inhibited with 
these inhibitors with some rebound effects seen with sorafenib. In sharp contrast, PLX4720 
activated the MAPK pathway by phosphorylation of MEK and ERK. These results raises the 
question what effects these differences at the MEK and ERK levels have on other signaling 
cascades and on downstream molecules. 
 
 
5.1.2 Effects of MAPK inhibitors on other signaling pathways 
 
Other signaling pathways are closely linked to the MAPK cascade and regulated to some 
extent through the same upstream molecules (Figure 4). The JNK and the p38 kinases belong 
also to the family of the MAP kinases and can be activated by the Ras protein. JNK is 
involved in a broad range of cellular processes like apoptosis, negative regulation of cell 
proliferation and cytokine production. The p38 pathway is also involved in cell differentiation 
and apoptosis. Both, JNK and p38 pathways are mainly activated through stress stimuli, such 
as UV radiation, cytokines, inflammatory signals, heat shock and changes in the level of 
reactive oxygen species. Another important pathway, which is not directly linked to the 
MAPK pathway, but in close connection, is the PI3K/Akt pathway (Figure 4). It regulates 
many different cell functions like cellular survival, inhibition of apoptosis, angiogenesis and 
tumor development. Therefore, I wanted to know whether the inhibition of the MEK/ERK 
pathway influences other signaling pathways (Figure 12). In addition to MEK and ERK, 
phosphorylated and total protein of JNK, p38 and Akt were analyzed as shown in Figure 14 
and in the appendix. 
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In HepG2 cells, phosphorylation of JNK was not affected by sorafenib, PD0325901 (data not 
shown) or AZD6244. Only U0126 and PLX4720 treatment resulted in an increased p-JNK. In 
Hep3B cells, a slight elevation of p-JNK was detectable after 6 h by sorafenib, U0126, 
PD0325901 (data not shown) and AZD6244 and a decline at a later time point was observed 
by sorafenib. In Huh-7 cells only AZD6244 treatment slightly increased p-JNK. 
In contrast, the p38 pathway was not generally affected by the MAPK inhibitors, which nicely 
shows that the observed effects were specific for the other molecules. Sorafenib increased 
phosphorylation in HepG2 and Hep3B cells transiently between 6 and 24 h, while PLX4720 
induced an increase of p-p38 in HepG2 and a decrease in Hep3B cells. The MEK inhibitors 
showed generally no effect and p-p38 in Huh-7 cells was not affected. 
Although the Akt pathway is not directly linked to the MAPK pathway, it was altered by the 
MAPK inhibitors, but the effects differed between the cell lines. In HepG2 cells, the MEK 
inhibitors U0126, PD0325901 (data not shown) and AZD6244 permanently increased p-Akt 
at Ser 473 which is an important regulatory phosphorylation site of Akt, while sorafenib and 
PLX4720 decreased p-Akt. In Hep3B cells, U0126 and PLX4720 did not affect p-Akt, but 
sorafenib, PD0325901 and AZD6244 led to late decline in phosphorylation with the strongest 
effects seen with sorafenib. In Huh-7 cells, sorafenib, AZD6244 and U0126 increased 
phosphorylation of Akt within the first 24 h, but at later time-points, p-Akt was below the 
DMSO control in sorafenib treated cells. 
 
With these experiments, it was observed that the MAPK inhibitors sorafenib, U0126, 
AZD6244, PD0325901 and PLX4720 could affect the phosphorylation status of MEK/ERK 
and also of Akt, and only to a certain extent of JNK and p38 (Figure 14). Since these 
pathways play a major role for the regulation of many different transcription factors, I looked 
at the downstream effects, analyzing the transcription factors CREB (data not shown), c-Jun 
and ATF-2 after MAPK inhibition (Figure 15). 
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c-Jun, which is a component of the transcription factor activating protein 1 (AP-1) complex 
together with c-fos, is mainly activated by JNK, but can also be phosphorylated by p38 and 
ERK. Among many other activities, it is involved in the negative regulation of cell 
proliferation.  
Sorafenib induced an increase in c-Jun phosphorylation in all three cell lines. PD0325901 
(data not shown) and AZD6244 slightly decreased p-c-Jun in HepG2 cells for the first 48 h, 
but in Hep3B and Huh-7 cells they increased p-c-Jun (Figure 15). U0126 showed only slight 
elevation of phosphorylation in all three cell lines. In HepG2 but not in Hep3B cells p-c-Jun 
was also elevated by PLX4720. These observations suggest that AP-1 transcriptional 
regulation is influenced by MAPK inhibitors. 
The transcription factor ATF-2, which is a member of the leucine zipper family, is activated 
primarily in response to signals that came on stress-activated protein kinases p38 and JNK. 
ATF-2 phosphorylation patterns were modulated by the MAPK inhibitors similarly to c-Jun 
with upregulation by sorafenib in all three cell lines and by AZD6244 in Huh-7 cells (Figure 
15). In HepG2 cells, U0126 and AZD6244 also resulted in an increase of p-ATF-2. 
Upregulation through PD0325901 was also detected for the first 24 h (data not shown). This 
modulation of ATF-2 suggests a link between ATF-2-driven transcription and MAPK 
inhibition. 
 
In contrast to the phosphorylation levels, the total protein levels of c-Jun and ATF-2 remained 
constant after the treatment period (see appendix). Only sorafenib induced substantial 
degradation of ATF-2 in HepG2 cells, c-Jun and ATF-2 in Hep3B cells and c-Jun in Huh-7 
cells. This finding supports the suggestion that apart from MAPK inhibition the stability and 
turnover of kinases and transcription factors is affected by sorafenib rather than by other small 
molecules inhibitors. 
 
  
Figure 14: JNK, p38 and Akt phosphorylation after treatment with MAPK inhibitor. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitor or DMSO as control for up to 96 h. 
The phosphorylation of JNK, p38 and Akt was measured. Effect of PLX4720 was not tested for 
Huh-7 cells. Shown is one representative experiment of up to three independent experiments. For 
each experiment, protein concentration was adjusted to 500 µg/ml and a minimum of 50 beads was 
measured and MFI was calculated. The readout of the phosphoplex is the MFI of > 50 beads 
detecting phospho-kinases. 
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In summary, it could be observed that besides modulation of the MEK/ERK pathway, Akt, p38 
and slightly JNK were also affected by MAPK inhibitors. Downstream transcription factors 
were also altered during drug treatment. In contrast, total protein levels of these signaling 
and transcription factor components remained mainly stable. These signaling pathways play 
a major role for cell survival and proliferation. Thereby, altering these signaling pathways by 
MAPK inhibitors would expect to have large-scale consequences for the cell that will be 
addressed with respect to surface expression of immune recognition molecules as well as 
secretion of chemokines and growth factors.  
 
5.1.3 MAPK inhibition limits proliferation of HCC cells  
 
In order to study the impact of the MAPK pathways on cell proliferation, HepG2, Hep3B and 
Huh-7 cells were treated with sorafenib, PLX4720, U0126, AZD6244 and PD0325901. Since 
these inhibitors are in a straight line connected in the MAPK cascade, it was of great interest 
to see whether differences in proliferation and adhesion could be detected between inhibitors 
and cell lines, respectively. Due to the different mutation status, it was also of interest to see 
whether NRas mutations or mutations in the p53 gene may have an effect on cell proliferation 
during drug treatment. 
Since significant reduction in the phosphorylation of the “surrogate” marker ERK1/2 was 
observed, it was expected to detect effects on proliferation during treatment with sorafenib, 
U0126, AZD6244 and PD0325901. Among this line, it was interesting to see whether the 
slight increase of p-ERK1/2 in HepG2 cells by sorafenib after 24 h would be visible at the 
level of cell proliferation. Because PLX4720 induced activation of the MEK/ERK pathway in 
HepG2 cells and to a certain extent also in Hep3B cells, an increase in cell proliferation in 
consequence would have been expected. Because the inhibitors have different affinities 
Figure 15: c-Jun and ATF-2 phosphorylation after treatment with MAPK inhibitor. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitor or DMSO as control for up to 96 h. 
Phosphorylation of c-Jun and ATF-2 was measured. Shown is one representative experiment of up 
to three independent experiments. For each experiment, protein concentration was adjusted to 
500 µg/ml and a minimum of 50 beads was measured and MFI was calculated. The readout of the 
phosphoplex is the MFI of > 50 beads detecting phospho-kinases. 
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towards their targets, the use of the same inhibitor concentrations should also show 
differences in inhibition of cell proliferation. 
To analyze the effects of the MAPK inhibitors on cell proliferation, different methods were 
used. The easiest, though old fashioned, method is to count the cells at different time points 
(Figure 16). With a “real-time” measurement method as the xCELLigence system, adhesion 
and cell growth can be constantly monitored for days at intervals of min (Figure 17). Finally, 
to analyze cell division, the CFSE method was used, whereby serial dilutions for each 
division are visualized (Figure 18). 
For analyzing cell proliferation, cells were grown for about 24 h before treatment. Looking at 
the effects of the five inhibitors on the cell number, it was observed that in all three cells lines 
treatment with 5 µM sorafenib, AZD6244 and PD0325901 had the strongest inhibitory effect 
with no increase in the cell numbers over time, indicating a block in cell divisions (Figure 16). 
In Huh-7 cells, sorafenib and in Hep3B cells, sorafenib, AZD6244 and PD0325901 
substantially decreased the cell number. U0126 had a weaker effect on cell proliferation with 
even slowly increasing cell numbers. The cell number did not really change with PLX4720 
treatment in Hep3B and Huh-7 cells. Surprisingly, in the NRas-mutant cells, where PLX4720 
induced hyperphosphorylation in MEK1 and ERK1/2, cell proliferation was blocked 
nevertheless to some extent by PLX4720 suggesting that increase in p-ERK alone is not 
sufficient to accelerate the cell cycle in these cells. 
 
 
 
 
Figure 16: Cell count of MAPK inhibitor-treated HCC cells. Cell numbers of HepG2, Hep3B and 
Huh-7 cells were counted after treatment of 5 µM MAPK inhibitors, DMSO and medium controls 
every 24 h for up to 96 h. Sorafenib, AZD6244 and PD0325901 induced strong inhibition of cell 
proliferation. U0126 has a slightly lesser effect in HepG2 and Hep3B, and barely inhibited cell 
proliferation in Huh-7 cells. PLX4720 induced reduction of cell number in HepG2 and Hep3B cells. 
n=2-3 ± SD. 
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To further evaluate the anti-proliferative effects of the MAPK inhibitors, the xCELLigence 
system was used to monitor the inhibition in real-time in comparison to the cell counting 
method where only certain time points were verified (Figure 17). Quantification of the cell 
proliferation status is based on the measured cell-electrode impedance, a dimensionless 
parameter termed cell index (CI) is used. CI is derived as a relative change in measured 
electrical impedance to represent the status of cells in the wells. In order to visualize the 
 
Figure 17: xCELLigence profile of HCC cells treated with MAPK inhibitors. HepG2, Hep3B 
and Huh-7 cells were grown for 24 or 48 h prior treatment with various concentrations of the MAPK 
kinase inhibitors sorafenib, U0126, AZD6244, PD0325901 and PLX4720 compared to DMSO 
controls for 96 h. Cell index was constantly measured and normalized to the start-point of 
treatment. n=3 ± SD. 
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relative changes of the different MAPK inhibitors, the CI was normalized to the time-point of 
treatment and set to one (for more details see 4.4).  
Figure 17 shows the effects of the MAPK inhibitors for HepG2, Hep3B and Huh-7 cells. 
Sorafenib nicely decreased proliferation in a concentration- and time-dependent manner in all 
three cell lines as indicated with a lower CI compared to DMSO treated cells. However, the 
effect of sorafenib differed between the cell lines. The strongest effect was observed in 
Hep3B cells, in which 5 µM sorafenib already led to a stop in cell proliferation. This can be 
seen in stable CI values around CI=1, i.e. no change in impedance. Higher concentrations 
reduced the CI values which indicate decreased proliferation and detachment of the cells. In 
HepG2 cells, 5 µM sorafenib reduced the proliferation to a lesser extent and only a slight 
effect was seen in Huh-7 cells. 10 and 15 µM sorafenib dramatically inhibited cell 
proliferation in all three cell lines. Although increasing p-ERK, PLX4720 did not increase cell 
proliferation, but rather inhibited proliferation in a concentration dependent manner. 
Interestingly, the MEK inhibitors U0126, AZD6244 and PD0325901 behaved differently in 
the xCELLigence system compared to sorafenib and PLX4720, and strong differences were 
seen between the cell lines. In HepG2 and Hep3B cells the MEK inhibitors decreased the CI 
in a concentration dependent manner at late time-points beyond 48 h. In Huh-7 cells treated 
with U0126, AZD6244 and PD0325901, the normalized CI curves did constantly raise and 
did not get below the DMSO control. This raise in CI in some MEK inhibitor treated cells was 
probably due to an enhanced cell adhesion which cannot be discriminated from proliferation 
by this method. Therefore, cell division was additionally analyzed by dilution of CFSE in 
flow cytometry in order to explain the effects in more detail. 
 
Besides cell counting and using the xCELLigence system for cell adhesion and cell 
proliferation, the capability of the cells to divide was analyzed under the influence of MAPK 
inhibitors by using the CFSE method (Figure 18). Cells were stained with CFSE and treated 
with 5 µM inhibitor for 96 h (see 4.4). CFSE intensity was not so strongly decreased when 
cells were treated with sorafenib indicating a strong inhibition of cell division. This effect was 
slightly less pronounced with AZD6244 and PD0325901. U0126 had only a weak effect on 
cell division indicated by strong CFSE dilution comparable to DMSO control. PLX4720 
achieved almost no block of cell division with only a slight reduction in HepG2 cells.  
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B 
 
Figure 18: MAPK inhibitor-mediated inhibition of cell division of HCC cells. CFSE-labeled 
HepG2, Hep3B and Huh-7 cells were treated with 5 µM sorafenib, U0126, AZD6244, PD0325901 
and PLX4720 and compared to DMSO and medium controls. Cells were analyzed using flow 
cytometry. Sorafenib induced strong inhibition of cell division whereas AZD6244 and PD0325901 
had a lesser effect. U0126 barely inhibited cell division and PLX4720 did not show any effects in 
Hep3B and Huh-7 cells but slightly in HepG2 cells. (A) Histogram layout (B) Analysis of two to 
three experiments. Shown are the median fluorescence intensities (MFI) of CFSE. 
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In summary, the MAPK inhibitors except for PLX4720 nicely inhibited cell proliferation and 
cell division with differences in the effectiveness between the cell lines. Although sorafenib, 
AZD6244 and PD0325901 inhibited similarly cell proliferation regarding cell number, 
differences between sorafenib and the MEK inhibitors were observed for cell adhesion and 
the inhibition of cell division. While sorafenib effectively blocked cell division, the MEK 
inhibitors reduced cell proliferation through other mechanisms. Therefore, it was next 
analyzed whether MAPK inhibition induces apoptosis and modulates factors involved in the 
regulation of apoptosis. 
 
5.1.4 Some MAPK inhibitors induce apoptosis in HCC 
 
Besides regulating cell proliferation, the MAPK family is also a very important regulator of 
apoptosis. The MEK/ERK pathway is mainly involved in cell proliferation and cell survival, 
but it has also been shown to impinge on apoptosis. High levels of p-ERK1/2 can reduce the 
apoptosis rate by inhibiting cytosolic caspase activation and the pro-apoptotic molecule Bad 
(Krishna and Narang, 2008). It has recently been published that hyperactivation of the 
MEK/ERK pathway induced by PLX4720 in NRas-mutant melanoma cells leads to resistance 
against apoptosis (Kaplan et al., 2011). On the basis of the phosphorylation data during drug 
treatment induction of apoptosis was addressed for the three cell lines during inhibitor 
treatment. To assess the role of the MAPK pathway for the induction of apoptosis in HCC, all 
five MAPK inhibitors were directly compared with a certain focus on sorafenib. 
To measure the amount of apoptosis induced by MAPK inhibitor treatment, DNA 
fragmentation (sub-G1 peak) was analyzed in HepG2, Hep3B and Huh-7 cells. To analyze 
time- and dose-dependent effects, tumor cells were treated for 48 and 96 h with 5 µM and 
10 µM inhibitor, respectively (Figure 19). Indeed, MAPK inhibitors induced apoptosis to a 
different extent and as expected from the p53 status, the three cell lines showed different 
sensitivities towards inhibitor treatment. In general, apoptosis was induced in a time- and 
dose-dependent manner. Interestingly, high rates in apoptotic cells were measured in Hep3B 
cells, which lack p53, after treatment with sorafenib, AZD6244, PD0325901 after 48 and 96 h 
with 5 and 10 µM inhibitors. In these cells, U0126 induced apoptosis substantial to a lesser 
extent and PLX4720 did not induce apoptosis although a tendency towards more apoptosis 
was observed with 10 µM. 
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Figure 19: MAPK inhibitors induce apoptosis in HCC cell lines to a different extent. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM (A) and 10 µM (B) of MAPK inhibitors or DMSO 
control for 48 and 96 h. Apoptosis was determined by measuring the sub-G1 peak using PI. 
n>3 ± SD. *:p < 0.05; **: p < 0.01; ***: p < 0.0001. 
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In p53-wild-type HepG2 cells, longer treatment and higher concentrations were needed to 
induce significant apoptosis with the MAPK inhibitors except for PLX4720 that did not 
induce apoptosis at all (Figure 19). With a 5 µM inhibitor concentration, primarily AZD6244 
and PD0325901 but not sorafenib significantly induced apoptosis. As expected for a dose-
dependent manner, 10 µM sorafenib increased apoptosis to a similar level as 10 µM 
AZD6244 and 10 µM PD0325901. Thus, despite strong inhibition of p-ERK1/2 by all 
inhibitors, induction of apoptosis is regulated partly independently from MEK/ERK 
phosphorylation. 
Remarkably, Huh-7 cells behaved differently compared to HepG2 and Hep3B cells. Huh-7 
cells have a gain of function mutation in p53 (Y200C), which induces an increased half-life of 
p53, whereby this mutation is associated with increased apoptosis resistance (Puisieux et al., 
1995). Accordingly, Huh-7 cells seemed to be rather apoptosis resistant especially for the low 
inhibitor concentrations (Figure 19). However, sorafenib showed a strong induction of 
apoptosis in a time- and dose-dependent manner again strongly indicating that apoptosis is 
induced independently from the MEK/ERK phosphorylation status. 
 
The regulation of apoptosis is complex and many different factors can be involved in different 
cell types. Apoptosis is regulated via several mechanisms coming from either the extrinsic or 
the intrinsic pathway. Therefore, it was analyzed to what extend the molecules of these 
pathways may be modulated during MAPK inhibition. A detailed analysis of the factors 
involved in apoptosis was mainly performed for sorafenib and in HepG2 and Hep3B cells. 
Some of the data were acquired in cooperation with the laboratory of Martina Müller-
Schilling (University Hospital Heidelberg, Germany). 
The tumor suppressor gene p53 has many important functions as regulating cell cycle, 
apoptosis, and gene stability which are all involved in prevention of malignant transformation. 
The tightly regulated p53 protein is induced by a variety of stress signals, including DNA 
damage, oxidative stress and activated oncogenes. Dysregulation of the p53 protein by MAPK 
inhibition might have effects on cell survival. Phosphorylated and total amounts of p53 were 
analyzed in HepG2, Hep3B and Huh-7 cells after MAPK inhibition by phosphoplex and 
western blot analysis (Figure 20, Figure 21). Figure 20 shows the kinetics of phophorylated 
(Ser15) and total protein p53 levels in HepG2, Hep3B and Huh-7 cells after sorafenib, U0126 
and AZD6244 treatment compared to DMSO control. In HepG2 cells, p-p53 was upregulated 
within the first 12 h by sorafenib and U0126 then went back to DMSO level and were  
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Figure 20: p53 phosphoplex and WB analysis in HCC cells after MAPK inhibition. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM sorafenib, U0126, AZD6244 or DMSO as control for 
up to 96 h. Western blot analysis confirmed the results obtained by phosphoplex analysis. β-actin 
was used as a loading control. p: phosphorylated protein; t: total protein. 
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increased again after 48 to 72 h, while during AZD6244 treatment, p-p53 was elevated within 
the first 48 h. Total protein levels were also increased by sorafenib during the first 12 h, but 
then decreased and dropped below the DMSO control. U0126 and AZD6244 induced an 
increase in t-p53 up to 48 h and then the curve also went below the DMSO control. 
Hep3B cells lack p53 and therefore no signal was detected for p- and t-p53. In Huh-7 cells, 
sorafenib induced an increase of p-p53 after 48 h and in t-p53 after 24 h. U0126 slightly 
increased t-p53 levels and AZD6244 induced late elevation of p-53 and slight upregulation of 
t-p53. 
Phosphoplex analysis is a rather recently established and sensitive method to analyze cell 
signaling. From the same lysates western blot analysis were performed to confirm our 
phosphoplex findings in HepG2 cells (Figure 20). Nice correlations were observed between 
phosphoplex and western blot analysis.  
 
Additionally, p53 modulation was analyzed after PD0325901 and PLX4720 treatment besides 
sorafenib, U0126 and AZD6244 treatment in HepG2 cells (Figure 21). Indeed, p53 was 
increased in the first 12 to 24 h by PD0325901 as it was seen for sorafenib and the other MEK 
inhibitors. In contrast, PLX4720 did not change the p53 levels compared to DMSO. Thus, p53 
was regulated by MEK and B-Raf inhibitors but in a drug-specific manner. Therefore, this 
p53 regulation is MEK/ERK independent. 
 
 
 
 
Figure 21: p53 expression is modulated by MAPK inhibitors in HepG2 cells. HepG2 cells were 
treated with 5 µM sorafenib or DMSO control for up to 96 h and p53 expression was analyzed by 
western blot. β-actin was used as a loading control. 
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Besides p53, the proteins p63 and p73 also belong to the p53 family and have partially 
overlapping but also distinct functions. The proteins p63 and p73 are required for p53-
dependent apoptosis in response to DNA damage (Flores et al., 2002). Besides the normal 
full-length protein, several isoforms of p63 and p73 can exist. The N-terminally truncated ∆N 
isoforms ∆Np63 and ∆Np73 have anti-apoptotic properties as intrinsic inhibitors and it has 
been recently published that ∆Np63 induces drug resistance in HCC (Mundt et al., 2010) and 
∆Np73 confers resistance to chemotherapy (Muller et al., 2005). In order to get a more 
comprehensive view on the regulation of the p53 family, p63 and p73 were analyzed from the 
same samples used in phosphoplex. 
 
 
Due to the limited amount of lysates, only sorafenib treated cells were analyzed in detail. For 
analyzing p63 and p73 in HepG2 and Hep3B cells after sorafenib treatment, cells were treated 
up to 72 h and western blot analyses were performed (Figure 22). In HepG2 cells, the ∆Np63 
isoform was induced after longer cultivation. Normal p63 was not detectable. Sorafenib 
treatment reduced the levels of ∆Np63 after 24 h. Treatment with sorafenib strongly increased 
the levels of p73 after 48 and 72 h. A similar effect of sorafenib was detected in Hep3B cells, 
which lack p53. ∆Np63 was strongly decreased after sorafenib treatment, although the slight 
p63 expression, which was detectable for the DMSO control, seemed to be also reduced by 
sorafenib. In contrast, p73 and also the ∆N isoform were increased by sorafenib. These 
experiments demonstrate that sorafenib, in particular, mediates a differential regulation of the 
p53 family members, p63 and p73 as well as their ∆N isoforms. Therefore, it is likely that this 
modulation also affects apoptosis induction.  
 
Figure 22: p53 family members p53, p63 and p73 are altered by sorafenib. HepG2 and Hep3B 
cells were treated with 5 µM sorafenib or DMSO up to 72 h. As a positive control, lysates 
expressing p63, p73 and their ∆N isoforms and as a loading control, β-actin were used 
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For the induction of apoptosis in tumor cells, various death receptors play a pivotal role. 
Therefore, we analyzed the expression of the cell surface death receptors CD95 (Fas), tumor 
necrosis factor receptor 1 (TNF-R1) and TNF related apoptosis inducing ligand receptor 2 
(TRAIL-R2) (Figure 23). HepG2 cell expressed CD95 to a low to medium level and Hep3B 
and Huh-7 cells were CD95-deficient. In contrast, TRAIL-R2 and TNF-R1 were expressed on 
all three HCC lines. 
 
MAPK pathway inhibition had an effect on surface expression of the death receptors CD95, 
TNF-R1 and TRAIL-R2. An increase of CD95 expression after 48 h was induced by 
sorafenib, AZD6244 and PD0325901, but not PLX4720 treatment in HepG2 cells (Figure 24). 
In Hep3B cells, which are deficient of CD95, no modulation was detected after treatment with 
these inhibitors (data not shown). Expression of TRAIL-R2 and TNF-R1 was only tested in 
HepG2 and Hep3B cells after 48 h sorafenib treatment. TRAIL-R2 was slightly increased in 
HepG2 and Hep3B cells, but TNF-R1 was not significantly modulated but showed a tendency 
of downregulation in both cell lines (data not shown). 
To show that upregulation of CD95 and TRAIL-R2 was also modulated on the RNA level, 
PCR analysis was performed by the laboratory of M. Müller-Schilling (University Hospital 
Heidelberg). A significant increase of CD95 and TRAIL-R2 mRNA was observed in HepG2 
 
Figure 23: Death receptor expression on HCC cells. Cells were characterized for the expression 
of the death receptors CD95, TRAIL receptor 2 (TRAIL-R2), and TNF receptor 1 (TNF-R1). Only 
HepG2 cells express CD95, while Hep3B and Huh-7 cells are deficient in CD95, presuming as a 
consequence of p53 deficiency. TRAIL-R2 is detected on all three cell lines and TNF-R1 is only 
slightly expressed. 
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cells, and an increase of TRAIL-R2 mRNA in Hep3B cells (data not shown). Moreover, we 
could see that the combination of sorafenib treatment with activation or stimulation of the 
death receptors increased the apoptotic rate indicating that sorafenib has sensitizes the death 
receptor signaling pathway (data not shown, manuscript in preparation). 
 
 
To complete the picture of sorafenib-mediated apoptosis, the effects of sorafenib on the 
intrinsic apoptosis signaling pathway were also analyzed. In HCC, the anti-apoptotic 
molecules Mcl-1 and Bcl-xL are often overexpressed and play a pivotal role for resistance 
against apoptosis (Fleischer et al., 2006; Sieghart et al., 2006; Watanabe et al., 2002; 
Watanabe et al., 2004). Using western blot analysis, sorafenib was shown to effectively 
reduce Mcl-1 levels in HepG2 and Hep3B cells and Bcl-xL in Hep3B cells (Figure 25A). 
Western blot bands were also quantified by density measurements which nicely visualize 
Mcl-1 and Bcl-xL degradation (Figure 25B). Bcl-xL and Mcl-1 expression was also tested 
after U0126, AZD6244, PD0325901 and PLX4720 treatment in Hep3B cells (Figure 26). In 
contrast to sorafenib, U0126 and PLX4720 did not reduce Bcl-xL expression. However, 
treatment with AZD6244 reduced Bcl-xL after 24 h with a slight recovery after 72 and 96 h 
though still below the DMSO control. The MEK inhibitor PD0325901 decreased Bcl-xL 
levels substantially beginning at 24 h and a stable disappearance until 72 h.  
 
 
Figure 24: MAPK inhibition increase CD95 expression in HepG2 cells. HepG2 cells were 
treated with 5 µM sorafenib, AZD6244, PD0325901, PLX4720 or DMSO for 48 h. Surface molecule 
expression of CD95 was measured by flow cytometry analysis using the FACS Calibur. Shown is 
one of three independent experiments. 
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Compared to Bcl-xL, Mcl-1 regulation displayed different kinetics under MAPK inhibition 
with “waves” of enrichment and degradation (Figure 26). Mcl-1 levels in general increased 
over time in the DMSO treated cells as well as with PLX4720 and AZD6244, and U0126 but 
to a lesser extent. In contrast, weak Mcl-1 bands were detectable in PD0325901 treated cells 
suggesting that this MEK inhibitor impaired Mcl-1 stability more than the other MEK 
inhibitors. Only sorafenib seemed to reduce Mcl-1 expression in Hep3B cells, indicating that 
different MEK/B-Raf inhibitors can mediate opposite effects on Mcl-1. Thus these alterations 
are obviously independent of the MEK/ERK pathway and the small molecules exert different 
“side effects”.  
 
 
 
Figure 25: Expression of Mcl-1 and Bcl-xL is reduced after sorafenib treatment. HepG2 and 
Hep3B cells were treated with 5 µM sorafenib or DMSO control for 24, 48 and 72 h. (A) Western 
blot analysis shows a decrease in Mcl-1 and Bcl-xL in HepG2 and Hep3B cells. β-actin was used 
as a loading control. (B) Quantitative analysis of western blot analysis. Intensities were measured 
with Quantitiy One (BioRad), normalized to β−actin and treatment was compared to the DMSO 
control and depicted as fold change. 
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In summary, several MAPK inhibitors induced apoptosis in liver tumor cells in a time- and 
dose dependent manner. However, remarkable differences were observed between cell lines 
as well as inhibitors. Therefore, it was of interest to address the nature of these differences in 
more detail. Looking at signal molecules involved in the regulation of apoptosis, it could be 
demonstrated that p53 and its family member p73 were partially stabilized and the anti-
apoptotic isoforms ∆Np63 and ∆Np73 were decreased by the MAPK inhibitors, sorafenib in 
particular. The anti-apoptotic molecules Bcl-xL and Mcl-1 were partially downregulated by 
sorafenib and three MEK inhibitors, but not by the mutation-specific B-RafV600E inhibitor 
PLX4720. Moreover, the three death receptors CD95, TRAIL-R2 and TNF-R1, which are 
important for the induction of apoptosis, were modulated by MAPK inhibition and, again, 
sorafenib differed from the other inhibitors, partly elevating death receptor surface 
expression which was in sharp contrast to PLX4720 and the MEK inhibitors. 
These observations point towards an ERK-independent side effect of certain MAPK 
inhibitors, sorafenib in particular, which may also account for the differences in clinical 
outcome of these drugs. 
 
Figure 26: Mcl-1 and Bcl-xL are partly modulated by MAPK inhibitors in Hep3B cells. Hep3B 
cells were treated with 5 µM sorafenib, PLX4720, U0126, AZD6244, PD0325901 or DMSO control 
for up to 96 h analyzed by western blot. Mcl-1 was decreased by sorafenib, but not by PLX4720, 
U0126 and AZD6244. Bcl-xL was mostly decreased by sorafenib, AZD6244 and PD0325901. 
β−actin was used as a loading control. 
 
Bcl-xL (26 kDa)
β-actin (44 kDa)
Bcl-xL (26 kDa)
β-actin (44 kDa)
Mcl- 1 (40kDa)
Time (h)     0.5   6   12   24   48  72  96
DMSO Sorafenib PLX4720
U0126 AZD6244 PD0325901
Time (h)     0   0.5   6   12   24   48  72  96 0.5   6   12   24   48  72  960.5   6   12   24   48  72  96
Mcl-1 (40kDa)
0.5   6   12   24   48  72  0.5   6   12   24   48  72  96
5 Results 
72 
 
5.2 Immunological Side Effects of MAPK Inhibitors 
 
Many surface molecules, also those which are important for cell-cell interaction and 
recognition by the immune cells, were shown to be influenced by the MAPK and closely 
linked pathways. In terms of microenvironment, secretion of cytokines, chemokines and 
growth factors is also often regulated by these pathways. Therefore, I wanted to assess the 
effect of MAPK inhibition on cell surface expression of immunologically relevant molecules, 
immune cell recognition and cytokine/chemokine secretion. For this, the three cell lines 
HepG2, Hep3B and Huh-7 were treated with the MAPK inhibitors sorafenib, PLX4720, 
U0126, AZD6244 and PD0325901 and several parameters were addressed. 
 
5.2.1 Characterization of hepatocellular carcinoma cell lines 
 
In a first set of experiments, the surface molecule expression especially those which are 
important for recognition by T and NK cells were characterized in the three HCC cell lines. 
The expression of HLA class I and II, c-Met, ULBP1-4, MICA/B and adhesion molecules are 
shown in Figure 27 to Figure 29. All three cell lines showed strong expression of HLA class I. 
HepG2 cells were HLA-A2 and HLA-A24 positive, whereas Hep3B and Huh-7 are both 
negative for those HLA class I alleles. HepG2 and Hep3B cells were negative for the HLA 
class II molecule HLA-DR, but low expression was detected on Huh-7 cells. 
In HCC, the c-Met receptor, which is an important receptor for the mitogen hepatocyte 
growth factor (HGF), is upregulated compared to non-malignant hepatocytes (Yang et al., 
2007). Accordingly, high c-Met expression was detectable in all three cell lines. 
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Figure 28: NKG2D ligand surface molecule expression of HCC cells. Cells were characterized 
for the expression of ULBP1-4 and MICA/B using flow cytometry analysis. All three cell lines 
express to a certain extent ULBP2 and ULBP4. HepG2 cells also express MICA and MICB 
whereas in Hep3B and Huh-7 showed only minimal to no expression. FI: fluorescence intensity 
measured in the PE channel using the FACS Calibur. 
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Figure 27: HLA and c-Met surface molecule expression of HCC cells. Untreated cells were 
characterized for the expression of HLA and c-Met using flow cytometry analysis. All three cell lines 
express HLA class I molecules (W6/32), whereas HepG2 are positive for HLA-A2 (HB54) and -A24 
(0497HA). HLA-DR (L243) is only weakly expressed on Huh-7 cells. c-Met (95106) is expressed on 
all three cell lines. FI: fluorescence intensity measured in the PE and APC (c-Met) channel using 
the FACS Calibur and LSR II, respectively. 
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In addition to HLA, the expression of the ligands ULBP1-4 and MICA/B for the activating 
NK cell receptor NKG2D was analyzed (Figure 28). All three cell lines showed no expression 
of ULBP1 and -3, but low levels of ULBP2, whereas the expression on Huh-7 cells was low 
to medium. ULBP4 was expressed at low levels on Huh-7 cells and at intermediate levels on 
HepG2 and Hep3B cells. Because ULBP4 expression in liver carcinoma cell lines was 
recently described for HepG2 cells (Cao et al., 2008), ULBP4 mRNA expression was 
confirmed in HepG2 cells with PCR (data not shown). MICA and MICB are only weakly 
expressed in HepG2 cells, while both molecules are absent in Hep3B and Huh-7 cells.  
 
CD155 (PVR) is another important ligand for the recognition of many tumor cells by the 
immune cells. It is unique among NK receptor ligands because CD155 possesses its own 
signaling capacity and feeds into the MAPK pathway and probably others (Casado et al., 
2009; Chan et al., 2010). CD155 binds to DNAM-1 (CD226) which is constitutively 
expressed on a majority of T and NK cells and mediates NK cell activation primarily. As 
shown in Figure 29, CD155 was strongly expressed on all three cell lines. 
In general, adhesion molecules play an important role for the interaction between tumor cells 
and immune cells. Therefore, the cell lines were also analyzed for the expression of ICAM-1 
(Inter-Cellular Adhesion Molecule 1), LFA-3 (Lymphocyte Function-associated Antigen 3) 
and CD166 (ALCAM). All three cell lines showed similar expression of these three adhesion 
molecules with high levels of ICAM-1 and intermediate levels of LFA-3 and CD166. 
 
Figure 29: CD155 (PVR) and adhesion molecule expression of HCC cells. Cells were 
characterized for the expression of the adhesion molecules CD155, CD166, ICAM-1 and LFA-3 
using flow cytometry analysis. All three cell lines express intermediate to high levels of these 
adhesion molecules. FI: fluorescence intensity measured in the PE channel using the FACS 
Calibur. 
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5.2.2 Influence of MAPK inhibition on HLA, NK receptor ligands and 
adhesion molecule expression  
 
For the recognition of tumor cells by the most relevant effector cells, i.e. T and NK cells, 
surface molecule expression on the tumor cells play an important role. Tumor cells often 
change their surface molecules in order to escape immune recognition. To see whether MAPK 
modulation also influences cell surface molecules relevant for immune recognition, HLA 
class I, c-Met, the NKG2D ligands MICA/B, ULBP2 and ULBP4, the DNAM-1 ligand 
CD155 and the adhesion molecules CD166, LFA-3 and ICAM-1 were analyzed. HepG2, 
Hep3B and Huh-7 cells were treated for 48 h with 5 µM sorafenib, U0126, AZD6244, 
PD0325901 and PLX4720 and surface molecules were measured using FACS analysis. 
 
HLA class I was differently modulated by the MAPK inhibitors and between the cell lines 
(Figure 30). No alteration in the expression was observed with U0126 and PLX4720 for all 
three cell lines, AZD6244 in HepG2 and sorafenib in Hep3B cells. While in HepG2 cells 
HLA class I was weakly downregulated by sorafenib, it was upregulated in sorafenib treated 
Huh-7 cells. In contrast, HLA class I expression was increased by AZD6244 in Hep3B and 
Huh-7 cells and strongly elevated by PD0325901 in all three cell lines. 
 
 
Figure 30: HLA class I is altered by certain MAPK inhibitors in HCC cells. Tumor cells were 
treated with 5 µM sorafenib, U0126, AZD6244, PD0325901 or PLX4720 for 48 h and HLA class I 
expression (W6/32) was analyzed. FI: fluorescence intensity measured in the PE channel using the 
FACS Calibur. 
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The c-Met receptor is often overexpressed in HCC and correlates with a shorter 5-year 
survival (Ueki et al., 1997). The high c-Met expression seen in HepG2, Hep3B and Huh-7 
cells (5.2.1) was decreased by sorafenib, AZD6244 and PD0325901 (Figure 31) while 
PLX4720 treatment upregulated c-Met receptor in HepG2 but not in Hep3B cells (Huh-7 cells 
not tested). 
 
The NKG2D ligand ULBP2 was not substantially altered with MAPK inhibitors (Figure 32). 
A small upregulation was observed with sorafenib, AZD6244 and PD0325901 in HepG2 and 
with AZD6244 in Huh-7 cells. In contrast, in Hep3B and Huh-7 cells sorafenib seemed to 
downregulate ULBP2. Also ULBP4 expression was modulated by the MAPK inhibitors. It 
was upregulated after sorafenib, AZD6244 and PD0325901 treatment in HepG2 and Hep3B 
cells, but not with PLX4720 (Huh-7 cells not tested). MICA and MICB were differently 
modulated after MAPK inhibitor treatment in all three cells lines (data not shown). 
In addition to the NKG2D ligands, CD155, which binds to the activating receptor DNAM-1 
on NK and T cells, was elevated in HepG2 and Huh-7 cells by sorafenib, AZD6244 and 
PD0325901, while in Huh-7, U0126 seemed to slightly increase CD155 expression (Figure 
33).  
 
Figure 31: c-Met surface molecule expression is altered by MAPK inhibitors in HCC cells. 
Tumor cells were treated with 5 µM sorafenib, U0126, AZD6244, PD0325901 or PLX4720 for 48 h 
and c-Met expression was analyzed. Fluorescence intensity measured in the APC channel using 
the LSR II. 
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For the recognition of tumor cells by NK and T cells, adhesion molecules play an important 
role. MAPK inhibition altered the expression of the adhesion molecules CD166, LFA-3 and 
ICAM-1. CD166 (ALCAM), which is a ligand for the CD6 receptor on NK and T cells, was 
upregulated by sorafenib, U0126, AZD6244 and PD0325901 in HepG2 and Huh-7 cells while 
no alteration was observed in Hep3B cells (Figure 34). PLX4720 did not influence CD166 
expression indicating that CD166 is negatively regulated via MEK/ERK signaling. LFA-3 is 
differently regulated in the three cell lines (Figure 34). While sorafenib and the MEK 
inhibitors downregulated LFA-3 expression in HepG2 and Hep3B cells, they induced an 
upregulation of LFA-3 in Huh-7 cells. In NRas-mutant HepG2 cells, PLX4720 treatment led 
 
 
Figure 32: ULBP2 and ULBP4 expression is altered by MAPK inhibitors in HCC cells. Tumor 
cells were treated with 5 µM sorafenib, U0126, AZD6244, PD0325901, PLX4720 or DMSO for 48 h 
and ULBP2 and ULBP4 expression was analyzed by flow cytometry. Fluorescence intensity 
measured in the PE channel using the FACS Calibur. Shown is one representative experiment. 
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to an increase in LFA-3 expression, indicating that LFA-3 is regulated via the MEK/ERK 
pathway.  
Regulation of the adhesion molecule ICAM-1 was different between sorafenib and the MEK 
inhibitors (Figure 34). While the MEK inhibitors AZD6244 and PD0325901 induced a 
downmodulation of ICAM-1 in all three cell lines, sorafenib treatment led to a slight 
upregulation of ICAM-1. Again this demonstrates that opposite effects can occur during 
treatment with sorafenib and the MEK inhibitors. PLX4720 also induced an elevation of 
ICAM-1 on HepG2, but not on Hep3B cells. 
 
 
 
 
 
Figure 33: CD155 expression is partly increased by sorafenib, AZD6244 and PD0325901 
treatment. Cells were characterized for the expression of CD155 after treatment with 5 µM 
sorafenib, U0126, AZD6244, PD0325901 and DMSO for 48 h using flow cytometry analysis. All 
three cell lines express CD155. Sorafenib, AZD6244 and PD0325901 partly increased CD155 
expression on HepG2 and Huh-7 cells. FI: fluorescence intensity measured in the PE channel 
using the FACS Calibur. 
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In summary, expression of several surface molecules was modulated in HCC cell lines after 
MAPK inhibitor treatment. The repeated observation that surface expression of NKG2D 
ligands CD155 and HLA in particular, was not always modulated by these MAPK inhibitors 
 
 
 
Figure 34: Adhesion molecules are altered by MAPK inhibitors in HCC cells. Tumor cells were 
treated with 5 µM sorafenib, U0126, AZD6244, PD0325901, PLX4720 or DMSO for 48 h and 
CD166, LFA-3 and ICAM-1 expression was analyzed by flow cytometry. Fluorescence intensity 
measured in the PE channel using the FACS Calibur. 
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in the same direction strongly suggests that this modulation occurs independently from 
suppression of ERK phosphorylation shown in Figure 13. In consequence of this observation, 
one has to postulate side effects resulting from off-target effects of these substances that either 
are directly mediated at the protein expression and stabilization (CD155 for example) or 
indirectly via concerted expression machineries (HLA peptide / β2m complex, for instance). 
Since most of these surface molecules are important for recognition by immune cells, like NK 
cells, it was of interest to know whether these changes in surface molecule expression also 
affect the recognition by NK cells. 
 
5.2.3 Consequences of altered HLA class I and NK ligand expression for 
NK cell degranulation 
 
As shown previously, MAPK inhibition modulated the surface molecule expression on tumor 
cell lines (5.2.2). Several of these surface molecules are important for the recognition and 
killing by NK cells. The crucial question is whether these alterations have a measurable 
impact on the recognition and lysis of the tumor cells by the immune effector cells. To try to 
answer this question, NK cell recognition of the three liver carcinoma cell lines with and 
without MAPK inhibition was analyzed. 
As a measurement for the cytotoxic activity of NK cells, the CD107a degranulation assay was 
used. Cytotoxic NK cells, which were activated through receptor engagement by ligands on 
their target cells, release granula into the immunological synapse. During this process, the NK 
cell lysosomes, which contain perforin and granzyme, fuse with the plasma membrane and 
LAMP-1, also called CD107a, becomes temporarily exposed at the surface of activated NK 
cells. This molecule can be fixed and stained and is used as a marker for active, ongoing 
degranulation. 
IL-2 pre-activated PBMCs from healthy donors were used as effector cells. Since 
degranulation assays are analyzed by flow cytometry, it was not necessary to isolate the NK 
cells, because NK cells can be defined as CD3- and CD56+ cells and the presence of CD107a 
positive NK cells were quantified. As positive control, the HLA class I negative cell line 
K562 was used as target cells and for spontaneous degranulation, PBMCs were also cultured 
alone for 4 h. 
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Degranulation of NK cells by transient CD107a staining was tested with PBMCs of healthy 
donors against HepG2, Hep3B and Huh-7 cells treated with different MAPK inhibitors 
(Figure 35). First of all, it could be observed that NK cells degranulated, as indicated with a 
transient increased CD107a expression, when co-cultured for 4 h with the target cells. 
Degranulation of NK cells against HepG2, Hep3B and Huh-7 cells was similar indicating that 
pre-activated NK cells are able to recognize these HCC cells and become subsequently 
activated. Degranulation against K562 cells was even higher, because K562 cells are HLA 
class I-negative but express ligands for activating receptors like NKG2D. Although some 
modulation of HLA class I and NK ligand surface expression was detectable, MAPK 
inhibition of these tumor cells did not significantly alter degranulation of NK cells. In a 
donor-dependent way, MEK inhibitors and also the B-RafV600E inhibitor PLX4720 slightly 
elevated degranulation in HepG2 cells, but not in Hep3B and Huh-7 cells. This observation 
that MAPK inhibitor treatment did not substantially alter NK cell activity against HCC cells 
nicely demonstrates the balance between activation and inhibition in NK cells. 
 
Figure 35: Degranulation of NK cells against HCC cells treated with MAPK inhibitors. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitors for 48 h and then used as target 
cells for NK cell degranulation. PBMCs were isolated from healthy donors, pretreated with IL-2 (500 
U/ml) for 48 h and co-cultured with HepG2, Hep3B and Huh-7 cells for 4 h. The amount of CD107a 
on NK cells was measured. The HLA class I negative cell line K562 was used as positive control. 
Background degranulation was measured without the target cells. No significant modulation of NK 
cell degranulation was observed with MAPK inhibitors in HepG2 and Hep3B cells. Shown is one 
representative experiment. 
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In addition to CD107a, NK cells were also stained for CD56 and CD16 in order to evaluate 
the NK subsets defined by these markers. We could previously show that CD56dim CD16+ NK 
cells loose/downregulate CD16 expression in the process of degranulation, e.g. when co-
cultured with K562 cells (Dissertation M. Braun 2008). To test whether this is also the case 
during co-cultivation of NK cells with HCC cells, CD16 expression was analyzed in parallel 
with the degranulation assays (Figure 36). As expected degranulating (CD107a positive) NK 
cells at the same time decrease to some extent their levels of CD16 following exposure to all 
three cell lines HepG2, Hep3B and Huh-7, although to a lesser extend compared to co-culture 
with K562 cells. This difference nicely shows the correlation between CD107a degranulation 
and CD16 loss. Moreover, we could see that degranulated cells are members of the CD56dim 
NK cell population. 
To analyze long-term effects of the co-culture, HCC target cells and isolated IL-2 activated 
NK cells were cultured together for 48 h (Figure 37). This long-term co-culture of NK cells 
alone alters already their phenotype regarding CD56 and CD16 expression. Although the 
culture started with highly enriched NK cells (d0), after 2 days most of the NK cells became 
CD56 and CD16 negative indicating that IL-2 culture activated NK cells and, thereby, 
modulates CD16 and CD56 surface expression. In contrast co-cultivation with HepG2 and 
Hep3B cells led to an increase of the CD56dim/bright CD16- population. A larger proportion of 
CD56dim CD16+ NK cells remained in this setting. Co-culture with Huh-7 cells resulted in an 
even higher representation of CD16+ NK cells suggesting that the three HCC lines are 
Figure 36: Degranulating NK cells downregulate CD16 expression. PBL were isolated from 
PBMCs of healthy donors, pretreated for 48h with IL-2 (500 U/ml) and co-cultured with HepG2, 
Hep3B and Huh-7 cells for 4 h. The expression of CD16, CD56 and the amount of CD107a was 
measured on gated NK cells. The HLA class I negative cell line K562 was used as positive control. 
CD16+ degranulating NK cells downregulate the expression of CD16.  
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recognized by different NK subsets. Co-culture with K562 cells also resulted in a mixture of 
NK cells with a higher percentage of CD16+ NK cells. Thus, contact with HCC lines shifted 
the NK cell repertoire towards CD16+ as well as CD56bright NK cells. This composition is 
closely related to the intrahepatic NK population (5.2.4). 
 
 
In summary, treatment of HCC cells with MAPK inhibitors resulted in modulation of HLA 
and NK ligand surface expression. However, this alteration did not significantly impinge on 
NK cell degranulation. This minimal influence on degranulation can be explained by the 
 
 
Figure 37: CD16 and CD56 phenotype of NK cells is altered after long-term co-cultivation 
with HCC cells. NK cells were isolated from PBMCs of healthy donors, co-cultured with HepG2, 
Hep3B, Huh-7 and K562 cells for 48 h with 100U/ml IL-2. The expression of CD16, CD56 on NK 
cells was measured. After day 2, NK cells lose CD16 and CD56 expression when cultivated alone. 
In the presence of tumor cells the CD56dim CD16- population gets enriched with co-cultivation with 
HepG2 and Hep3B cells. n=2 
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balance between activating and inhibitory receptors on NK cells which results from slight 
modulations of ligand expression due to the integration of the different signals. 
Degranulation also altered the phenotype of NK cells, i.e. degranulating CD56dim CD16+ NK 
cell and to some extend down-modulate CD16 surface expression following co-culture with 
HCC cells. However, long-term culture of NK cells with HCC cells changed the CD56 CD16 
phenotype towards the maintenance of CD16+ NK cells and CD56bright NK cells. It would be 
interesting to see whether the NK cell phenotype is also altered in HCC tumor tissue. 
Therefore, the hepatic NK cell compartment was investigated in detail. The next question was 
whether MAPK inhibitors induce the tumor cells to change their chemokine secretion pattern, 
which then in turn might influence the attraction of NK cell subsets towards the tumor tissue. 
 
5.2.4 Lymphocytes in normal, cirrhotic and HCC liver 
 
Infiltration of immune cells into the tumor is dependent on chemokine and cytokine milieu. In 
chapter 5.3.1, it will be described in detail that the chemokine milieu differs significantly in 
healthy vs. cirrhotic and HCC tissue. The liver has also been described as a “lymphoid 
organ”, having important functions in innate and adaptive immunity (Crispe, 2009; Parker and 
Picut, 2005). CD8+ T cells, NK cells and NKT cells are enriched in the liver compared to 
other organs (Morsy et al., 2005). Here, the composition of NK and T cells was investigated 
exemplarily in normal, cirrhotic and HCC tissue in comparison to peripheral blood 
lymphocytes. As shown in 5.2.3, co-culture of peripheral NK cells with HCC lines reserved 
the composition significantly. As expected, the proportion of NK and T cells are modulated in 
liver tissue. 
 
 
 
Table 15: Proportion of peripheral blood NK and T cells in HCC. Lymphocytes were isolated 
from blood of healthy donors and patients with HCC and analyzed by flow cytometry. (A) 
Proportions of NK (CD3-, CD56+) and T (CD3+) cells were determined. (B) Gating on T cells, 
 the expression of CD4+ T helper cells vs. CD8+ cytotoxic T cells was calculated. n=3 ± SD.  
 
A B
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In sharp contrast, the distribution of NK cells in liver tissue differed substantially to 
peripheral blood. The healthy liver was enriched in NK cells and made up to about 30% of 
hepatic lymphocytes (Table 16). As depicted in Figure 38, NK cell phenotype regarding 
CD56 and CD16 expression was significantly altered. The difference was due to a higher 
proportion of CD56bright CD16- NK cells and reduced CD56dim CD16+ hepatic NK cells 
compared to PBMC. The NK cell number and phenotype changed even more in cirrhotic 
liver, non-malignant liver tissue of HCC patients and HCC tumor tissue (Figure 38). In 
cirrhosis, CD56bright NK cells were drastically increased with even less CD16+ NK cells, but 
the total NK cell proportion was slightly reduced. Remarkably, NK cells were virtually absent 
in HCC tumor tissue. However, in adjacent non-malignant tissue, the proportion of NK cell 
was highly increased. The majority of these NK cells displayed a CD56dim/CD56bright CD16- 
phenotype. 
We have recently shown that the scavenger receptor CD6 is differentially expressed by a 
subpopulation of peripheral CD56dim but not CD56bright NK cells (Braun et al., 2010). In the 
periphery most CD56dim CD16+ NK cells also express CD6. However, in liver tissue, 
regardless of a malignant, cirrhotic or healthy origin, the NK cell population expressing CD6 
was strongly reduced compared with the blood counterparts and the most prominent reduction 
was observed in the cirrhotic tissue (Figure 38). 
 
The proportion of T cells was also changed in the liver tissue compared to PBMC of healthy 
individual and patients (Table 16). In the normal liver, T cells made up about 40% of liver 
lymphocytes. In cirrhotic and tumor tissue, this proportion was increased to about 50% and 
80%, respectively. This shows that in the tumor tissue, T cells are still present while NK cells 
are absent although the mechanism for the disappearance of NK cells still remains elusive. 
 
 
Table 16: Proportion of hepatic NK and T cells in healthy, cirrhotic and tumor tissue. 
Lymphocytes were isolated from healthy liver, cirrhotic liver, healthy party of HCC liver, HCC tumor 
liver tissue. Lymphocytes were analyzed by flow cytometry and gated on (A) NK cells (CD3-, 
CD56+) and T cells (CD3+), and (B) T cells were further analyzed for the expression of CD4 and 
CD8. n=1  
Tissue NK cells T cells
Normal Liver 31.5 38.5
Cirrhosis 27.1 52.8
HCC Normal 55.9 25.6
HCC Tumor 1.5 83.4
Tissue CD4 T cells CD8 T cells CD4- CD8- T cells CD4+ CD8+ T cells
Normal Liver 39.9 46.9 12.7 0.5
Cirrhosis 31.7 59.4 8.2 0.6
HCC Normal 53.4 33.8 9.1 3.7
HCC Tumor 20.5 75.9 1.7 1.9
A B
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Figure 38: Hepatic NK cells differ to peripheral NK cells regarding CD16 and CD6 
expression. Lymphocytes were isolated from healthy liver, cirrhotic liver, healthy party of HCC 
liver, HCC tumor liver tissue and from peripheral blood of a healthy donor. Lymphocytes were 
analyzed by flow cytometry: CD16 and CD6 expression were determined on gated NK cells (CD3-, 
CD56+). In the liver, more NK cells are CD16- and CD6- compared to peripheral NK cells. In 
cirrhotic liver an increase in CD56bright NK cells was detected and in HCC tumor most NK cells are 
lost. 
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The 2:1 ratio of CD4+ T helper cells to CD8+ cytotoxic T cells, which was observed in 
peripheral blood, was nearly switched to a 1:2 ratio in normal liver tissue (Figure 39). Even 
more CD8+ T cells were found in cirrhosis and in HCC tumor tissue. The adjacent healthy 
HCC tissue contained more CD4+ than CD8+ T cells. 
This reversed distribution of CD4+ vs. CD8+ T cells in healthy as well as in cirrhotic and 
malignant liver tissue is rather unique and may result from a special hepatic 
microenvironment which is described in the section 5.3.1. 
 
 
In summary, the proportion and the phenotype of hepatic NK and T cells were changed 
compared to the blood counterparts. Liver NK cells showed a reduced expression of CD16 
and CD6. The ratio of CD4+ to CD8+ T cells was almost switched from 2:1 in peripheral 
blood to 1:2 in liver tissue. In cirrhotic liver tissue, NK cells showed an increased activated 
(CD56bright) phenotype and CD8+ T cells were enriched. In HCC tumor tissue, NK cells were 
absent and mostly CD8+ T cells were present. It would be of great interest to see whether 
these compositions and phenotypes would change in HCC patients treated with sorafenib or 
other MAPK inhibitors. 
 
Figure 39: Hepatic T cells differ to peripheral T cells regarding the ratio between CD4+ and 
CD8+ T cells. Lymphocytes were isolated from healthy, cirrhotic, healthy party of HCC liver, HCC 
tumor liver tissue and from peripheral blood. Lymphocytes were analyzed by flow cytometry. 
Proportion of CD8 and CD4 expression on gated T cells (CD3+) were determined. Compared to the 
CD4 to CD8 ratio of 2:1 in peripheral blood, CD8+ T cells are increased in the liver. 
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5.2.5 MAPK inhibitors modulate chemokine and growth factor secretion in 
HCC cells 
 
In the tumor microenvironment many different cytokines, chemokines and growth factors are 
secreted by a variety of immune and parenchymal, endothelial cells. The release of the 
chemokines by the tumor cells can lead to a “reprogramming” of the tumor surrounding often 
favoring a pro-angiogenic and anti-immune situation. Infiltration of immune cells into a 
tumor is dependent on the chemokine and cytokine milieu. Therefore, we hypothesized that 
modulation of the tumor cells by small molecules does not only change the tumor cell activity 
itself, but also has an influence on the microenvironment. By using the three cell lines HepG2, 
Hep3B and Huh-7, the different chemokines and growth factors produced by these cells and 
the impact of the different MAPK inhibitors were analyzed. For this analysis, cells were 
cultured for 48 h with and without MAPK inhibitors. The multiplex method was used to 
simultaneously quantify up to 50 different cytokines, chemokines and growth factors. For the 
detailed analysis of the secretion profile by the HCC cell lines, a selection of chemokines and 
growth factors was addressed for the effects of MAPK inhibition (Figure 40 - Figure 42). 
 
 
 
Figure 40: Secretion of chemokines is modulated by MAPK inhibitors. HepG2, Hep3B and 
Huh-7 cells were treated with 5 µM MAPK inhibitors or DMSO control for 48 h and supernatant was 
analyzed for chemokines. 
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The three cell lines secreted a variety of different chemokines and growth factors. High 
amounts of the chemokines IL-8 (CXCL8), IP-10 (CXCL10), the angiogenic factor VEGF, 
the growth factor TGFβ and the soluble adhesion molecule ICAM-1 were secreted. The 
chemokine SDF-1α  (CXCL12), M-CSF, the growth factor SCGF and MIF were released to a 
medium level. The chemokine RANTES (CCL5) and the growth factor HGF, as well as 
soluble IL-1 receptor antagonist (IL-1RA) and adhesion molecule VCAM-1 were only 
secreted to a small amount. Substantial differences in the amount of the factors were seen 
between the cell lines. For example, the highest secretion of CXCL10 was detected for Hep3B 
cells, but 8-fold less CXCL10 was secreted in Huh-7 cells and another 20-fold less in HepG2 
cells. In the supernatant of Huh-7 cells, no CCL5, M-CSF and IL-1RA were detected. 
 
The chemokines CXCL8, CCL5 and CXCL10 were differently modulated by the MAPK 
inhibitors and differences were also seen between the three cells lines (Figure 40). Sorafenib 
reduced the secretion of these three chemokines in all cell lines. In HepG2 cells, the MEK 
inhibitors U0126, AZD6244 and PD0325901 inhibited secretion of CXCL8 and CCL5, but 
not CXCL10, where a substantial increase was detected. In Hep3B cells, PD0325901 reduced 
CXCL8 secretion, all MEK inhibitors reduced CCL5 secretion. Interestingly, U0126 reduced, 
but AZD6244 and PD0325901 increased CXCL10 secretion, suggesting that even different 
MEK inhibitors can have opposite effects on CXCL10 secretion. In Huh-7 cells, U0126 but 
not AZD6244 treatment led to a higher amount of CXCL8 while CXCL10 secretion was not 
affected by AZD6244 but reduced by U0126. 
Most remarkably, the increase in MEK and ERK phosphorylation by PLX4720 was reflected 
by chemokine secretion of CXCL8 and CCL5 suggesting that these two chemokines are 
directly influenced by the NRas mutation. In contrast, a downregulation of CXCL10 was 
observed in HepG2 cells, and PLX4720 generally reduced all three chemokines in Hep3B 
cells. 
 
The patterns for the growth factors VEGF and M-CSF in HepG2 cells after treatment were 
similar to CXCL8 and CCL5 (Figure 41). Sorafenib, U0126, AZD6244 and PD0325901 
reduced and PLX4720 increased secretion again indicating a strong direct regulation by the 
oncogene-driven MAPK pathway. Although sorafenib and PLX4720 had opposite effects on 
the phosphorylation of ERK, both inhibitors increased secretion of the c-kit ligand SCGF 
(Figure 41), indicating that this growth factor is not directly regulated by the MAPK pathway. 
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In Hep3B cells, only sorafenib could inhibit VEGF and M-CSF secretion, while the other 
inhibitors had only minor effects. SCGF secretion was only weakly influenced by the 
inhibitors. In Huh-7 cells, the growth factor VEGF is reduced by sorafenib and AZD6244, but 
not by U0126 treatment while sorafenib increased secretion of SCGF. In all three cell lines 
TGFβ secretion is slightly reduced with sorafenib, U0126 and AZD6244 (PD0325901 and 
PLX4720 not tested), indicating that TGFβ secretion is influenced but not dependent on the 
MAPK pathway (Figure 41). 
 
 
The three cell lines also differed substantially in the secretion of IL-1RA with the highest 
amount secreted by HepG2 and no detection in Huh-7 cells (Figure 42). While sorafenib, 
U0126, AZD6244 and PD0325901 reduced IL-1RA secretion in HepG2 cells, PLX4720 led 
to an increase. In Hep3B cells, the weak IL-1RA secretion was slightly enhanced by U0126 
and AZD6244 with the exception of PLX4720. Soluble ICAM-1 was strongly decreased by 
MAPK inhibitors across the cells with the exception of PLX4720 in HepG2 cells. 
In strong contrast to chemokine and growth factors, an increase in secretion by the four 
inhibitors was only seen for MIF (Figure 42). In HepG2 cells, U0126, AZD6244 and 
PD0325901 induced MIF even stronger than sorafenib. In Hep3B cells, PD0325901 treatment 
 
Figure 41: Secretion of growth factors is modulated by MAPK inhibitors. HepG2, Hep3B and 
Huh-7 cells were treated with 5 µM MAPK inhibitors or DMSO control for 48 h and supernatant was 
analyzed for growth factors. 
 
HepG2
Hep3B
Huh-7
VEGF M-CSF SCGF TGFβ
 5.2 Immunological Side Effects of MAPK Inhibitors 
91 
 
led to the highest raise in MIF. In contrast to HepG2 and Hep3B, sorafenib induced a strong 
increase in the secretion of MIF in Huh-7 cells whereas U0126 and AZD6244 only raised 
MIF concentration to a slight amount (PD0325901 was not tested). Since MIF has a number 
of tumor protective functions, this upregulation may be associated with an acquisition of 
severe resistance mechanisms by the tumor cells. 
 
 
In addition to NKG2D ligand surface expression, soluble variants were also addressed. These 
soluble MICA (sMICA) and MICB (sMICB) are formed by metalloprotease-mediated 
cleavage. Soluble MICB is increased in sera of cancer patients and are postulated to impair 
anti-tumor immune responses by downregulating expression of NKG2D on T and NK cells 
(Tamaki et al., 2010). Soluble MICA was not detected for HepG2, Hep3B and Huh-7 cells, 
probably due to alleles that are not recognized by the used ELISA. Soluble MICB was 
measured, with higher concentrations in HepG2 and no detection in Huh-7 cells (Figure 43). 
Treatment with 5µM MAPK inhibitors almost completely inhibited sMICB secretion in 
HepG2, but in Hep3B cells only sorafenib showed strong reduction of sMICB. This 
differential effect of MAPK inhibitors between HepG2 and Hep3B cells may be linked to a 
different dependency of metalloproteases (MMPs) by the MEK/ERK pathway. 
 
Figure 42: Secretion of soluble adhesion molecules is modulated by MAPK inhibitors. 
HepG2, Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitors or DMSO control for 48 h 
and supernatant was analyzed for soluble adhesion molecules and other factors such as soluble 
receptors (IL-1RA). 
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In summary, it was detected that the three cell lines HepG2, Hep3B and Huh-7 secrete 
different chemokines and growth factors to an individual degree. Treatment with the B-Raf 
inhibitor sorafenib and the MEK inhibitors U0126, AZD6244 and PD0325901 mostly reduced 
the secretion of chemokines like CXCL8 for instance. Nevertheless, an increase in chemokine 
secretion was also detected, but remarkably not in all cell lines and for all inhibitors. The 
degree of inhibition varied between the cell lines and inhibitors. However, the strongest 
correlation between pathway inhibition and reduction in secretion was observed for CXCL8 
and VEGF indicating that these strong tumor promoting factors are tightly linked to the 
oncogenic MAPK pathway. Remarkably, MIF was the only factor, which was increased with 
sorafenib and the MEK inhibitors, but effects were dependent on the cell line. The specific B-
Raf inhibitor PLX4720 behaved partially different. For several factors like CXCL8, CCL5, 
VEGF and IL-1RA a strong increase in secretion was detected. In the NRas-mutant HepG2 
cell line, this effect was most pronounced.  
Although all these inhibitors except PLX4720 were shown to inhibit the MAPK pathway in 
section 5.1.1, they show different effects in the three different cell lines. Since hepatocellular 
carcinoma varies substantially between patients, it is of great interest to see whether these 
inhibitors have also different effects in the patients regarding the microenvironment in tumor 
tissue. Therefore, I analyzed HCC tissue in collaboration with H. Bantel (Hannover Medical 
School, Germany). 
 
 
Figure 43: Soluble MICB secretion is partially reduced by MAPK inhibitors. HepG2, Hep3B 
and Huh-7 cells were treated with 5 µM MAPK inhibitors for 48 h. Supernatant was collected and 
sMICB was measured by ELISA. In HepG2 cells, sMICB is reduced with all MAPK inhibitors 
including PLX4720. In Hep3B cells, only sorafenib and only partly PD0325901 and PLX4720 show 
an inhibition of sMICB. In Huh-7 cells, sMICB was not detected. Shown is one representative 
experiment out of two independent experiments. n=2 ± SD 
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5.3 Modulation of MAPK Pathway in Healthy and HCC Tissue 
5.3.1 Hepatic microenvironment 
Before analyzing the effect of MAPK pathway inhibition on the tumor microenvironment, the 
cytokine, chemokine and growth factor milieu was determined in liver tissue samples of 
healthy liver, healthy liver tissue derived during resection of colorectal metastases, cirrhotic 
liver tissue and HCC, respectively. The healthy liver tissue was derived from two donor liver 
that finally were not transplanted and from a hemangioma. Using the multiplex method, 50 
cytokines, chemokines and growth factors were simultaneously measured in tissue lysates and 
some results are depicted in Figure 44 and Figure 45. 
Chemokines, which are separated into four families, the C, CC, CXC and CX3C chemokines, 
play a pivotal role for the recruitment of circulating immune cells, but also a variety of them 
have many other important functions involved in angiogenesis and carcinogenesis (Keeley et 
al., 2011; Simpson et al., 2003).  
For the CXC chemokines, it could be detected that the protein expression of CXCL8 (IL-8), 
CXCL9 (MIG) and CXCL10 (IP-10) was already increased in resected liver tissue of 
colorectal metastases, cirrhosis and HCC, although the increase of CXCL10 in liver tissue of 
patients with colorectal metastases and cirrhosis was not significant. The significant 
differences between healthy liver tissue and liver tissue obtained in the course of colon 
metastases resection demonstrate that the microenvironment in the metastatic situation is 
already influenced by the primary colon tumor. The levels of CXCL1 (Gro-α) and CXCL12 
(SDF-1α) did not significantly differ between the patient groups. 
The CC chemokines CCL2 (MCP-1) and CCL4 (MIP-1β) showed a tendency of increased 
levels in resected liver tissue from colorectal metastases, liver tissue of cirrhosis and HCC 
patients. The profile in cirrhosis and HCC seemed to be separated in two populations, one 
increased and one reduced for CCL3 (MIP-1α), CCL7 (MCP-3) and CCL27 (CTACK). This 
subgroup formation in a high vs. a low concentration group was also observed for other 
proteins; however, the basis for this distribution remains elusive. For resected liver tissue 
from colorectal metastases, the CCL3 and CCL27 chemokine levels were increased. The 
chemokine CCL5 (RANTES) showed a tendency of higher levels in resected liver tissue of 
colorectal metastases and cirrhotic liver, but not in HCC. 
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Figure 44: Chemokine milieu in healthy liver, liver resection of colorectal metastases, 
cirrhosis and HCC. Lysates were generated from frozen liver tissue and protein concentration was 
set to 1500 µg/ml. CXC chemokine (A) and CC chemokine (B) concentrations were simultaneously 
measured by multiplex analysis. N: Normal healthy tissue (n=3), CoCa: resected liver tissue of 
colorectal metastases (n=4), Cirrh: cirrhotic tissue (n=13), HCC: HCC tissue (n=15). 
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Figure 45: Cytokine milieu and adhesion molecules in healthy liver, liver resection of 
colorectal metastases, cirrhosis and HCC. Lysates were generated from frozen liver tissue and 
protein concentration was set to 1500 µg/ml. IFNγ and interleukin (A) and growth factor and 
adhesion molecule (B) concentrations were simultaneously measured by multiplex analysis. N: 
Normal healthy tissue (n=3), CoCa: resected liver tissue of colorectal metastases (n=4), Cirrh: 
cirrhotic tissue (n=13), HCC: HCC tissue (n=15). 
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Interferons and interleukins, which are cytokines and act as mediators between cells, were 
also differently accumulated in the different tissue. IFNγ, the most important effector 
interferon, was partly reduced in cirrhosis and HCC, compared to healthy and resected liver 
tissue of colorectal metastases, suggesting that effector functions are reduced in these tissues. 
Remarkably, IL-6 levels were increased in resected liver tissue of colorectal metastases and 
HCC by not a significant extend as expected from the literature where IL-6 is postulated to 
drive the tumor microenvironment (Germano et al., 2008; Yang et al., 2011). In contrast, IL-9 
and IL-10 surprisingly were reduced in cirrhosis and HCC, but not in resected liver tissue of 
colorectal metastases, which is unexpected because IL-10 is postulated to protect tumor tissue 
by counteracting an IFNγ-mediated effector milieu. An increased level of IL-1RA and IL-16 
was observed for liver tissue of colorectal metastases resection, cirrhosis and HCC. There 
were also interleukins, which were not altered in liver tissue of colorectal metastases 
resection, cirrhosis and HCC. IL-2, IL-4, IL-5 and IL-13 secretion was at a very low level in 
all four different liver tissues (data not shown). Other interleukins like IL-12 and IL-18 were 
secreted to a medium amount, but also no real differences were observed in the different 
tissues (data not shown) indicating that these interleukins do not seem to play a role in the 
development of cirrhosis and HCC. 
 
Stimulating factors and growth factors play an important role in carcinogenesis since growth 
factors are often overexpressed in tumor tissue. As expected, the growth factors VEGF and 
SCGF-β were both increased in HCC, and SCGF-β was also increased in the cirrhotic tissue. 
Since both growth factors were shown to be secreted by HCC cells (5.2.5), these high 
amounts could be indeed be produced by tumor cells. Interestingly, HGF was only 
significantly increased in cirrhotic tissue, but not in HCC, indicating that HGF is not needed 
for the maintenance of HCC but maybe for the development into HCC. In contrast, G-CSF 
was reduced in resected liver tissue, cirrhosis and HCC. 
Soluble adhesion molecules like ICAM-1 and VCAM-1 are often found to be increased in 
patients with tumors. It could be detected that in resected liver tissue of colorectal metastases, 
in cirrhotic and HCC tissue the concentrations of ICAM-1 and VCAM-1 was increased 
compared to healthy liver tissue. 
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The multiplex analysis generated a huge amount of data, because 50 different factors were 
measured in four different types of liver tissue. In cooperation with Anne Skoeries (Niels 
Halama, Hamamatsu TIGA Center, University of Heidelberg), a bioinformatic approach was 
used to analyze differences and possible classifications of the healthy liver, resected liver 
tissue of colorectal metastases, cirrhosis and HCC.  
A classification tree of cytokines, chemokines or growth factors was generated to predict the 
pathological state of the liver whether it is healthy, cirrhotic, HCC or comes from a colorectal 
metastasis, on the basis of the cytokine and chemokine milieu (Figure 46). The classification 
tree showed that using around four different factors, the different liver tissues can be grouped 
 
Figure 46: Classification tree of analyzed cytokines, chemokines and growth factors. 
Classification tree was generated by using the 50 different measured cytokines, chemokines and 
growth factors. NL: Normal healthy tissue (n=3), nCM: resected liver tissue of colorectal 
metastases (n=4), Zir: cirrhotic tissue (n=13), HCC: HCC tissue (n=15). Analysis was performed by 
A. Skoeries (Hamamatsu TIGA Center, University of Heidelberg). 
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and predicted. An important classification factor is HGF, where high levels of HGF nicely 
separate the majority of the cirrhotic tissue from the rest. From the remaining samples, HCC 
tissue can be classified by using high levels of SCGF-β. Normal healthy liver and histological 
“healthy” liver tissue from patients with colorectal metastasis can be distinguished by using 
IL-17, where IL-17 levels are lower in healthy liver, and IL-1RA can be further used to 
clearly separate the healthy liver tissue. This method shows that the classification tree is a 
very helpful tool to interpret large amount of data, which were generated by the multiplex 
analysis. 
 
In summary, several CXC but not so much CC chemokines were increased in cirrhotic and 
HCC liver tissue compared to healthy liver tissue. Some CC chemokines showed a tendency of 
decreased levels in the tumor tissue. Interleukins were differentially altered in cirrhotic and 
HCC tissue. Tissue concentrations of growth factors and adhesion molecules were elevated in 
cirrhotic and HCC tissue. With the help of a classification tree, HGF, SCGF-β, IL-17 and 
IL-1RA can be used to predict the status of the liver tissue. 
These results raise the question whether treatment of HCC tumor with small molecules like 
sorafenib and the MEK inhibitors would normalize the cytokine and chemokine milieu in 
HCC tumor tissue. Moreover, it is interesting to analyze whether these alterations of the 
microenvironment have an effect in the composition of immune cells in cirrhotic and HCC 
liver compared to healthy liver, as indicated in section 6.2.2. 
  
 5.3 Modulation of MAPK in Liver and HCC Tissue 
99 
 
5.3.2 Modulation of cytokine and chemokine secretion by MAPK inhibitors 
in ex vivo hepatic tissue 
 
As described in 5.3.1, several different cytokines, chemokines and growth factors can be 
detected in liver tissue and the composition seems to vary substantially according to the 
condition, i.e. healthy, cirrhosis, HCC. The microenvironment in HCC tissue is associated 
with an increase in several chemokines and growth factors. In addition, the chemokine 
secretion of tumor cells was modulated by MAPK inhibitors in vitro (5.2.5). Most of the 
factors which were increased in the tumor were downregulated with these inhibitors. In order 
to analyze the effects of the MAPK inhibitors on ex vivo liver tissue, which consist a variety 
of different cells, fresh liver tissue samples from patients with HCC or normal liver were 
treated in vitro for 8 h with medium or 7.5 µg/ml sorafenib. In a first experiment also the 
MEK inhibitors U0126, AZD6244 and PD0325901 and the B-RafV600E inhibitor PLX4720 
were used for tissue treatment (data not shown). After 8 h, tissue lysates of these HCC and 
normal liver tissues were prepared and both supernatants and tissue lysates were analyzed in 
parallel for 50 cytokines, chemokines and growth factors. Parts of these parameters are 
depicted in Figure 47 to Figure 50. These experiments were performed in cooperation with 
Kristin Wahl (Laboratory H. Bantel, Hannover Medical School, Germany). 
The chemokines CXCL8, CXCL9, CXCL10 and CCL4 were significantly upregulated and 
CXCL1, CCL2 and CCL3 were partly increased in HCC tissue as described in 5.3.1. 
Treatment of HCC tissue for 8 h with sorafenib clearly reduced the secretion of the CXC 
chemokines CXCL8, CXCL9, CXCL10 and CXCL1 in both tissue and supernatant (Figure 
47). In contrast, for CXCL1 and CXCL9 one and two out of the six tissue samples showed a 
significantly increase in concentration after sorafenib treatment indicating that these 
chemokines are independently regulated in tissues. 
With respect to CC chemokines, CCL2 and CCL4 secretion was inhibited by sorafenib in 
tissues and supernatants with only one exception (Figure 47B). The content of CCL5, CCL7 
and CCL27 was not significantly altered by sorafenib treatment. For CCL5, a tendency of 
downregulation in four out of six samples was detectable, while in supernatants the high 
CCL5 levels were reduced and low levels were increased after sorafenib treatment. The 
difference between tissue and supernatants may be due to different modes of chemokine 
secretion into interstitial tissue which may be easily “washed out” into the supernatant. Other 
chemokines, however, may be rather cell-bound and not released into the supernatant. 
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Figure 47: Sorafenib alters the chemokine milieu in HCC tissue. Fresh HCC tissue was treated 
in vitro with medium or 7.5 µg/ml sorafenib for 8 h (*). Supernatant (SN) was collected, tissue 
lysates were generated and protein concentration was set to 500 µg/ml. CXC chemokine (A) and 
CC chemokine (B) concentrations of supernatants and tissue lysates were simultaneously 
measured by multiplex analyses. M: medium; S: sorafenib; n=6.  
(
*
)
 Treatment was performed by Kristin Wahl (H. Bantel, Hannover Medical School). 
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Alterations of the chemokines after treatment with sorafenib were also seen in the supernatant 
of healthy liver tissue (Figure 48). Due to the limited tissue material, only supernatants of 
healthy liver tissue was available. Similar to HCC, CXCL8, CXCL10 and CXCL1 were 
downregulated after sorafenib treatment with one exception for CXCL8, were an increased 
concentration was detected. In contrast to HCC tumor tissue, CXCL9 showed no substantial 
alteration after treatment. Again similar to HCC tissue, CXCL12 was mostly upregulated 
following sorafenib exposure. Overall in healthy liver, it seems that sorafenib has more 
consistent effects on CC chemokines than in HCC where the etiology may have a more 
dominant impact. The secretion of CCL2, CCL4, CCL5 and CCL7 was rather inhibited while 
CCL27 could be modulated in both directions. 
  
 
Figure 48: Sorafenib alters the chemokine milieu in healthy liver. Fresh healthy liver tissue 
was treated in vitro with medium or 7.5 µg/ml sorafenib for 8 h and supernatant (SN) was collected 
(
*
)
. CXC chemokine (A) and CC chemokine (B) concentrations were simultaneously measured by 
multiplex analyses. M: medium; S: sorafenib; n=8. 
(
*
)
 Treatment was performed by Kristin Wahl (H. Bantel, Hannover Medical School). 
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Besides the chemokines, also interleukins, growth factors and adhesion molecules were 
analyzed after sorafenib treatment (Figure 49 for HCC and Figure 50 for healthy liver). 
IL-1RA is an inhibitor of the pro-inflammatory cytokine IL-1. In HCC tissue, high amounts of 
IL-1RA were detectable (5.3.1). Treatment with sorafenib decreased IL-1RA in the 
supernatant, while in tissue lysates, it could be modulated in both directions. IL-6, which acts 
as a pro- and as an anti-inflammatory cytokine, seems to be highly soluble, because it is found 
in HCC supernatant. Sorafenib treatment reduced IL-6 in the supernatants with one exception. 
 
Figure 49: Sorafenib alters the cytokine milieu and adhesion molecules in HCC. Fresh HCC 
tissue was treated in vitro with medium or 7.5 µg/ml sorafenib for 8 h (*). Supernatant (SN) was 
collected, tissue lysates were generated and protein concentration was set to 500 µg/ml. 
Interleukin (A), growth factor and adhesion molecule (B) concentrations were simultaneously 
measured by multiplex analyses. M: medium; S: sorafenib; n=6. For ICAM-1 and VCAM-1 only the 
supernatants were analyzed (n=3). 
(
*
)
 Treatment was performed by Kristin Wahl (H. Bantel, Hannover Medical School). 
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The Th2 response inducing cytokine IL-9 was found in low concentrations and was reduced 
in tissue lysates by sorafenib. Similarly, IL-16 and IL-18 were both reduced in the tissue 
lysates after treatment, while no tendency was observed in supernatants.  
Growth factors were not clearly modulated by sorafenib treatment of HCC. The 
concentrations of VEGF in tissue showed a broad range that was influenced in both directions 
which, again, may be influenced by the HCC etiology. The two adhesion molecules ICAM-1 
and VCAM-1 were highly concentrated in supernatants and even elevated by sorafenib.  
In healthy tissue, in general, alteration of interleukins, growth factors and adhesion molecules 
were also observed, but appeared to be more homogeneous. IL-1RA, IL-6 and IL-16 were 
mainly decreased by sorafenib treatment, while somewhat higher concentrations of IL-9 and 
IL-18 were measured. VEGF concentrations were not influenced by sorafenib treatment and 
SCGF-β was elevated in some samples and decreased in others. 
Interestingly, the effect of sorafenib on the adhesion molecules ICAM-1 and VCAM-1 was 
different in healthy liver compared to HCC tumor tissue. While in HCC, sorafenib induced an 
elevation of ICAM-1 and VCAM-1, they were rather decreased in healthy liver. 
 
 
Figure 50: Sorafenib alters the cytokine milieu and adhesion molecules in healthy liver. 
Fresh healthy liver tissue was treated in vitro with medium or 7.5 µg/ml sorafenib for 8 h and 
supernatant (SN) was collected (*). Interleukin (A), growth factor and adhesion molecule (B) 
concentrations were simultaneously measured by multiplex analyses. M: medium; S: sorafenib; 
n=8. (*) Treatment was performed by Kristin Wahl (H. Bantel, Hannover Medical School). 
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In summary, in HCC tumor tissues, several chemokines and cytokines were found to be 
present of higher concentrations compared to non-malignant liver tissue. This observation 
supports the assumption that the hepatic microenvironment is comprised by tissue- and 
etiology-specific mixture of soluble mediators like cytokines, chemokines and growth factors. 
This dynamic composition can be influenced by viruses, cirrhotic and, finally malignant 
transformation and also by inhibition of signaling pathways. 
Treatment with sorafenib mostly reduced the secretion of several CXC and CC chemokines in 
the tumor tissue, which nicely resembles the observation with HCC cell lines. In healthy tissue 
these chemokines were also partly reduced in a homogeneous fashion. Rather rarely, 
chemokines were elevated after sorafenib treatment indicating that the MAPK pathway is 
involved in chemokine secretion at various positions. Sorafenib also reduced interleukin and 
growth factor secretion in tumor tissue, but increased the release of adhesion molecules into 
supernatant. In healthy tissue, these effects were less pronounced suggesting that the 
malignant transformation into HCC impinges on the microenvironment, presumably driven by 
mutations as well as the individual etiology.  
Since the microenvironment is important for the composition, recruitment and infiltration of 
immune cells into the liver tissue, it would be of great interest to see whether treatment with 
these MAPK inhibitors has an effect on the immune cell infiltration into the tumor site and the 
adjacent tissue. To date, no such immune monitoring is performed in the clinical trials, 
unfortunately. 
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6 Discussion and Conclusions 
 
Hepatocellular carcinoma is one of the most prevalent tumors worldwide. The MAPK 
pathway plays a central role in carcinogenesis and seems to be a good therapeutic target. So 
far, sorafenib is the only treatment option with some stabilization of the disease, but survival 
benefits are not sustained with only three to four months longer compared to non-treated 
patients. Although sorafenib treatment cannot cure HCC, it is very important to gain detailed 
insights in the action of sorafenib and other MAPK inhibitors. With this knowledge, more 
effective drugs could be developed or new combinations of drugs might be administered to 
achieve the desired effects, e.g. prolongation of survival. 
To comprehensively analyze the effects of the MAPK pathway and the effects of its inhibition 
in hepatocellular carcinoma, sorafenib was compared to other MAPK inhibitors used in 
clinical and pre-clinical evaluations for the treatment of HCC. Therefore, the effects were 
determined regarding the impact on (1) signaling pathways, (2) proliferation and apoptosis, 
(3) surface molecule expression involved in NK cell recognition, (4) secretion of chemokines 
and growth factors by tumor cells, (5) the hepatic microenvironment upon exposure to MAPK 
inhibitors, sorafenib in particular. 
 
 
6.1 Signaling Pathways 
 
Cellular behavior and cell fate is regulated through diverse signaling pathways rather than 
regulated by just one pathway. Often, it is a combination of different signaling pathways 
which determines the cellular response. In tumor development, often one or more of these 
pathways are constantly activated. In HCC, The MAPK pathway, in particular, is often over-
activated because it plays a pivotal role for cell proliferation and survival. Constant activation 
of the MAPK pathway is frequently due to mutations in components upstream of the pathway. 
Through these mutations, often other signaling pathways are also affected in compensatory or 
feedback loops. Because different signaling pathways are connected to some extend through 
these cross-talk or feedback connections, it is very important to perform a broad analysis 
when analyzing signaling pathways and effects of signaling inhibitors like sorafenib. Because 
of its contribution to tumorigenesis, tumor progression and disease metastasis formation, 
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intensive research has been performed on the MAPK pathway as a therapeutic target (Friday 
and Adjei, 2008; Leicht et al., 2007). Still, the systemic effects of MAPK inhibition in tumor 
and non-tumor cells are poorly understood.  
 
6.1.1 MEK/ERK signaling in HCC cells 
Increased MAPK expression and activity has been described in primary human hepatocellular 
carcinoma, which is normally measured as phosphorylation of MEK1 at Ser217/Ser221 and 
ERK1/2 at Thr202/Tyr204 and Thr185/Tyr187. This is often due to a mutation in the receptor 
tyrosine kinases or the Ras protein (Downward, 2003; Gollob et al., 2006). The HepG2 cell 
line has an NRas (Q61L) mutation leading to an activation of the MAPK pathway. Although 
Hep3B and Huh-7 cells do not have a mutation directly in the MAPK pathway, the phospho-
MEK/ERK levels were at the level of HepG2 cells indicating that Hep3B and Huh-7 cells can 
constantly activate the MEK/ERK pathway through other mechanisms. This activation can be 
inhibited by the treatment with the Raf inhibitor sorafenib and the MEK inhibitors U0126, 
AZD6244 and PD0325901 and is depicted in a schematic diagram in Figure 51. Inhibition is 
demonstrated by an immediate and sustained decrease in phosphorylation of ERK1/2. 
Sorafenib binds and thereby inhibits Raf which is upstream of MEK (Figure 12) and as a 
consequence, MEK phosphorylation is blocked (Figure 13). The MEK inhibitors U0126, 
AZD6244 and PD0325901, in contrast, bind to and inhibit the MEK kinase (Figure 13). 
Although they inhibit MEK, they do not necessarily block the phosphorylation site of MEK, 
meaning that Raf can still phosphorylate MEK. Due to a block in the kinase activity of MEK, 
the phosphate group is not transferred to downstream ERK. Thus, p-MEK accumulates which 
is in accordance with earlier reports (Hennig et al., 2010; Huynh et al., 2007). Huynh et al. 
also described that AZD6244 was even able to activate B-Raf which then led to an increase in 
p-MEK. 
Remarkably, ERK phosphorylation was not always constantly inhibited by the concentrations 
of 5 µM sorafenib and U0126. Although p-MEK1 was inhibited by sorafenib in HepG2 cells 
and p-MEK1 was increased by U0126, p-ERK was elevated after 24 h in HepG2 cells. Maybe 
MEK1 inhibition was not complete, so that some MEK1 or even MEK2 can still transfer the 
phosphate group to ERK1/2. When using higher concentrations of sorafenib (10 µM), no 
increase of p-ERK1/2 was detected in HepG2 cells (data not shown). It still has to be 
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determined whether this increase is just an effect of the concentration or whether resistance to 
drug treatment has already occurred, because it was described that Hep3B cells showed signs 
of resistance during treatment with U0126 (Yip-Schneider et al., 2009). 
In contrast to sorafenib and the MEK inhibitors, the mutation-specific B-RafV600E inhibitor 
PLX4720, which also inhibits to some extent the wild-type B-Raf, induced a hyperactivation 
of p-MEK1 and p-ERK1/2 in the tested NRas-mutant HepG2 and NRas-wild-type Hep3B 
cells (Figure 13). PLX4720 is currently tested for melanoma treatment, where the B-Raf has 
often a point mutation at position 600 leading to a strong MAPK activation (Tsai et al., 2008). 
In mutant B-RafV600E cells, the MAPK pathway is inhibited by PLX4720, but it has been 
reported that PLX4720 induces hyperactivation of the MEK/ERK pathway in NRas-mutant 
melanoma cells (Heidorn et al., 2010; Kaplan et al., 2011). Because PLX4720 is only 
inhibiting B-Raf and not C-Raf, it is speculated that C-Raf dimerizes with B-Raf and is taking 
over the part of the inhibited B-Raf, and, thereby, activates the MEK/ERK pathway (Figure 
51). This could explain the results for the NRas-mutant HepG2 cells. Interestingly, in NRas-
wild-type Hep3B cells a slight increase of MEK and ERK was also detected indicating that 
the described hyperactivation induced by PLX4720 is not limited to NRas-mutant cells. 
 
 
 
Figure 51: Effects of MAPK inhibitors on MEK/ERK signaling in HCC cells. Sorafenib inhibits 
both B- and C-Raf leading to an inhibition of downstream MEK and ERK. PLX4720 inhibits B-Raf, 
but not C-Raf leading to an activation of MEK and ERK via C-Raf in NRas-mutant and NRas-wild-
type HCC cells. U0126, AZD6244 and PD0325901 inhibit the MAPK pathway at the MEK level and 
downstream ERK is inhibited. Pathway was generated with the help of the pathway builder from 
www.proteinlounge.com. 
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Besides analyzing the phosphorylated kinases, it is also important to measure the total amount 
of kinases to see whether degradation has taken place. Treatment with sorafenib, U0126 and 
AZD6244 showed different effects on the total MEK levels which may be associated with 
their different mechanisms of action. Degradation of MEK1 was extreme with AZD6244 
treatment and only low with sorafenib and U0126. The differences between the two MEK 
inhibitors U0126 and AZD6244 might be explained by their different binding sites to MEK1. 
This strong decrease of t-MEK is in contrast to the strong increase of p-MEK. In contrast, the 
total amount of the downstream ERK levels was not substantially changed indicating that the 
modulation of total kinases was not due to different protein concentrations. 
 
Our findings indicate that AZD6244 and PD0325901 have a high efficacy for the inhibition of 
the MEK/ERK pathway even better than sorafenib, the currently used treatment for HCC. 
These findings are in accordance to other reports, where it was described that PD0325901 and 
AZD6244 are specific MEK inhibitors leading to a blockage of the conversion of ERK to its 
activated, phosphorylated form (Hennig et al., 2010; Huynh et al., 2007). 
6.1.2 Akt, JNK and p38 signaling pathways 
Because different signaling pathways are often closely connected, possible side-effects of 
MAPK inhibition on linked signaling pathways, i.e. JNK, p38 and Akt, were evaluated. The 
JNK and the p38 pathways can mainly be activated through stress stimuli, such as UV 
radiation, cytokines, inflammatory signals, heat shock and changes in the level of reactive 
oxygen species and also be activated by the Ras protein (Krishna and Narang, 2008). JNK has 
been reported to be a double-edged sword with pro- and anti-apoptotic functions (Liu and Lin, 
2005). In general, low levels of phosphorylated JNK were observed in all three cell lines 
(Figure 14). Increase in phosphorylation was mostly seen in Hep3B and Huh-7 cells with the 
MEK inhibitors, indicating that the MEK inhibitors induce a link to JNK phosphorylation, 
which might be induced through stress signals.  
For the p38 kinase it has been reported that it is negatively regulated by the MEK/ERK 
pathway (Chen et al., 2000). We could observe that in HCC cell lines, the basal p38 levels 
were in general low (Figure 14). Only sorafenib treatment shortly induced p38 
phosphorylation in HepG2 and Hep3B cells indicating that in HCC cells p38 is not closely 
linked to the constitutive MEK/ERK pathway. 
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Both JNK and p38 regulate several transcription factors like c-Jun and ATF-2. Activated 
c-Jun, in turn, can regulate gene expression together with c-Fos by forming one of several 
different AP-1 complexes at the DNA AP-1 binding site, which regulate several target genes 
involved in differentiation, cell migration, cytokine production, apoptosis and wound healing 
(Shaulian, 2010). c-Jun is also a double-edged sword with pro- and anti-apoptotic functions 
(Bossy-Wetzel et al., 1997; Eferl et al., 2003; Shaulian, 2010). In HCC cell lines, c-Jun 
activation does not correlate with JNK and p38 activation, indicating that c-Jun is regulated 
by other mechanisms. Basal c-Jun levels were high in these cell lines showing an already 
constitutive activation (Figure 15). While in Hep3B and Huh-7 cells, c-Jun gets even more 
activated by sorafenib and the MEK inhibitors, in HepG2 cells only sorafenib induced a 
strong phosphorylation of c-Jun suggesting different regulation mechanisms in the cell lines. 
The transcription factor ATF-2, which is regulated by JNK and p38, can form homodimers or 
heterodimers with c-Jun and the complex stimulates CRE-dependent transcription (De Cesare 
et al., 1995). The increase in p-ATF-2 cannot be explained by JNK or p38 activation, 
indicating that other molecules are also responsible for ATF-2 phosphorylation. These results 
suggest that there might be a negative feedback loop between the MEK/ERK pathway and 
c-Jun and ATF-2, but both transcription factors seem to be regulated by some MEK/ERK-
independent mechanisms. 
 
In several tumor cells, the PI3K/Akt pathway is connected to the MAPK pathway. Both 
MEK/ERK and PI3K/Akt pathways can be regulated by Ras and interact with each other for 
the regulation of cell growth, but also tumorigenesis (Figure 4) (McCubrey et al., 2007). In 
addition, Akt is also activated independently of Ras through RTKs and PI3Ks. The PI3K/Akt 
pathway is stimulated through growth factors and survival factors and regulates many 
different cell functions like cellular survival, inhibition of apoptosis, angiogenesis and tumor 
development (Osaki et al., 2004). In HCC cell lines, intermediate p-Akt was observed in 
HepG2 and Huh-7 cells, but high basal levels in Hep3B cells (Figure 14). During MAPK 
inhibitor treatment, differences were especially seen in HepG2 cells where MEK inhibitors 
induced long-term activation of Akt while sorafenib initially increased phosphorylation but 
then inhibited p-Akt. These results show that sorafenib and the MEK inhibitors have partially 
opposite effects on p-Akt. The Inhibition of RTKs by sorafenib but not by the MEK inhibitors 
might contribute to the different effects observed for the regulation of Akt. Is has been 
reported that constitutive activation of the Raf-MAPK pathway causes negative feedback 
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inhibition of PI3K/Akt (Menges and McCance). This may explain why Akt phosphorylation 
was decreased by PLX4720 in HepG2 cells. 
Akt phosphorylation has been implicated in early HCC recurrence and high p-AktSer473 is 
associated with poor prognosis (Whittaker et al., 2010). For the treatment of HCC, the MEK 
inhibitors AZD6244 and PD0325901 are currently under clinical and pre-clinical evaluation, 
respectively. Both induced phosphorylation of Akt in the NRas-mutant HepG2 cells 
indicating that the combination of NRas mutation and inhibition of ERK lead to increased Akt 
phosphorylation. Moreover, it raises the question whether this Akt phosphorylation has an 
influence on the progression of tumor growth, prognosis and tumor recurrence. There are 
several studies indicating that an increase in p-Akt leads to resistance towards MAPK 
inhibition (Balmanno et al., 2009; Chen et al., 2011; McCubrey et al., 2006). Therefore, it 
would be of great interest to see whether increased Akt phosphorylation, early HCC 
recurrence and NRas mutations can be correlated in HCC patients. 
In conclusion, our analyses showed that inhibition of Raf as well as of MEK affects other 
signaling pathways (JNK, Akt, p38) and downstream transcription factors (c-Jun, ATF-2), but 
the exact mechanisms are still unclear. 
6.1.3 Proliferation 
Since the MAPK pathway plays a prominent role for cell proliferation and migration (Katz et 
al., 2007), it is not surprising that inhibition of the MAPK pathway led to a decrease in cell 
proliferation (Figure 16). The decrease in cell number was comparable in sorafenib, 
AZD6244 and PD0325901 treated cells, while U0126 had weaker effects. It has recently been 
described that sorafenib, U0126, AZD6244 and PD0325901 inhibit cell proliferation in 
HepG2, Hep3B and primary HCC cells (Hennig et al., 2010; Huynh et al., 2007; Liu et al., 
2006). I could also detect that cell division was inhibited mainly by sorafenib and to a lesser 
extent by the MEK inhibitors (Figure 18), indicating that regulation of cell division is only 
partly dependent on the MEK/ERK pathway (Figure 52). It has been reported by Liu et al. 
that sorafenib treatment of HepG2 cells lead to a downregulation of cyclin D1 (Liu et al., 
2006), which is regulated through MEK/ERK and PI3K/Akt (Figure 52). They described the 
downregulation of cyclin D1 as MEK/ERK dependent, since U0126 also induced inhibition of 
cyclin D1. 
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In contrast to sorafenib and the MEK inhibitors, the B-RafV600E inhibitor PLX4720 induced 
hyperactivation of the MEK/ERK signaling pathway in the NRas-mutant HepG2 cells and to 
some extent also in the NRas-wild-type Hep3B cells (Figure 52). Despite this hyperactivation, 
no enhanced but rather decreased proliferation was detected. This is in agreement with a 
recent study where in NRas-mutant melanoma cells PLX4720 induced hyperactivation of the 
MEK/ERK pathway, but did not enhance cell cycle properties (Kaplan et al., 2011). In 
another study, Menges and McCance could show that the constitutive activation of the 
MEK/ERK pathway causes cellular arrest through the ephrin type-A2 receptor (Menges and 
McCance, 2008). 
In addition to the MEK/ERK pathway, the PI3K/Akt pathway plays also an important role for 
cell cycle regulation. Akt can phosphorylate p21 and p27 and inhibits their anti-proliferative 
effects, the inhibition of the cyclin D1/Cdk4 complex (Figure 52) (Osaki et al., 2004). We 
could detect that phosphorylation of AktSer473 is decreased and Akt is degraded by sorafenib 
after 24 h. This decrease in Akt would cause an increase in p21 and p27 and an inhibition of 
the cyclin/Cdk complex leading to a cell cycle arrest which indeed was recently described by 
Huynh et al. (Huynh et al., 2009). 
The group of Erwin Wagner has published that p38α negatively regulates cell proliferation by 
antagonizing the JNK–c-Jun pathway in multiple cell types and in liver cancer development 
(Hui et al., 2007). We could observe that phosphorylation of p38 was mainly upregulated by 
sorafenib in the first 6 to 24 h in HepG2 and Hep3B cells which might contribute to the 
inhibition of cell proliferation. 
 
 
Figure 52: Effects of MAPK inhibitors on cell cycle progression. Sorafenib probably induces 
cell cycle stop via inhibition of the MEK/ERK and PI3K/Akt signaling pathway and activation of 
c-Jun and ATF-2 in HCC cells. PLX4720 induces hyperactivation of the MEK/ERK pathway and in 
NRas-mutant HepG2 cells, Akt signaling was reduced and c-Jun increased. MEK inhibitors 
inhibited MEK/ERK signaling, but increased Akt and slightly ATF-2 leading to a partial inhibition of 
the cell cycle. Red arrows indicate that the observed effects were in mutant N-Ras HepG2 cells 
only. Pathway was generated with the help of the pathway builder from www.proteinlounge.com. 
6 Discussion and Conclusions 
112 
 
While c-Jun has mostly been implicated as an enhancer of proliferation and tumor promoter,  
several studies have also shown that c-Jun can prevent tumorigenesis (Shaulian, 2010). It was 
described that in HRas-mutant cells, c-Jun is able to upregulate the transcription of the tumor 
suppressor Dmp1, which in turn increases the expression of the tumor suppressor p19ARF 
(Figure 52) (Sreeramaneni et al., 2005). This tumor suppressor can directly repress cyclin D1 
transcription and can also increase p53 stabilization. In HCC cells, c-Jun was highly 
expressed and phosphorylated and the phosphorylated form was increased by treatment with 
sorafenib and MEK inhibitors. PLX4720 also increased c-Jun in the NRas-mutant HepG2 
cells, but not in Hep3B cells (Figure 52). Since cell proliferation and cell division was 
decreased by MAPK inhibitors, c-Jun seems to be implicated as an inhibitor rather than an 
activator of cell proliferation in HCC cells. 
Besides c-Jun, an increase in p-ATF-2 induced by MAPK inhibitors could be also observed. 
For the regulation of proliferation, it has been reported that high levels of p-ATF-2 inhibit the 
G1/S phase transition of the cell cycle and, thereby, can decrease the proliferation rate (Crowe 
and Shemirani, 2000). Moreover, it has been shown that activated ATF-2 can inhibit the 
transcription of CDK4 (Xiao et al., 2010). CDK4 regulates together with cyclin D the 
progression of the G1 phase into the S phase (Figure 52). In my system, sorafenib induced the 
highest induction of p-ATF-2 which might explain why sorafenib induced the most prominent 
cell cycle arrest. 
6.1.4 Apoptosis 
The goal of tumor treatment is besides inhibition of tumor growth the induction of apoptosis 
in tumor, but not in normal cells. Although several studies have been published about the 
effects of sorafenib, the molecular links towards apoptosis remain not completely understood. 
The problem we are facing in tumor therapy is that tumor cells are often resistant towards 
apoptosis induction. The Ras/Raf/MEK/ERK and PI3K/Akt pathways are often enhanced in 
many HCC cells, leading to resistance against apoptotic stimuli (Fabregat, 2009). HCC cell 
lines with different mutations revealed to have different apoptosis sensitivities upon MAPK 
inhibition in a concentration and time-dependent manner (Figure 19). In cooperation with 
Martina Müller-Schilling (University Hospital Heidelberg), we could show that sorafenib did 
not induce apoptosis in isolated primary human hepatocytes even by increasing the 
concentration, indicating tumor selective effects of sorafenib (manuscript in preparation). The 
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effects of the other MAPK inhibitors still have to be tested on primary human hepatocytes. Of 
the three analyzed HCC cell lines, the p53-deficient Hep3B cells were the most responsive 
cells for inducing apoptosis with 5 µM sorafenib or MEK inhibitor U0126, AZD6244 and 
PD0325901. In contrast, the p53-mutant (Y220C) cell line Huh-7 was resistant to apoptosis 
induction by MEK inhibitors, but not by sorafenib in a dose-dependent manner. These data 
suggest that in Huh-7 cells, apoptosis is induced independently of the MEK/ERK pathway, 
since also AZD6244 and PD0325901 strongly decreased proliferation. Because these two 
inhibitors only inhibited cell cycle to a certain extent, the decrease in cell number seems to 
have other reasons. By using the xCELLigence system, which detects cell impedance, I could 
observe that especially in Huh-7 cells, the MEK inhibitors induced an increase in cell 
attachment and cell size. Therefore, MEK inhibitors seem to induce rather necrotic than 
apoptotic cell death in Huh-7 cells since necrosis is characterized by a gain in cell volume 
(Kroemer et al., 2009). 
In the p53 wild-type and NRas-mutant HepG2 cells, apoptosis was induced by the MAPK 
inhibitors, but to a lesser extent compared to Hep3B cells. At concentrations of 5 µM, mainly 
the MEK inhibitors but not sorafenib significantly induced apoptosis. 5 µM sorafenib did not 
seem to be as effective for the inhibition of the MEK/ERK pathway, which might explain the 
differences in the induction of apoptosis. In contrast, 10 µM sorafenib constantly inhibited 
ERK phosphorylation over 96 h (data not shown) and similar apoptosis rates as by 10 µM of 
the MEK inhibitors were also observed. Therefore, it seems that in NRas-mutant HepG2 cells 
using 5 µM of the inhibitor sorafenib inhibits cell proliferation and cell division more 
effectively than the MEK inhibitors, but the MEK inhibitors induced more apoptosis. This 
indicates that in HepG2 cells, regulation of proliferation is less dependent on the MEK/ERK 
pathway than the induction of apoptosis. This is in contrast to Huh-7 cells, where apoptosis 
and cell proliferation regulation seems to be at least partly MEK/ERK independent. 
 
While sorafenib and the MEK inhibitors did not have strong effects on JNK and p38 
phosphorylation, they induced differences for Akt and the transcription factor ATF-2. 
Sorafenib reduced the level of Akt phosphorylation and induced phosphorylation of ATF-2. 
Moreover in Hep3B and Huh-7 cells, only sorafenib, but not the MEK inhibitors induced 
degradation of total Akt. Our data suggest that Akt plays an important role for the induction 
of apoptosis in some but not all HCC cells. In a study by Chen et al., it was shown that 
downregulation of p-Akt leads to an overcome of apoptosis resistance (Figure 53) (Chen et 
6 Discussion and Conclusions 
114 
 
al., 2008). This group recently demonstrated that activation of Akt in Huh-7 cells leads to 
resistance against sorafenib induced apoptosis (Chen et al., 2011). This nicely fits with my 
findings where sorafenib seems to induce apoptosis through inhibition of Akt. The role of Akt 
for apoptosis resistance in Huh-7 cells against the MEK inhibitors will be further analyzed in 
our lab. 
 
There are many regulators for apoptosis (Figure 53), among them the tumor suppressor p53, 
which is central player for the cell. The high induction of apoptosis in Hep3B cells was 
surprising, because p53-deficient cancer cells are often reported to be less responsive to 
chemotherapy (Alsafadi et al., 2009). In Hep3B cells, the other p53 family members p63 or 
p73 might be able to take over the proapoptotic function of p53. We could observe that 
Hep3B cells express p63 and p73 and during sorafenib treatment, p73 was upregulated 
(Figure 22). In p53 wild-type HepG2 cells, p53 protein was modulated, i.e. phosphorylated at 
Ser15 by sorafenib and the MEK inhibitors, but not by PLX4720. An early induction in 
phosphorylation and, thus, stabilization, was observed by sorafenib and the MEK inhibitors, 
however, p53 was partially degraded after 24 to 48 h (Figure 20, Figure 21). It was published 
that c-Jun can antagonize the activity and repress p53 (Eferl et al., 2003; Stepniak et al., 
2006). This could explain the decrease of p53 at the late time point, due to increased phospho-
c-Jun levels. In Huh-7 cells, sorafenib but not the MEK inhibitors induced slight upregulation 
of p53 indicating that p53 regulation in Huh-7 cell is independent of the MEK/ERK pathway.  
In cooperation with Martina Müller-Schilling, we could detect that blocking p53, p63 and p73 
reduced sorafenib-induced apoptosis in HepG2 and Hep3B cells (data not shown). Our results 
show that the p53 family plays an important role for the induction of apoptosis in HCC cells. 
 
Besides p53, many pro- and anti-apoptotic molecules are involved in the regulation of 
apoptosis, such as the anti-apoptotic molecules Bcl-xL and Mcl-1 (Figure 53). Both are 
regulated via the PI3K/Akt and the MEK/ERK pathway. Akt and also ERK can phosphorylate 
and, thereby, block the pro-apoptotic molecule Bad (Krishna and Narang, 2008; Whittaker et 
al., 2010). Normally, Bad can bind to the anti-apoptotic molecules Bcl-2, Bcl-xL and Mcl-1, 
and inhibit their function by the induction of their degradation. Moreover, Bad influences the 
integrity of the mitochondrial membrane and, therefore, leads to a release of cytochrome C. 
This release induces apoptosis by the activation of caspase 9. In addition, Akt and ERK1/2 
can phosphorylate Bim, which binds and inhibits the anti-apoptotic molecules Bcl-xL, Mcl-1 
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and Bcl-2 (Figure 53) (Balmanno and Cook, 2009; McCubrey et al., 2007). This 
phosphorylation leads to the dissociation of Bim with the anti-apoptotic molecules, its 
ubiquitination and degradation by proteasomes. 
We detected that Bcl-xL and Mcl-1 were altered by both sorafenib and MEK inhibitor 
treatment. In HepG2 cells, Bcl-xL was slightly degraded by sorafenib treatment (Figure 25). 
This may be explained by an early, though weak dephosphorylation of ERK and inhibition of 
p-Akt after 24 h. In Hep3B cells, Bcl-xL was mainly decreased by sorafenib, along with 
inhibition of ERK1/2 and strong dephosphorylation and degradation of Akt (Figure 14, Figure 
26 and Appendix). Interestingly, the MEK inhibitors did not show any effects on Akt 
phosphorylation and Bcl-xL expression. In HepG2 and Hep3B cells, sorafenib induced partial 
degradation of Mcl-1, which is consistent with a previous report showing that sorafenib, in 
contrast to the MEK inhibitor U0126, downregulates Mcl-1 in HepG2 and PLC/PRF/5 cells 
(Liu et al., 2006). 
 
 
 
 
 
Figure 53: Schematic drawing of regulation of apoptosis by MAPK and death receptor 
signaling pathways. Pathway was generated with the help of the pathway builder from 
www.proteinlounge.com. 
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The mutant-specific B-Raf inhibitor PLX4720, which induced hyperactivation of the 
MEK/ERK pathway, slightly enhanced the levels of the pro-survival proteins Mcl-1 and 
Bcl-xL. This indicates that PLX4720 could promote tumor progression in NRas-mutant HCC 
cells, which is in accordance with a recent publication where Mcl-1 was upregulated by 
PLX4720 and conferred resistance to apoptosis (Kaplan et al., 2011). I could observe that 
although PLX4720 did partly inhibit cell proliferation, it did not significantly induce 
apoptosis. It has been reported that C-Raf is able to directly prolong cell survival and inhibit 
apoptosis by Mcl-1 stabilization and inhibition of Mcl-1 degradation (Gollob et al., 2006). 
This could explain why in Hep3B cells, only sorafenib inhibits Mcl-1, but not the MEK 
inhibitors and PLX4720. In sorafenib-treated cells, B- and C-Raf are blocked and Mcl-1 can 
be degraded, which is not the case for PLX4720, where only B-Raf is inhibited. Moreover, 
Gollob et al. could show that C-Raf can inhibit the pro-apoptotic molecule Bad and activates 
the anti-apoptotic molecule Bcl-2. Thus, C-Raf could be a major regulator for apoptosis 
independent of the MEK/ERK pathway. 
Besides downregulation of the anti-apoptotic molecules Bcl-xL and Mcl-1 in HepG2 and 
Hep3B cells, we could observe in cooperation with Martina Müller-Schilling that sorafenib 
induced elevation of the pro-apoptotic molecules Bim, Bax, Noxa and Puma (Figure 53) 
(manuscript in preparation). Sorafenib induced at least partial phosphorylation of p38, JNK, 
p73 and p53, and inhibited p-ERK and p-Akt, which might lead to the increase of Bim, Bax, 
Noxa and Puma. 
 
Treatment of HCC cells has not only an effect on intracellular signaling, but it also modulates 
death receptor expression, which play a role in the extrinsic apoptosis pathway. We could 
show CD95 expression was induced by sorafenib and the MEK inhibitors, but not by 
PLX4720, indicating that CD95 regulation is dependent on the MEK/ERK signaling pathway. 
It has been reported that increased c-Jun and ATF-2 levels, which was induced by sorafenib 
and the MEK inhibitors (Figure 15), can upregulate CD95 expression (Liu and Chang, 2010). 
Moreover, we could see that TRAIL-R2 was increased following sorafenib treatment. This 
could explain the results obtained by the El-Deiry group where sorafenib sensitizes the cell 
towards TRAIL (Ricci et al., 2007). This is also in accordance to our results where sorafenib 
revealed a sensitizing effect towards TRAIL-R2-, CD95- and TNF-R1- mediated apoptosis 
(manuscript in preparation). Because many HCCs are resistance to apoptosis induced by 
CD95L (FasL) or TRAIL, treatment with sorafenib might overcome this resistance. 
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6.1.5 Conclusion 
 
Taken together, our findings indicate that AZD6244 and PD0325901 have a high efficacy for 
the inhibition of the MEK/ERK pathway even better than sorafenib, the current treatment 
regimen for HCC. One reason for the poor survival benefit of sorafenib in patients with 
advanced HCC could be a suboptimal sorafenib concentration, which is not high enough for a 
sustained inhibition of the MEK/ERK pathway. Moreover, our analyses show that Raf as well 
as MEK inhibition affects other pathways like JNK, Akt, p38 and the transcription factors c-
Jun and ATF-2, however the exact mechanisms have to be solved. The advantage of sorafenib 
compared to the MEK inhibitors is that it also inhibits the Akt pathway, which is very 
important for regulation of cell proliferation and apoptosis. Proliferation and apoptosis are 
regulated via MEK/ERK and Akt signaling. In addition, proliferation is also regulated in a 
MEK/ERK independent way in HCC cells. ATF-2 and c-Jun seem to be implicated as 
inhibitors of cell proliferation in HCC cells.  
Moreover, the data show that sorafenib engages the intrinsic as well as the extrinsic apoptotic 
pathway. Inhibition of Akt seems to be very important for the induction of apoptosis in HCC. 
These results imply that for the treatment of HCC, it may be necessary to target both 
MEK/ERK and PI3K/Akt signaling pathways. The results indicate that the mutational status 
of the cancer cell is involved in the decision whether inhibition of the MEK/ERK pathway 
leads to apoptosis or not. Therefore, screening for the mutational status of HCC should be 
performed in future treatment strategies in order to improve the development of a more 
effective therapeutic intervention. 
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6.2 Immunological Side Effects 
6.2.1 Modulation of immune cell recognition following MAPK inhibition 
In addition to the inhibition of tumor growth and induction of apoptosis, new potential cancer 
therapeutics should also modulate the immune system in such a way that immune cells can 
recognize and kill the tumor. This is very difficult to achieve, because tumor cells have 
several immune escape mechanisms. Besides being resistant towards apoptosis, they can 
modulate their surface molecule expression at several levels to be less efficiently recognized 
by immune cells. For the recognition of tumor cells by T and NK cells, HLA class I, 
MICA/B, ULBPs, CD155 and several adhesion molecules are important. While in HCC cells 
HLA class I molecules were still expressed, several NKG2D ligands like MICA/B, ULBP1-3 
were only weakly expressed or even absent (Figure 27, Figure 28). This constellation of weak 
NK cell ligands and normal HLA class I molecules implies that HCC cells are poorly 
recognized by NK cells. Thus, killing experiments using the CD107a degranulation assays 
showed that indeed HCC cells can be weakly killed by NK cells. Treatment of tumor cells 
with MAPK inhibitors only partially influenced the degranulation capacity of NK cells 
(Figure 35). These observations demonstrate that minor changes in surface expression do not 
always lead to substantial changes in NK cell degranulation. 
Treatment of HCC cells with MAPK inhibitors modulated the expression of surface 
molecules, which are important for cell growth and recognition by NK cells (Figure 29, 
Figure 32). The growth factor receptor c-Met is often highly expressed in HCC and 
overexpression has been associated with increased tumor grade and poor prognosis (Ueki et 
al., 1997; Whittaker et al., 2010). I could detect that c-Met was highly expressed in HepG2, 
Hep3B and Huh-7 cells. This is in accordance with a previous publication showing that c-Met 
is highly expressed in HepG2 and Hep3B cells and HGF treatment induced slight increase in 
cell growth through c-Met (Lee et al., 2008b). They also described that activation of the 
HGF/c-Met signaling pathway via the MAPK pathway leads to an enhanced cell motility and 
invasion through extracellular matrix substrates. Treatment of HCC cells with sorafenib and 
the MEK inhibitor reduced the expression of c-Met, while activation of the MEK/ERK 
pathway by PLX4720 led to enhanced expression of c-Met indicating that c-Met can be 
positively regulated via the MEK/ERK pathway (Figure 54). Inhibition of the MEK/ERK 
pathway by sorafenib and the MEK inhibitors suggest reducing cell motility and cell 
invasiveness and therefore, prevents formation of metastasis. 
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It was previously shown by Monika Braun that in the KRas-mutant colorectal cancer cell line 
HCT116, HLA class I and ULBP1-3 expression was increased by the inhibition of the MAPK 
pathway (Sers et al., 2009). In this system, increased HLA class I expression was 
accompanied by enhanced tumor killing by T cells. In the HCC system, a decrease of HLA 
class I was only seen by sorafenib in HepG2 cells, but an increase in HLA class I expression 
was achieved by the MEK inhibitors in Huh-7 cells. Most importantly, modulation of HLA 
class I did not correlate with degranulation of NK cells. These results indicate that in contrast 
to colon carcinoma, looking at the HLA class I molecule expression after MAPK inhibitor 
treatment does not directly correlate with NK cell cytotoxicity. Therefore, other factors or 
activating molecules might have a stronger influence on NK cell cytotoxicity. 
 
There are several ligands, which bind to the activating receptors on NK cells. The NKG2D 
receptor represents one of the most important activating receptors and it binds to a variety of 
molecules, which include ULBP1-6 and MICA/B (Eagle et al., 2009a; Eagle et al., 2009b; 
Nausch and Cerwenka, 2008). HepG2, Hep3B and Huh-7 cells express ULBP2 and 4, but not 
ULBP1 and 3 (Figure 27). To my knowledge we are the first to report that ULBP4 is 
expressed in Hep3B and Huh-7 cells. While sorafenib and the MEK inhibitors induced an 
increase in ULBP4 on HepG2, Hep3B and Huh-7 cells, PLX4720 reduced ULBP4 expression 
indicating a MEK/ERK dependent regulation of ULBP4 (Figure 54). The expression of 
ULBP2 was not substantially modulated by MAPK inhibitors. The observation that NKG2D 
ligands are modulated in both directions by different inhibitors demonstrates the complexity 
of their regulation which is not only influenced by the MAPK pathway alone. 
 
Also soluble forms of MICA and MICB, which can be shedded from the cell surface by 
metalloproteases like ADAM7 and ADAM9 (Kohga et al., 2010; Salih et al., 2006), 
contribute to the immune regulation. Soluble MICA and B were described to be often 
elevated in the sera of HCC cancer patients {Kohga, 2008 #1940;Salih, 2006 #489}. In the 
soluble form, they can impair the antitumor activity by downregulating the expression of the 
activating receptor NKG2D on T and NK cells (Kohga et al., 2010; Tamaki et al., 2010). 
HepG2 and Hep3B secrete soluble MICB and the secretion was inhibited by the MAPK 
inhibitors, thereby reducing the potency of tumor cells to inhibit the immune response. It has 
to be further analyzed to what extend downregulation of soluble MICB helps the immune 
system to fight against the tumor. 
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Another important activating receptor on NK and T cells is DNAM-1 (CD226) with its ligand 
CD155. In HCC, the role of CD155 for the recognition by NK and T cells is still unclear. 
Here, we show for the first time that the three HCC cell lines express CD155. So far, it has 
been described that TuAg1/TagE4, which is the rat ortholog of the human poliovirus receptor 
CD155, is expressed on a high percentage of rat hepatocellular carcinomas and is induced 
during rat liver regeneration and acute liver injury (Erickson et al., 2006). In my studies, 
CD155 expression could be increased by sorafenib and MEK inhibitors in HCC cells, 
indicating that CD155 expression is regulated via the MEK/ERK signaling pathway (Figure 
54). In a SFB project, we will further analyze whether CD155 is an important ligand for the 
activation of NK cells in the liver. Using melanoma cell lines, we could observe that 
downregulation of CD155 reduced the levels of NK cell degranulation (Dissertation S. Maßen 
2010), indicating the importance of the interaction of CD155 on the tumor cell with DNAM-1 
on the NK cells. Moreover, it has been reported that NK cells require DNAM-1 for the 
elimination of tumor cells (Gilfillan et al., 2008). On the other hand it could be shown that 
 
Figure 54: Scheme of surface molecule expression regulated by MAPK pathway. Several 
surface molecules like HLA class I, ULBPs. CD155, CD166 and Fas are negatively regulated by 
the MAPK pathway in HCC cells. Some molecules like c-Met are positively regulated by the MAPK 
pathway. Pathway was partly generated with the help of the pathway builder from 
www.proteinlounge.com and some molecules were adapted and modified from C. Falk. 
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primary ovarian carcinoma cells, which express CD155, can impair tumor targeting by the 
downregulation of DNAM-1 on NK cells (Carlsten et al., 2009). In this setting, DNAM-1 
contributes to the immune escape and plays a crucial role in NK cell-mediated recognition of 
several types of human tumors (Carlsten et al., 2009). Moreover, CD155 has been implicated 
in tumor cell invasion and migration suggesting that CD155 itself contributes to 
tumorigenesis via its own signaling capacity (Sloan et al., 2004). This shows that CD155 can 
has pro- and anti-tumorigenesis functions. 
Overall, these data show that ligands for the inhibitory and activation receptor are mostly 
upregulated by MAPK inhibitors (Figure 54). Depending on the balance between activating 
and inhibitory receptors, NK cell cytotoxicity is increased or decreased.  
 
Adhesion molecules are also important for the interaction between tumor and immune cells. 
They play an important role for cancer progression, tumor invasion and metastasis. Moreover, 
they are important for signal transduction, cell proliferation, morphogenesis and many other 
functions.  
The adhesion molecule CD166 (ALCAM), which binds to CD6, was highly expressed on 
HepG2, Hep3B and Huh-7 cells, which has not been described so far. In a study from Horst et 
al. CD166 is defined as a surface marker associated with colorectal cancer stem cells (Horst et 
al., 2009). Increased CD166 expression in colorectal carcinoma has been correlated with 
shortened patient survival (Weichert et al., 2004). I could observe that treatment of HepG2, 
Hep3B and Huh-7 cells with sorafenib and MEK inhibitors, but not PLX4720, resulted in an 
upregulation of CD166 expression, indicating a negative regulation through the MEK/ERK 
pathway (Figure 54). Whether increased CD166 leads to a shortened patient survival in HCC 
is still unclear. 
The adhesion molecule ICAM-1 is also important for the adhesion of tumor cells to and 
recognition by NK and T cells via their LFA-1 complex (Bryceson et al., 2006; Sirim et al., 
2001). Interestingly, while sorafenib and PLX4720 increased, MEK inhibitors decreased 
ICAM-1 expression on HCC cells. A decrease in this ICAM-1/LFA-1 interaction would lead 
to presumably weaker immune cell recognition. Although the MEK inhibitors mediated a 
decrease of ICAM-1, a slight increase in NK cell degranulation against HepG2 cell was still 
seen, indicating that the adhesion is still good enough for inducing NK cell cytotoxicity. 
Taken together, my results show that inhibition of the MAPK pathway modulates expression 
of several surface molecules (Figure 54). Due to the complex interaction between HCC and 
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NK cells, these changes of the surface molecules result in rather slight alterations of NK cell 
degranulation against HCC cells. 
6.2.2 Hepatic NK and T cells 
As described in the introduction, the liver has important functions in innate and adaptive 
immunity (Crispe, 2009; Parker and Picut, 2005). Interestingly, in the liver, the proportion 
and the phenotype of NK and T cells were different compared to the blood counterparts 
(Table15+16; Figure38+39). In healthy liver tissue, NK and CD8+ T cells were enriched, 
which is accordance to a previous report (Morsy et al., 2005; Norris et al., 1998).  
Despite the enrichment, the NK cell phenotype was different in the liver compared to 
peripheral blood counterparts (Figure 38). Liver NK cells showed a reduced proportion of 
CD56dim NK cells expressing CD16 and CD6, which is somewhat in accordance to a 
previously study where it was shown that liver NK cells have a higher proportion of CD16- 
NK cells (Burt et al., 2009). Still, the mechanisms contributing to the regulation of the 
different NK cell composition is unclear. One possibility could be that at the endothelial cell 
layer there is a stop signal for CD56dim CD16+ NK cells (Figure 55) or there are factors in the 
liver which contribute to a change of the NK cell phenotype. For the constellation of the 
immune cells in the liver, the microenvironment seems to play an important role (Crispe, 
2009; Parker and Picut, 2005).  
It has been described that TGFβ can promote the conversion of CD16+ peripheral blood NK 
cells into CD16- NK cells (Keskin et al., 2007). In the liver, LSECs, Tregs, MDSCs and HCC 
cells can secrete TGFβ, which may induce this conversion. In co-culture of peripheral NK 
cells with HCC cell lines, I could observe that the proportion of CD16+ NK cells was reduced. 
It has to be further analyzed whether CD16 is downregulated on CD56dim NK cells or whether 
HCC cells differentially stimulate the CD16- NK fraction. Moreover, it has to determined 
whether the reduced proportion of CD16+ NK cells has an effect on the cytotoxicity. It has 
been reported that hepatic NK cells with fewer CD16+ NK cells have a reduced cytotoxicity 
compared with their peripheral blood counterparts (Burt et al., 2009). In contrast, it has been 
described that hepatic NK cells can spontaneously lyse NK-sensitive K562 target cells 
showing that hepatic NK cells are still cytotoxic (Doherty et al., 1999). Although it was 
generally classified that CD56bright CD16- NK cells are mainly cytokine and chemokine 
producer and less cytotoxic (Di Santo, 2006), we could observe that both peripheral CD56bright  
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CD16- and CD56dim CD16+ NK cells can degranulate to the same extent when they were 
stimulated with IL-2 and co-cultured with HLA class I negative target cells (Dissertation M. 
Braun 2008). 
During cirrhosis and HCC, the composition of NK and T cells changed in the liver tissue. In 
cirrhosis a strong increase of CD56bright CD16- NK cells was detected. While in HCC tumor 
tissue NK cells were significantly reduced, higher percentages of NK cells were found in the 
surrounded “healthy” HCC tissue, indicating that the invasion of NK cells into the tumor 
tissue may be blocked. In a previous report it was observed that HCC patients displayed a 
substantial reduction in peripheral CD56dim CD16+ NK cells compared with healthy subjects 
(Cai et al., 2008). In contrast, CD8+ T cell migration into the tumor tissue was not blocked, 
but rather enriched compared to CD4+ T cells. These results are similar to the situation of NK 
and T cells in colorectal carcinoma tumor tissue. There, we could show that migration of NK 
cells into colorectal carcinoma tumor tissue is impaired during tumor development by 
 
Figure 55: Schematic diagram of T and NK cell population in liver tissue and peripheral 
blood. While peripheral blood consist of ~10% CD56bright and CD16- NK cells and ~90% CD56dim 
CD16+ NK cells, the liver tissue has a higher proportion of CD56bright CD16- NK cells and reduced 
proportion of CD56dim CD16+ NK cells. The 2:1 ratio of CD4+ to CD8+ T cells in the blood was 
nearly switched to a 1:2 ratio in the liver tissue. The mechanisms, which lead to this altered NK and 
T cell proportions, are still unknown. Blood vessel was adapted from pathway builder from 
www.proteinlounge.com and cells were adapted from C. Falk. 
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mechanisms that do not affect T cell infiltration and despite high levels of chemokines and 
cytokines (Halama et al., 2011). In HCC tissue, CCL4 concentration was elevated, indicating 
that CCL4 might be involved in increased CD8+ T cell recruitment into the tumor tissue. In 
cirrhotic and HCC tissue, high chemokine levels like CXCL8, 9 and 10 were also observed. 
These chemokines are ligands for the chemokine receptor CXCR3, which is highly expressed 
on CD56bright CD16- NK cells and only to a low level on CD56dim CD16+ NK cells, but 
expression levels also depend on the activation status (Robertson, 2002). This high 
concentration can be an explanation for the strong increase of CD56bright CD16- NK cells in 
cirrhotic tissue, but not for the absence in the tumor tissue. CCL5 is increased in cirrhotic 
tissue, but not in HCC tumor tissue, which might explain the increase in CD56bright NK cell in 
the cirrhotic liver tissue, because CCR5, the receptor for CCL5, is higher expressed on 
CD56bright NK cells. Another possibility could be that the concentrations of some chemokines 
like CXCL10 were too high in HCC tissue leading to an inhibition of NK cell migration. In a 
recent publication it was shown that CXCL10 might block the migration of NK cells to the 
liver (Hintermann et al., 2010). This group could show that CXCL10 is implicated in liver 
fibrosis, where NK cells are also reduced. Using CXCL10 deficient mice, they observed 
reduced fibrosis with less B- and T cells infiltration, but increased NK cells in the liver 
indicating that CXCL10 negatively regulates NK cell migration in this model. Besides the 
regulation by chemokines, it has been reported that MDSCs and Tregs are enriched in tumor 
tissue (Cao et al., 2008). It was shown that addition of Tregs from HCC patients efficiently 
inhibited the anti-tumor ability of autologous NK cells in vitro (Cai et al., 2008). MDSCs can 
inhibit NK cells in patients with HCC via the NKp30 receptor (Hoechst et al., 2009). 
Interestingly, it has been reported that sorafenib treatment decrease MDSC and Treg numbers 
in the liver (Cao et al., 2008). It has to be analyzed whether these cells also contribute to the 
blockage of NK cell migration into the tumor and whether sorafenib treatment increases NK 
cell numbers in the tumor tissue. 
 
These results indicate that just the presence or absence of a chemokine is not enough to decide 
whether NK cells are recruited to the liver or not. Recruitment of NK cells into the liver seem 
to be differently regulated compared to the recruitment of T cells. The mechanisms of how 
NK cells are impaired in HCC tumor tissue is still unknown and has to be determined in the 
future. Moreover, the role of chemokines for the recruitment of NK cells has to be further 
analyzed. Due to the importance of NK cells for fighting against the tumor and it was reported 
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that higher NK cell numbers in HCC patients correlate with longer survival (Chew et al., 
2010). Therefore, it can be a successful approach to modulate the chemokine milieu towards 
infiltration of NK cells into the tumor tissue. It has to be shown, whether the reduced 
chemokine levels induced by sorafenib has an impact on the recruitment of NK cell into the 
tumor tissue. 
6.2.3 Secretion of chemokines and growth factors by HCC cells 
Features of tumorigenesis are uncontrolled growth, the development of new blood vessels and 
downregulation of the immune response. For this purpose, tumor cells secrete a variety of 
chemokines and growth factors. It could be observed that HCC cells secrete high amounts of 
CXCL8, CXCL10, VEGF, TGFβ and ICAM-1 and to intermediate level CXCL12, M-CSF, 
SCGF-β and MIF (Figure 40 – Figure 42). Many of these factors are involved in angiogenesis 
and tumor escape mechanisms. 
 
Because several chemokines are regulated via the MAPK pathway (Liu et al., 2008; 
Whittaker et al., 2010), I wanted to know how chemokine and growth factor secretion is 
affected by inhibition of MAPK pathway. Although there are several reports about the MAPK 
inhibitors, only a few have analyzed their effects on some chemokine secretion. I could 
observed that in HCC cells, CCL5, VEGF, M-CSF, TGFβ and soluble ICAM-1 were 
positively regulated via the MAPK pathway and, therefore, were significantly reduced by 
MAPK inhibitors. In HepG2 cells, also CXCL8 and IL-1RA seemed to be positively 
regulated by the MEK/ERK pathway. Curry et al. could show that M-CSF induces secretion 
of VEGF through the MEK/ERK signaling pathway (Curry et al., 2008). In trophoblast cells, 
CCL5 was inhibited by the MEK inhibitor U0126 but also by the JNK inhibitor SP600125 
(Renaud et al., 2009). The p38 and ERK pathway inhibitors SB203580 and U0126 revealed 
that MAPK signaling regulates CXCL10 and CXCL8 at the mRNA level (Lee et al., 2008a; 
Tibbles et al., 2002). CXCL8 was also inhibited by the MEK inhibitor PD98059, the p38 
inhibitor SB203580 and the JNK inhibitor II (Liu et al., 2008). These data show that 
dependent on the cell type the secretion of chemokines and growth factors is not regulated by 
the MEK/ERK pathway alone, but also by other signaling pathways like JNK or p38 (Figure 
56). 
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Of the factors regulated by the MAPK pathway, CXCL8, CCL5, VEGF, M-CSF and TGFβ 
have been shown to be involved in angiogenesis. For their regulation, the hypoxia-inducible 
factor (HIF) seems to be a central regulator. HIF gets activated in the nucleus by several 
pathways like Ras/Raf/MEK/ERK, PI3K/Akt and by STATs (Whittaker et al., 2010). 
Downregulation of these molecules by the MAPK inhibitors suggests a reduction in the 
potential for angiogenesis in HCC. In addition, it was reported that sorafenib blocks 
angiogenesis by inhibiting VEGFR and PFGFR, which resulted in reduced microvessels in 
the tumor (Liu et al., 2006). Besides inducing angiogenesis, CXCL8 has also been shown to 
act as a growth promoter in several tumor cells. Therefore, inhibition of CXCL8 by sorafenib 
and the MEK inhibitors represent an important side effect for the treatment of HCC. 
Thus, sorafenib seems to have broader and stronger effect on the inhibition of chemokines 
and growth factors than the MEK inhibitors. This indicates that other signaling pathways 
besides MEK/ERK play an important role for the regulation of chemokine and growth factor 
secretion (Figure 56). For some chemokines like CXCL10, their secretions seem to be 
differently regulated by sorafenib and the MEK inhibitors. Importantly, other factors like 
SCGF-β were not altered by MAPK inhibitors indicating that the MAPK pathway specifically 
regulates some but not all chemokines and growth factors. 
 
 
 
Figure 56: Regulation of chemokines and growth factors by different signaling pathways. 
Cytokines, chemokines and growth factors are often regulated by at least one of MEK/ERK, 
PI3K/Akt, JNK or p38 signaling pathways. Pathway was partly generated with the help of the 
pathway builder from www.proteinlounge.com. 
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In contrast to the downregulation of many chemokines by MAPK inhibitors, the macrophage 
migration inhibitory factor (MIF) showed a different regulation, i.e. an upregulation by 
sorafenib and MEK inhibitors. In several tumors, such as colon cancer, melanoma and HCC, 
MIF is generally overexpressed (Han and Zhang, 2010; Lugrin et al., 2009; Ren et al., 2003). 
Among other effects, MIF is important for the development and progression of HCC and 
plasma MIF levels decreased after HCC resection. Thus, MIF is currently investigated as a 
prognostic marker for HCC (Han and Zhang, 2010; Zhao et al., 2011). MIF has several 
different functions; it plays a pivotal role for cell proliferation, for inhibition of apoptosis, 
tumorigenesis, angiogenesis and inflammation (Baron et al., 2011; Lugrin et al., 2009). 
Moreover, it regulates the secretion of other cytokines, chemokines and growth factors. In 
HCC, it could be shown that MIF induced increased secretion of CXCL8 and VEGF (Ren et 
al., 2003). For its mechanism of action, MIF binds to the CD74/CD44 receptor complex, 
which leads to activation of the MEK/ERK pathway, to activation or inhibition of the JNK 
pathway depending on the cell type, and to activation of p38 (Figure 57) (Baron et al., 2011; 
Cheng et al., 2010; Lue et al., 2011). All these signals lead to an enhanced cell proliferation 
and cell survival (Lue et al., 2011). Furthermore, MIF can act in an autocrine loop inducing 
the expression of angiogenic factors like CXCL8 and VEGF, and the migration of tumor cells, 
therefore, stimulating angiogenesis and metastasis in HCC (Ren et al., 2003). Inhibition of the 
MEK/ERK pathway in MIF-treated cells reduces the secretion of the angiogenic factors 
CXCL8 and VEGF, which is in accordance with my results where CXCL8 and VEGF is 
reduced in HCC cells after MAPK inhibitor treatment (Lue et al., 2011).  
In tumor biology, MIF also contributes to tumorigenesis by providing a tumor escape 
mechanism by downregulating NKG2D on T and NK cells (Krockenberger et al., 2008). 
Furthermore, MIF is a potent apoptosis inhibitor and a modulator of pro-oxidative stress-
induced apoptosis, but the exact mechanisms are still unclear. It has been reported that MIF 
can suppress p53 activity (Fingerle-Rowson et al., 2003; Han and Zhang, 2010; Hudson et al., 
1999), which could in part explain why p53 is decreased in HCC cells after MAKP inhibitor 
treatment.  
Although all these aspects are known about the function of MIF, it is still unclear, how MIF 
secretion is regulated. I could observe that in all three HCC cell lines MIF secretion was 
rather enhanced and the profile of MIF concentrations with MAPK inhibitor treatment 
correlated with the profile of apoptosis induction (Figure 18 and Figure 36). The question is 
whether MIF secretion is induced by apoptosis or whether MIF is directly regulated by 
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signaling pathways like MEK/ERK and PI3K/Akt (Figure 57). It is interesting to see that in 
Huh-7 cells induction of apoptosis and secretion of MIF are only induced by sorafenib and 
not by the MEK inhibitors, indicating that the secretion of MIF and the induction of apoptosis 
follow the same regulatory mechanisms. Because MIF is implicated in cell proliferation, 
angiogenesis and inhibition of apoptosis, the secretion of MIF in apoptotic cells could be a 
rescue mechanism for other cells to become resistance against apoptosis or through the 
inhibition of immune cells by downregulation of NKG2D. 
 
It will be further analyzed in our lab whether increased MIF lead to tumor escape through 
inducing resistance or whether MIF is “just” a factor in HCC cells correlating with apoptosis. 
Because MIF has been associated with tumor aggressiveness and metastasis (Lugrin et al., 
2009), increased MIF secretion might lead to the recurrence of the tumor in sorafenib-treated 
HCC patients. Therefore, it would be of great interest to see whether survival of sorafenib-
treated HCC patients correlates with the plasma and/or tissue MIF levels and whether 
blocking of MIF could improve HCC therapy. 
 
 
 
Figure 57: Possible regulation mechanisms of MIF in HCC cells. MIF might be regulated by 
MEK/ERK signaling, Akt signaling or other signaling pathways. Moreover, apoptosis could 
positively induce MIF secretion. Secreted MIF can stimulate the same cell in an autocrine loop or 
other cells in a paracrine loop. There, MIF might induce resistance against apoptosis. Pathway was 
partly generated with the help of the pathway builder from www.proteinlounge.com. 
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6.2.4 Conclusion 
 
Taken together, my findings show that HCC cell lines highly express a variety of surface 
molecules which are associated with tumorigenesis and poor survival. In contrast, several 
ligands, which are important for NK cell cytotoxicity, are only slightly expressed or absent. 
Inhibition of the MAPK pathway modulates surface molecule expression with some ERK-
independent side effect of certain MAPK inhibitors, in particular sorafenib. Due to the 
complex interactions with the balance of activating and inhibitory receptor ligands, it cannot 
be precisely defined which of these surface molecules influences NK and T cell cytotoxicity 
the most. Nevertheless, HCC cells induce NK cell killing to a certain extent, however, MAPK 
inhibition does not strongly improve the killing capacity of NK cells. 
HCC tumor cells altered the phenotype of NK cells in vitro and NK cells were absent in HCC 
tumor tissue despite high chemokine levels indicating that NK cells might be a key effector 
cell type for fighting against HCC. Therefore, one goal for HCC treatment besides inducing 
apoptosis in tumor tissue and reducing angiogenesis should be to increase the number of 
activated NK cells in the tumor tissue.  
Moreover, a variety of chemokines and growth factors are produced by HCC cells, which 
favor tumorigenesis and can induce angiogenesis. The chemokines produced by these tumor 
cells have been postulated as key factors in modulating immune response either against or in 
favor of tumorigenesis in the microenvironment. MAPK inhibition led to a downregulation of 
the cytokine, chemokine and growth factor secretion. Through this blockage, the potency of 
HCC cells to induce angiogenesis and tumor progression is reduced. Furthermore, MIF might 
be responsible for the resistance of the tumor against therapy suggesting a general resistance 
mechanism in cancer. Blocking of MIF might improve HCC treatment. 
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6.3 HCC and MAPK Pathway in the Tissue 
6.3.1 Hepatic microenvironment 
The hepatic microenvironment is heterogeneous with many different cytokines and 
chemokines, which are secreted by a variety of different cells (Chew et al., 2010). During 
tumor development and progresssion, microenvironment is often changed in a pro-angiogenic 
and anti-immune situation. There, the chemokine milieu may be altered in the direction that 
immune cells cannot migrate into the tumor tissue. While in cirrhotic and HCC liver tissue 
some chemokines showed a tendency of decreased levels, other chemokines were increased, 
indicating distinct roles of chemokines for the development of cirrhosis and the progression 
towards HCC (Figure 44). It has been described that chemokines play an important role for 
several pathological conditions, including cancer (Platanias, 2005). For example, it has been 
shown that fibrosis can be induced by CXCL10 (Hintermann et al., 2010). The chemokine 
CXCL8 is implicated in angiogenesis and was elevated in both cirrhotic and HCC tumor 
tissue. In a previous study, we could show that the concentration of several chemokines was 
higher in colorectal cancer than in the surrounding healthy tissue indicating a general 
mechanism for the progression of some tumors (Halama et al., 2011). In cirrhotic and HCC 
tumor tissue, not all chemokines were elevated. For some chemokines like CCL3, CCL7 and 
CCL27 the profile in cirrhosis and HCC seemed to be separated in two populations with one 
increased and one decreased population showing the diversity of cirrhosis and HCC patients. 
Moreover, there are differences in the microenvironment between cirrhosis and HCC. For 
example, CCL5 seems to play a role for cirrhosis, but not for HCC. 
Besides the chemokines, other factors like VEGF and PDGF also induce angiogenesis and are 
upregulated in HCC (Figure 45) showing that in HCC the angiogenic balance is disrupted. 
HCC has been described as a highly vascular tumor and angiogenesis seems to play a pivotal 
role for HCC development and progression (Whittaker et al., 2010; Yang et al., 2011).  
 
There is currently the debate whether the HCC tumor microenvironment is pro- or anti-
inflammatory (Schrader and Iredale, 2011). In general, the liver is rather tolerogenic than 
immunogenic, due to the immunosuppressive cytokines (Crispe, 2009). In HCC patients, it 
has been described that in the tumor tissue the number of Tregs and MDSCs are increased 
(Cai et al., 2008; Hoechst et al., 2009; Korangy et al., 2010b). This enhancement of Tregs in 
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HCC has been associated with poor prognosis (Gao et al., 2007). In cirrhosis and HCC, the 
pro-inflammatory molecules IFNγ and TNFα were partly reduced indicating that the tumor is 
trying to evade immune recognition. This is probably achieved by recruited Tregs and 
MDSCs (Kao et al., 2011). Moreover, it has been described that HCC patients, which have a 
predominant Th1 signaling (e.g IFNγ, IL-2 and TNFβ) in the tumor tissue, develop less 
frequently metastases indicating that a certain inflammatory microenvironment is favorable in 
controlling the tumor and enhancing survival of HCC patients (Chew et al., 2010). In 
addition, an increased level of IL-1RA, which is an inhibitor of the pro-inflammatory 
cytokine IL-1, was observed in liver tissue of colorectal carcinoma resections, cirrhosis and 
HCC showing that anti-inflammatory factors are increased in HCC tumor development. 
Not only inflammatory cytokines are reduced in cirrhosis and HCC, but also important anti-
inflammatory cytokines like IL-10, indicating that it is not a clear shift towards anti-
inflammatory or tolerogenic conditions. Other cytokines like IL-9 were also reduced in 
cirrhosis and HCC, but not in liver tissue of colorectal metastasis. IL-9 is mainly produced by 
CD4+ T cells and implicated in Th2 responses and humoral immunity (Pilette et al., 2002). In 
HCC and cirrhotic tissue, CD4+ T cells are decreased and CD8+ T cells increased compared to 
healthy liver tissue. This might explain the decreased level of IL-9. Besides IL-9, it has been 
described that CCL3 and CCL4 actively recruit CD8+ T cells (Castellino et al., 2006).  
In contrast, the inflammatory and growth-promoting factor IL-6 was elevated in some HCC 
tissue samples and has been reported as a mediator for HCC progression in liver inflammation 
(Germano et al., 2008; Yang et al., 2011). On the other hand, it has been described that IL-6 
together with CCL2 correlate positively with patient survival (Chew et al., 2010). It has to be 
determined whether IL-6 tissue concentration correlates with progression of HCC. Besides 
IL-6, also the pro-inflammatory cytokine IL-16, which is mostly secreted by CD8+ T cells 
was increased in resected liver tissue of colorectal metastases, cirrhosis and HCC, showing 
that not all pro-inflammatory cytokines are decreased in HCC. 
Besides chemokines and cytokines, stimulating and growth factors play an important role in 
carcinogenesis. Growth factors like VEGF and SCGF-β are often overexpressed in tumor 
tissue. SCGF-β is a good marker for discriminating HCC tissue from healthy liver tissue and 
resected liver tissue of colorectal metastases (Figure 46). Interestingly, HGF was increased in 
cirrhotic tissue, but not in HCC tissue indicating that HGF plays a pivotal role in cirrhosis and 
seems to be necessary HCC pathogenesis (Yang et al., 2011). HGF is mainly expressed by 
hepatic stellate cells and myofibroblasts, which get activated during fibrosis and cirrhosis and 
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then secrete HGF. With the help of a bioinformatic approach, we could detect that HGF is as 
a good prediction marker for cirrhosis.  
Soluble adhesion molecules like ICAM-1 and VCAM-1 are often found to be increased in 
patients with tumors like colorectal carcinoma (Halama et al., 2011). We could detect that in 
resected liver tissue of colorectal metastases, in cirrhotic and HCC tissue the concentrations of 
ICAM-1 and VCAM-1 were increased compared to healthy liver tissue. Increased levels of 
ICAM-1 and VCAM-1 have been associated with increased risk of invasion and metastasis. It 
shows that pathologic “healthy” liver tissue of patients with colorectal carcinoma resection 
has already a changed microenvironment favoring the migration of tumor cells into the liver, 
which is a preferred organ for metastasis of colorectal carcinoma. 
 
6.3.2 Modulation of the microenvironment by MAPK inhibitors 
HCC tumor cells secrete a variety of chemokines and growth factors and their secretion was 
modulated by MAPK inhibition. In the tissue, there are several different cell types 
contributing to the microenvironment and it is more difficult to evaluate the effects of the 
MAPK inhibitors, since different cell types react differently to these inhibitors. In HCC tissue, 
several chemokines but also cytokines and growth factors were elevated probably 
contributing to the progression of HCC. Ex vivo tissue treatment with sorafenib for only 8 h 
already mediated a change in the microenvironment in the HCC tissue showing that the 
microenvironment can be rapidly modulated (Figure 47, Figure 49). Moreover, the 
microenvironment was also altered in the adjacent “healthy” tissue indicating that sorafenib 
has effects beyond the tumor tissue (Figure 48, Figure 50). 
In the HCC tumor tissue, the increased angiogenic factors like CXCL8, VEGF and CXCL1 
could be reduced with sorafenib treatment showing that sorafenib has angiostatic activity in 
the tumor tissue and that this effect seems to be partly MAPK independent. This indicates that 
for an effective inhibition of angiogenesis in HCC, specific MAPK inhibitors are not 
sufficient for HCC treatment.  
Sorafenib reduced not only the concentration of factors involved in angiogenesis, but also 
some others. For example, IL-6, which has been implicated in the progression of HCC, was 
reduced after sorafenib treatment indicating that sorafenib has a broad effect for the fight 
against HCC. In HCC tumor tissue, CXC chemokines were increased and could be decreased 
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with sorafenib treatment. In the future, it has to be analyzed what consequence this 
modulation of chemokine has for the constellation of the immune cells of the liver.  
 
In a first experiment, we could observe that the MEK inhibitors U0126, AZD6244 and 
PD0325901 had an effect on the microenvironment as well (data not shown). Already, the 
results clearly show that sorafenib and the other tested MAPK inhibitors have also an effect 
on the healthy liver tissue. Interestingly, even the mutant-specific B-Raf inhibitor PLX4720 
seems to have an effect on the HCC tumor tissue and the healthy liver, indicating that the 
inhibition of the wild-type B-Raf is strong enough to induce an alteration of the 
microenvironment. 
Our preliminary data show that sorafenib, the MEK inhibitors and the mutant-specific B-Raf 
inhibitor PLX4720 have some opposing effects suggesting partly independent effects of the 
MAPK pathway. Sorafenib seems to have broader “side effects” on other signaling pathways 
and for the regulation of cytokine and chemokine secretion in the tissue, which is in 
accordance to the in vitro studies. As other groups have shown, the JNK, p38 and NFκB 
pathways are important for the secretion of several cytokines, chemokines and growth factors 
(Kumar et al., 2009; Nagai et al., 2011; Venkatesha et al., 2005; Wong et al., 2005). 
In the future it has to be analyzed to what extend the microenvironment is altered by the 
MAPK inhibitors and whether treatment of HCC normalize the cytokine and chemokine 
milieu in the tumor tissue. Moreover, it is interesting to analyze how these alterations of the 
microenvironment effect the composition of immune cells in HCC tumor tissue and what 
consequences this will have for the patient.  
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6.3.3 Conclusions 
 
The tumor microenvironment is a very complex network and the progression towards 
cirrhosis and HCC changes the microenvironment in the liver. Several different cytokine and 
chemokine modifications are involved in liver diseases and the development into HCC, but 
the exact mechanisms are still to be solved. The data indicate that the cirrhotic and tumor 
microenvironment are not clearly shifted to a pro-inflammatory or an anti-inflammatory 
direction, but rather both pro- and anti-inflammatory sides are altered. The decrease of pro-
inflammatory factors in HCC tumor tissue suggests that a partial inflammatory condition is 
essential to suppress tumor development in the liver. In the future, it has to be analyzed which 
cytokines and chemokines are the key players for regulating the immune system in the tumor 
tissue. Since HCC is different among patients, which is probably induced e.g. by etiology, it is 
difficult to unravel these key players for tumor development and progression. Thus, 
modulation of the tumor microenvironment might be one strategy for tumor treatment in the 
future. Sorafenib or MEK inhibitor treatment seems to be on the right way for the modulation 
of the microenvironment, since factors important for angiogenesis and tumor growth are 
reduced. However, the consequences of the reduction of the cytokine and chemokine milieu 
for the healthy and tumor liver tissue have to be revealed. Due to the broader effects of 
sorafenib on the modulation of the microenvironment, inhibition of only the MAPK pathway 
seems not to be sufficient. A combinational therapy targeting different pathways might be a 
more effective strategy for HCC treatment. 
Alterations of the tumor but also the healthy microenvironment will have an effect on the 
migration and composition of intrahepatic lymphocytes like NK cells. Hopefully, alterations 
of the microenvironment (e.g. reduction of the chemokines induced by sorafenib), will 
reconstitute NK cell numbers in the tumor tissue.  
 
In my opinion, it is an important approach to combine small molecule treatment like sorafenib 
with other drugs to trigger tumor cell death on the one hand and but also to alter the tumor 
microenvironment in such a way that lymphocyte migration into the tumor tissue is increased 
and the immune system is stimulated to recognize and kill the tumor cells. By this approach, 
the tumor is attacked by different mechanisms and it will be harder for the tumor to develop 
evasion or resistance mechanisms.  
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Appendix 2: Total amount of c-Jun and ATF-2 after MAPK inhibitor treatment. HepG2, Hep3B 
and Huh-7 cells were treated with 5 µM MAPK inhibitor or DMSO as control for up to 96 h. The 
total level of c-Jun and ATF-2 was measured. Effect of PLX4720 was not tested for Huh-7 cells. 
Shown is one representative experiment of up to three independent experiments. For each 
experiment, protein concentration was adjusted to 500 µg/ml and a minimum of 50 beads was 
measured and MFI was calculated. The readout of the phosphoplex is the MFI of > 50 beads 
detecting total-kinases. 
 
Appendix 1: Total amount of JNK, p38 and Akt after MAPK inhibitor treatment. HepG2, 
Hep3B and Huh-7 cells were treated with 5 µM MAPK inhibitor or DMSO as control for up to 96 h. 
The total level of JNK, p38 and Akt was measured. Effect of PLX4720 was not tested for Huh-7 
cells. Shown is one representative experiment of up to three independent experiments. For each 
experiment, protein concentration was adjusted to 500 µg/ml and a minimum of 50 beads was 
measured and MFI was calculated. The readout of the phosphoplex is the MFI of > 50 beads 
detecting total-kinases. 
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